BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Longo DL, Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018;378:158-68. [DOI: 10.1056/nejmra1703481] [Cited by in Crossref: 2011] [Cited by in F6Publishing: 2160] [Article Influence: 402.2] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Lyu B, Yang C, He B, Zhang H, Wang X, Zhang Q, Dai W. An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer. Bioactive Materials 2023;22:47-59. [DOI: 10.1016/j.bioactmat.2022.08.020] [Reference Citation Analysis]
2 Deng M, Ran P, Chen L, Wang Y, Yu Z, Cai K, Feng J, Qin Z, Yin Y, Tan S, Liu Y, Xu C, Shi G, Ji Y, Zhao JY, Zhou J, Fan J, Hou Y, Ding C. Proteogenomic characterization of cholangiocarcinoma. Hepatology 2023;77:411-29. [PMID: 35716043 DOI: 10.1002/hep.32624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huo CW, Gunadasa I, Gkolia P, Shackleton M, Hunn M. Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases. Melanoma Res 2023;33:58-65. [PMID: 36545922 DOI: 10.1097/CMR.0000000000000864] [Reference Citation Analysis]
4 Brongiel S, Rychalsky KL, Luon D, Johnson AR, Price C, Abdelghany O. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Ann Pharmacother 2023;57:148-55. [PMID: 35656843 DOI: 10.1177/10600280221094330] [Reference Citation Analysis]
5 Li L, Zhen M, Wang H, Sun Z, Cao X, Li J, Liu S, Zhao Z, Zhou C, Wang C, Bai C. Tumor microenvironment-modulated multiple nanotherapeutic system for potent cancer immunotherapy and metastasis inhibition. Nano Today 2023;48:101702. [DOI: 10.1016/j.nantod.2022.101702] [Reference Citation Analysis]
6 Guan H, Zhou Z, Hou X, Zhang F, Zhao J, Hu K. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy. Asia Pac J Clin Oncol 2023;19:35-50. [PMID: 35538049 DOI: 10.1111/ajco.13688] [Reference Citation Analysis]
7 Chao Y, Liu Z. Biomaterials tools to modulate the tumour microenvironment in immunotherapy. Nat Rev Bioeng 2023. [DOI: 10.1038/s44222-022-00004-6] [Reference Citation Analysis]
8 Zhang Y, Qu Z, Zhang T, Zhao Z, Zhang Y, Gu K. Research progress on mechanisms and predictive biomarkers for immune-related adverse events.. [DOI: 10.21203/rs.3.rs-2494743/v1] [Reference Citation Analysis]
9 Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36697706 DOI: 10.1038/s41575-022-00741-4] [Reference Citation Analysis]
10 Zhao N, Jiang A, Shang X, Zhao F, Wang R, Fu X, Ruan Z, Liang X, Tian T, Yao Y, Li C. Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels.. [DOI: 10.21203/rs.3.rs-2501974/v1] [Reference Citation Analysis]
11 Luo Y, Yao Y, Wu P, Zi X, Sun N, He J. Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2023;:103922. [PMID: 36696933 DOI: 10.1016/j.critrevonc.2023.103922] [Reference Citation Analysis]
12 Jiang N, Yu Y, Wu D, Wang S, Fang Y, Miao H, Ma P, Huang H, Zhang M, Zhang Y, Tang Y, Li N. HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. J Cancer Res Clin Oncol 2023. [PMID: 36662304 DOI: 10.1007/s00432-022-04493-1] [Reference Citation Analysis]
13 Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A, Salvatore MM, Lagos GG, Reiner SL, Dallos MC, Mathew M, Rizvi NA, Mor A. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med 2023;4:100868. [PMID: 36513074 DOI: 10.1016/j.xcrm.2022.100868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Khadela A, Chavda VP, Postwala H, Ephraim R, Apostolopoulos V, Shah Y. Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers (Basel) 2023;15. [PMID: 36672492 DOI: 10.3390/cancers15020543] [Reference Citation Analysis]
15 Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
16 Isa M, Hongo Y, Sakamoto N, Yamazaki K, Takazaki H, Asakuma J, Ikewaki K, Suzuki K. Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/-associated antibodies. J Neurol Sci 2023;444:120528. [PMID: 36565689 DOI: 10.1016/j.jns.2022.120528] [Reference Citation Analysis]
17 Paragliola RM, Torino F, Barnabei A, Iannantuono GM, Corsello A, Locantore P, Corsello SM. Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. Cancers (Basel) 2023;15. [PMID: 36672478 DOI: 10.3390/cancers15020529] [Reference Citation Analysis]
18 Wako S, Ikeguchi R, Toda K, Kobayashi M, Miyata R, Kuramochi H, Ichihara A, Shimizu Y, Kitagawa K. Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report. J Neuroimmunol 2023;374:578010. [PMID: 36508929 DOI: 10.1016/j.jneuroim.2022.578010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Gutiérrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends Cancer 2023:S2405-8033(22)00270-9. [PMID: 36642575 DOI: 10.1016/j.trecan.2022.12.007] [Reference Citation Analysis]
20 Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 2023:S2666-6340(22)00523-2. [PMID: 36693381 DOI: 10.1016/j.medj.2022.12.007] [Reference Citation Analysis]
21 Qian Y, Eppley S, Baer D, Melles RB. Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population. Ocul Immunol Inflamm 2023;:1-7. [PMID: 36637986 DOI: 10.1080/09273948.2022.2159447] [Reference Citation Analysis]
22 Taylor J, Gandhi A, Gray E, Zaenker P. Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.991433] [Reference Citation Analysis]
23 Lianova AA, Vladimirova LY, Abramova NA, Teplyakova MA, Popova IL, Tikhanovskaya NM, Storozhakova AE, Ryadinskaya LA, Udalenkova IA, Kalabanova EA, Trifanov D. Anti-PD‑1-induced type 1 diabetes mellitus in patient with recurrent oropharyngeal squamous cell cancer. Medicinskij alfavit 2023. [DOI: 10.33667/2078-5631-2022-31-28-34] [Reference Citation Analysis]
24 Mei H, Wen W, Fang K, Xiong Y, Liu W, Wang J, Wan R. Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1088659] [Reference Citation Analysis]
25 Pan L, Meng F, Wang W, Wang X, Shen H, Bao P, Kang J, Kong D. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1072612] [Reference Citation Analysis]
26 Xing X, Zhao Q, Zhou J, Zhou R, Liu Y, Qin X, Zhang M, Zhong Y, Wang J, Tian M, Zhang H. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging 2023. [PMID: 36622406 DOI: 10.1007/s00259-022-06084-1] [Reference Citation Analysis]
27 Seligman C, Chang YM, Luo J, Garden OA. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. Front Neurol 2022;13:1004810. [PMID: 36698907 DOI: 10.3389/fneur.2022.1004810] [Reference Citation Analysis]
28 Xing H, Wang Y, Qu B, Wei Q, Li C, Pan C, Li H. The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Transl Oncol 2023;28:101619. [PMID: 36623392 DOI: 10.1016/j.tranon.2023.101619] [Reference Citation Analysis]
29 Grümme L, Schulze-Koops H. [Rheumatological side effects of checkpoint inhibitors and their treatment]. Z Rheumatol 2023. [PMID: 36607420 DOI: 10.1007/s00393-022-01311-4] [Reference Citation Analysis]
30 Kim S, Sun JH, Kim H, Kim HK, Yang Y, Lee JS, Choi IA, Han HS. Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: A case report. World J Clin Cases 2023; 11(1): 218-224 [DOI: 10.12998/wjcc.v11.i1.218] [Reference Citation Analysis]
31 Fujita Y, Kamitani F, Yamamoto M, Fukuoka H, Hirota Y, Nishiyama N, Goda N, Okada Y, Inaba Y, Nakajima H, Kurematsu Y, Kanie K, Shichi H, Urai S, Suzuki M, Yamamoto N, Bando H, Iguchi G, Suto H, Funakoshi Y, Kiyota N, Takahashi Y, Ogawa W. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors. J Endocr Soc 2023;7:bvad002. [PMID: 36694808 DOI: 10.1210/jendso/bvad002] [Reference Citation Analysis]
32 Kwak SH, Shah CV. A brief review of renal-limited thrombotic microangiopathy associated with immune checkpoint inhibitors. Journal of Onco-Nephrology 2023. [DOI: 10.1177/23993693221147769] [Reference Citation Analysis]
33 Yoshimura K, Tamano Y, Nguyen Canh H, Zihan L, Le Thanh D, Sato Y, Terashima T, Shimoda S, Harada K. A novel pathologic marker, indoleamine 2,3-dioxygenase 1, for the cholangiopathy of immune checkpoint inhibitors-induced immune mediated hepatotoxicity as adverse events and the prediction of additional ursodeoxycholic acid treatment. Med Mol Morphol 2023. [PMID: 36599971 DOI: 10.1007/s00795-022-00344-7] [Reference Citation Analysis]
34 Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer 2023;11. [PMID: 36593068 DOI: 10.1136/jitc-2022-005493] [Reference Citation Analysis]
35 Renz M, Dorigo O. Immunotherapy in gynecologic malignancies. DiSaia and Creasman Clinical Gynecologic Oncology 2023. [DOI: 10.1016/b978-0-323-77684-4.00026-x] [Reference Citation Analysis]
36 Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes 2023;72:59-70. [PMID: 35709010 DOI: 10.2337/db21-1172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Vogel A, Lleo A. Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry? Liver Int 2023;43:6-7. [PMID: 36588300 DOI: 10.1111/liv.15474] [Reference Citation Analysis]
38 De Grado A, Cencini F, Priori A. Neurology of cancer immunotherapy. Neurol Sci 2023;44:137-48. [PMID: 36112276 DOI: 10.1007/s10072-022-06297-0] [Reference Citation Analysis]
39 Rodrigo-Aliaga M, Bosquet-Sanz M, Barrios-Arnau L, Sánchez-Llopis A, Ponce-Blasco P, Monsonís-Usó R, Planelles-Soler P, Garau-Perelló C. Development and implementation of an immunotherapy unit in a urology department. Actas Urol Esp (Engl Ed) 2023;47:56-63. [PMID: 36442795 DOI: 10.1016/j.acuroe.2022.11.006] [Reference Citation Analysis]
40 Smith-uffen M, Tselios K. Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series. AIM Clinical Cases 2023;2. [DOI: 10.7326/aimcc.2022.0815] [Reference Citation Analysis]
41 Herrmann J, Sahni G, Gallardo A, Spahillari A, Galsky M, Eschenhagen T, Schaffer W, Neilan TG, Ak G, Donisan T, Balanescu DV, Iliescu C, Stewart K, Larsen C. Cancer therapeutic drug guide. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 2023. [DOI: 10.1016/b978-0-323-68135-3.00063-5] [Reference Citation Analysis]
42 Abadi B, Rezaei N. Introduction on Personalized Immune-Oncology. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_286-1] [Reference Citation Analysis]
43 Liu J, Yu H. A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. PGPM 2023;Volume 16:29-36. [DOI: 10.2147/pgpm.s391756] [Reference Citation Analysis]
44 Berry P, Kotha S, Zen Y, Papa S, El Menabawey T, Webster G, Joshi D, Heneghan M. Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort. Liver Int 2023;43:147-54. [PMID: 35704341 DOI: 10.1111/liv.15340] [Reference Citation Analysis]
45 Lee M, Jeong K, Park YR, Rhee Y. Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database. Metabolism 2023;138:155311. [PMID: 36122764 DOI: 10.1016/j.metabol.2022.155311] [Reference Citation Analysis]
46 Zhu J, Wu W. Clinical Analysis of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation Combined with Targeted Therapy and Immunotherapy in the Treatment of Large Hepatocellular Carcinoma. JBM 2023;11:18-25. [DOI: 10.4236/jbm.2023.111003] [Reference Citation Analysis]
47 Baldwin XL, Spanheimer PM, Downs-canner S. A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research 2023;281:289-298. [DOI: 10.1016/j.jss.2022.08.040] [Reference Citation Analysis]
48 Myers G, Stevens J, Flewelling A, Richard J, London M. Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors. J Oncol Pharm Pract 2023;29:145-54. [PMID: 34846197 DOI: 10.1177/10781552211061133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Darvishi M, Tosan F, Nakhaei P, Manjili DA, Kharkouei SA, Alizadeh A, Ilkhani S, Khalafi F, Zadeh FA, Shafagh SG. Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathol Res Pract 2023;241:154241. [PMID: 36543080 DOI: 10.1016/j.prp.2022.154241] [Reference Citation Analysis]
50 Pyrgidis N, Hatzichristodoulou G, Sokolakis I. [Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients. A commentary]. Urologie 2023;62:71-4. [PMID: 36576534 DOI: 10.1007/s00120-022-02001-4] [Reference Citation Analysis]
51 Lim JU. Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse. Tuberc Respir Dis (Seoul) 2023;86:14-22. [PMID: 36594192 DOI: 10.4046/trd.2022.0081] [Reference Citation Analysis]
52 Xia S, Gong H, Zhao Y, Guo L, Wang Y, Zhang B, Sarangdhar M, Noguchi Y, Yan M. Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Cancers (Basel) 2022;15. [PMID: 36612235 DOI: 10.3390/cancers15010240] [Reference Citation Analysis]
53 Spagnolo CC, Giuffrida G, Cannavò S, Franchina T, Silvestris N, Ruggeri RM, Santarpia M. Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. Cancers (Basel) 2022;15. [PMID: 36612243 DOI: 10.3390/cancers15010246] [Reference Citation Analysis]
54 Cosci I, Grande G, Di Nisio A, Rocca MS, Del Fiore P, Benna C, Mocellin S, Ferlin A. Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. Int J Mol Sci 2022;24. [PMID: 36614041 DOI: 10.3390/ijms24010599] [Reference Citation Analysis]
55 Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Target Oncol 2022. [PMID: 36571708 DOI: 10.1007/s11523-022-00940-8] [Reference Citation Analysis]
56 Marco C, Simó M, Alemany M, Casasnovas C, Domínguez R, Vilariño N, Calvo M, Martín-Liberal J, Brenes J, Sabater-Riera J, Bruna J, Velasco R. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series. J Clin Med 2022;12. [PMID: 36614930 DOI: 10.3390/jcm12010130] [Reference Citation Analysis]
57 Zhao J, Li D, Xie S, Deng X, Wen X, Li J, Wu Z, Yang X, Li M, Tang Y, Zhang X, Ding Y. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis. Front Immunol 2022;13:1083840. [PMID: 36618343 DOI: 10.3389/fimmu.2022.1083840] [Reference Citation Analysis]
58 Fujiu K, Utsumi Y, Omi F, Suzuki M, Suzuki H. Two Cases of Retroperitoneal Fibrosis During Anti-programmed Cell Death 1 Antibody Treatment. JJLC 2022;62:1044-1047. [DOI: 10.2482/haigan.62.1044] [Reference Citation Analysis]
59 Furuyama T, Ueda M, Okada A, Hato S, Watabe Y, Inui Y, Ibaraki T, Mito F, Takenaka H, Choh S. A Case of Limbic Encephalitis Presenting as Paraneoplastic Neurological Syndrome with Possible Involvement of Immune Checkpoint Inhibitors. JJLC 2022;62:1048-1055. [DOI: 10.2482/haigan.62.1048] [Reference Citation Analysis]
60 Jaffe AS. Biomarkers for Immune Checkpoint Inhibitor-Induced Myocarditis: Caution Needed. JACC CardioOncol 2022;4:701-3. [PMID: 36636433 DOI: 10.1016/j.jaccao.2022.11.014] [Reference Citation Analysis]
61 Suero-Abreu GA, Zanni MV, Neilan TG. Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:598-615. [PMID: 36636438 DOI: 10.1016/j.jaccao.2022.11.011] [Reference Citation Analysis]
62 Mulholland M, Kritikou E, Katra P, Nilsson J, Björkbacka H, Lichtman AH, Rodriguez A, Engelbertsen D. LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice. JACC CardioOncol 2022;4:635-45. [PMID: 36636446 DOI: 10.1016/j.jaccao.2022.09.005] [Reference Citation Analysis]
63 Pergolini D, Botticelli A, Fascetti R, Rocchetti F, Cirillo A, Tenore G, Palaia G, Polimeni A, Romeo U. Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series. Applied Sciences 2022;12:12994. [DOI: 10.3390/app122412994] [Reference Citation Analysis]
64 Liu F, Wang Z, Li X, Zhang Z, Yang Y, Chen J, Chen D, Wu L, Liu X, Han S, Wang F, Wahafu W, Gao Y, Ren S, Xing N, Cai G, Chen X. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. Cancer Communications 2022. [DOI: 10.1002/cac2.12396] [Reference Citation Analysis]
65 Dobrzynski JL, Vest BE, Swick BL. Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung. Case Rep Dermatol Med 2022;2022:5360113. [PMID: 36567751 DOI: 10.1155/2022/5360113] [Reference Citation Analysis]
66 Jiang ST, Liu YG, Zhang L, Sang XT, Xu YY, Lu X. Immune-related adverse events: A bibliometric analysis. Front Immunol 2022;13:1096806. [PMID: 36591239 DOI: 10.3389/fimmu.2022.1096806] [Reference Citation Analysis]
67 François A, Descarpentrie J, Badiola I, Siegfried G, Evrard S, Pernot S, Khatib A. Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. Br J Cancer 2022. [DOI: 10.1038/s41416-022-02073-1] [Reference Citation Analysis]
68 Ichihara S, Ogino H, Yoneda H, Haji K, Kagawa K, Murakami K, Mima M, Aoi Y, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Sato S, Nokihara H, Nishioka Y. Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody. Respir Med Case Rep 2023;41:101797. [PMID: 36583061 DOI: 10.1016/j.rmcr.2022.101797] [Reference Citation Analysis]
69 Song SJ, Song Y, Jang M, Shin E, Suh SY, Cho YS, Lee J, Oh JM. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targ Oncol 2022. [DOI: 10.1007/s11523-022-00936-4] [Reference Citation Analysis]
70 Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Traglia SD, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Cervati V, Ledda RE, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, De Rimini ML. Ita-immuno-pet: the Role of Fdg Pet/ct for Assessing Response to Immunotherapy.. [DOI: 10.21203/rs.3.rs-2354958/v1] [Reference Citation Analysis]
71 Piening A, Ebert E, Khojandi N, Alspach E, Teague RM. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. Front Immunol 2022;13:1022732. [PMID: 36582225 DOI: 10.3389/fimmu.2022.1022732] [Reference Citation Analysis]
72 Meng X, Shang M, Wang Q, Yan R, Jiang K, Xiang J, Liu W, Li J, Wang D, Xu J. Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator. Qual Life Res 2022. [DOI: 10.1007/s11136-022-03318-5] [Reference Citation Analysis]
73 Zhu L, Li J, Guo Z, Kwok HF, Zhao Q. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy. J Nanobiotechnology 2022;20:521. [PMID: 36496381 DOI: 10.1186/s12951-022-01736-8] [Reference Citation Analysis]
74 Sylvain Raoul Simeni Njonnou, Sandrine Aspeslagh, Marie-Josiane Ntsama Essomba, Marie-Lucie Racu, Fernando Kemta Lekpa, Frédéric Vandergheynst. Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report. J Med Case Rep 2022;16:456. [PMID: 36482425 DOI: 10.1186/s13256-022-03663-6] [Reference Citation Analysis]
75 Zhang X, Fu Z, Yan C. Cytokine release syndrome induced by pembrolizumab: A case report. Medicine (Baltimore) 2022;101:e31998. [PMID: 36626467 DOI: 10.1097/MD.0000000000031998] [Reference Citation Analysis]
76 Gao L, Li X, Guo Z, Tang L, Peng J, Liu B. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review. Medicine (Baltimore) 2022;101:e32240. [PMID: 36626474 DOI: 10.1097/MD.0000000000032240] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Zheng J, Huang B, Xiao L, Wu M, Li J. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Front Oncol 2022;12:821626. [PMID: 36568203 DOI: 10.3389/fonc.2022.821626] [Reference Citation Analysis]
78 Wang S, Peng D, Zhu H, Min W, Xue M, Wu R, Shao Y, Pan L, Zhu M. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. Front Oncol 2022;12:1053370. [PMID: 36568231 DOI: 10.3389/fonc.2022.1053370] [Reference Citation Analysis]
79 Chi P, Jiang H, Li D, Li J, Wen X, Ding Q, Chen L, Zhang X, Huang J, Ding Y. An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets. Front Immunol 2022;13:1012673. [PMID: 36569825 DOI: 10.3389/fimmu.2022.1012673] [Reference Citation Analysis]
80 Thol K, Pawlik P, McGranahan N. Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Med 2022;14:137. [PMID: 36476325 DOI: 10.1186/s13073-022-01138-3] [Reference Citation Analysis]
81 Dercle L, Sun S, Seban R, Mekki A, Sun R, Tselikas L, Hans S, Bernard-tessier A, Mihoubi Bouvier F, Aide N, Vercellino L, Rivas A, Girard A, Mokrane F, Manson G, Houot R, Lopci E, Yeh R, Ammari S, Schwartz LH. Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. Radiology 2022. [DOI: 10.1148/radiol.210518] [Reference Citation Analysis]
82 Zeng Z, Qu J, Yao Y, Xu F, Lu S, Zhang P, Yao Y, Li N, Zhou J, Wang Y. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. BMC Pulm Med 2022;22:458. [PMID: 36456932 DOI: 10.1186/s12890-022-02190-w] [Reference Citation Analysis]
83 Wang X, Wu C, Wei H. Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy. Antioxid Redox Signal 2022;37:1291-302. [PMID: 35403435 DOI: 10.1089/ars.2022.0039] [Reference Citation Analysis]
84 Yuan H, Duan DD, Zhang YJ. Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2022;46:102031. [PMID: 36261109 DOI: 10.1016/j.clinre.2022.102031] [Reference Citation Analysis]
85 Hayashi H, Sawada K, Hasebe T, Nakajima S, Sawada J, Takiyama Y, Takiyama Y, Okumura T, Fujiya M. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Intern Med 2022;61:3497-502. [PMID: 35491133 DOI: 10.2169/internalmedicine.9393-22] [Reference Citation Analysis]
86 Robert C, Vagner S, Mariette X. Using genetics to predict toxicity of cancer immunotherapy. Nat Med 2022;28:2471-2. [PMID: 36526721 DOI: 10.1038/s41591-022-02096-4] [Reference Citation Analysis]
87 Capaccione KM, Valiplackal JP, Huang A, Roa T, Fruauff A, Liou C, Kim E, Khurana S, Maher M, Ma H, Ngyuen P, Mak S, Dumeer S, Lala S, D'souza B, Laifer-Narin S, Desperito E, Ruzal-Shapiro C, Salvatore MM. Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. Acad Radiol 2022;29:1869-84. [PMID: 35382975 DOI: 10.1016/j.acra.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Noori M, Mahjoubfar A, Azizi S, Fayyaz F, Rezaei N. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis. International Immunopharmacology 2022;113:109317. [DOI: 10.1016/j.intimp.2022.109317] [Reference Citation Analysis]
89 Su L, Hao Y, Li R, Pan W, Ma X, Weng J, Min Y. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Acta Biomater 2022;154:401-11. [PMID: 36241013 DOI: 10.1016/j.actbio.2022.10.001] [Reference Citation Analysis]
90 Garbarino MC, Manzano N, Messina O, Zylberman M. Eventos adversos reumatológicos secundarios al uso de inhibidores de punto de control inmunitario. Reumatología Clínica 2022. [DOI: 10.1016/j.reuma.2022.09.004] [Reference Citation Analysis]
91 Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med 2022;28:2584-91. [PMID: 36526723 DOI: 10.1038/s41591-022-02094-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Lotfy A, Wang H. Immune Checkpoint Inhibitors and Mesenchymal Stem/Stromal Cells Combination Therapy Might Offer a Promising Treatment Option for Cancer. Stem Cell Rev and Rep 2022. [DOI: 10.1007/s12015-022-10474-1] [Reference Citation Analysis]
93 Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer 2022;22:703-22. [PMID: 36253536 DOI: 10.1038/s41568-022-00513-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Wu C, Liu W, Pu J, Feng T, Chang Y, Wang X, Liang X, Kai J. Fractional exhaled nitric oxide in checkpoint inhibitor pneumonitis: a case report and literature review. Immunotherapy 2022;14:1361-7. [PMID: 36472185 DOI: 10.2217/imt-2022-0094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Mahdavi Gorabi A, Sadat Ravari M, Sanaei M, Davaran S, Kesharwani P, Sahebkar A. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology 2022;113:109300. [DOI: 10.1016/j.intimp.2022.109300] [Reference Citation Analysis]
96 Casals J, Acosta Y, Caballero G, Morantes L, Zamora C, Xipell M, Viladot M, Guillen E, Piñeiro G, Blasco M, Marco J, Padrosa J, Pereira A, Jhaveri KD, Quintana L, García-herrera A. Differentiating acute interstitial nephritis from immune checkpoint inhibitors from other causes. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.12.017] [Reference Citation Analysis]
97 Farooqui N, Zaidi M, Vaughan L, Mckee TD, Ahsam E, Pavelko KD, Villasboas JC, Markovic S, Taner T, Leung N, Dong H, Alexander MP, Herrmann SM. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated with Immune Checkpoint Inhibitors. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.11.020] [Reference Citation Analysis]
98 Bernstein E, Sabari J. Immune-mediated pneumonitis: A clinical conundrum in a patient with stage IV lung adenocarcinoma with a dramatic and durable response to checkpoint inhibitor case report. Current Problems in Cancer: Case Reports 2022;8:100195. [DOI: 10.1016/j.cpccr.2022.100195] [Reference Citation Analysis]
99 Athale J, Busch LM, O’grady NP. Cytokine Release Syndrome and Sepsis. Infectious Disease Clinics of North America 2022;36:735-748. [DOI: 10.1016/j.idc.2022.07.001] [Reference Citation Analysis]
100 Torrente M, Blanco M, Franco F, Garitaonaindia Y, Calvo V, Collazo-lorduy A, Gutiérrez L, Sánchez JC, González-del-alba A, Hernández R, Méndez M, Cantos B, Núñez B, Sousa PAC, Provencio M. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1062858] [Reference Citation Analysis]
101 Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, Xue JS, Dong ZR, Chen ZQ, Hong JG, Wang DX, Han CL, Mao XC, Li T. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy 2022;14:1481-96. [PMID: 36537255 DOI: 10.2217/imt-2022-0133] [Reference Citation Analysis]
102 Kačar M, Markelj G, Avčin T. Autoimmune and autoinflammatory manifestations in inborn errors of immunity. Curr Opin Allergy Clin Immunol 2022;22:343-51. [PMID: 36165421 DOI: 10.1097/ACI.0000000000000860] [Reference Citation Analysis]
103 Zekić T, Benić MS. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. Rheumatol Int 2022. [DOI: 10.1007/s00296-022-05247-5] [Reference Citation Analysis]
104 Nishimura Y, Yamanaka K, Kato T, Hatano K, Kawashima A, Fukuhara S, Uemura M, Imamura R, Nonomura N. Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma. IJU Case Reports 2022. [DOI: 10.1002/iju5.12560] [Reference Citation Analysis]
105 Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, Miyata Y, Okada M, Hattori N, Sugiyama K, Yoshioka Y, Toratani S, Takechi M, Ichinohe T, Ueda T, Takeno S, Kobayashi T, Ohdan H, Teishima J, Hide M, Nagata Y, Kudo Y, Iida K, Chayama K. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. BMC Cancer 2022;22:1232. [PMID: 36447159 DOI: 10.1186/s12885-022-10327-7] [Reference Citation Analysis]
106 Lievense LA, Heukels P, van Walree NC, van der Leest CH. Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects. JTO Clin Res Rep 2023;4:100441. [PMID: 36578272 DOI: 10.1016/j.jtocrr.2022.100441] [Reference Citation Analysis]
107 Kushiya H, Hiraoka K, Suzuki T, Inoko K, Inagaki A, Niwa H, Sasaki K, Nakamura T, Tsuchikawa T, Shichinohe T, Jolly DJ, Kasahara N, Hirano S. Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer. Cancers (Basel) 2022;14. [PMID: 36497300 DOI: 10.3390/cancers14235820] [Reference Citation Analysis]
108 Bai XF, Chen Y, Zou MZ, Li CX, Zhang Y, Li MJ, Cheng SX, Zhang XZ. Homotypic Targeted Photosensitive Nanointerferer for Tumor Cell Cycle Arrest to Boost Tumor Photoimmunotherapy. ACS Nano 2022;16:18555-67. [PMID: 36341683 DOI: 10.1021/acsnano.2c06871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Ohwada S, Ishigami K, Yokoyama Y, Kazama T, Masaki Y, Takahashi M, Yoshii S, Yamano H, Chiba H, Nakase H. Immune-related colitis and pancreatitis treated with infliximab. Clin J Gastroenterol 2022. [DOI: 10.1007/s12328-022-01731-4] [Reference Citation Analysis]
110 Luo J, Liu K, Wang Y, Li H. Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury. Front Immunol 2022;13:1021452. [PMID: 36479124 DOI: 10.3389/fimmu.2022.1021452] [Reference Citation Analysis]
111 Ammann NL, Schwietzer YF, Mess C, Stadler JC, Geidel G, Kött J, Pantel K, Schneider SW, Utikal J, Bauer AT, Gebhardt C. Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. Cancers (Basel) 2022;14. [PMID: 36428768 DOI: 10.3390/cancers14225676] [Reference Citation Analysis]
112 Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346 [DOI: 10.5500/wjt.v12.i11.331] [Reference Citation Analysis]
113 Winges KM, Gordon LK. Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. Front Ophthalmol 2022;2. [DOI: 10.3389/fopht.2022.1044904] [Reference Citation Analysis]
114 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
115 Liu S, Ma G, Wang H, Yu G, Chen J, Song W. Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. Medicine (Baltimore) 2022;101:e31873. [PMID: 36401466 DOI: 10.1097/MD.0000000000031873] [Reference Citation Analysis]
116 E. Omar N, M. Afifi H, O. Sahal A, Mekkawi R, Elewa H. The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. Immune Checkpoint Inhibitors - New Insights and Recent Progress [Working Title] 2022. [DOI: 10.5772/intechopen.107833] [Reference Citation Analysis]
117 Chen Y, Jiang N, Chen M, Sui B, Liu X. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1064754] [Reference Citation Analysis]
118 Tang B, Zhang X, Yang X, Wang W, Li R, Liu Y. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1013248] [Reference Citation Analysis]
119 Li J, Huang F, Jiang Y, Zhao J, Wan J, Hao S. A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4+ T cell vaccine efficiently enhances anti-leukemia immunity. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1043484] [Reference Citation Analysis]
120 Tian J, Liu H, Yan L, Ding Z, Han C, Tian B, Tan S, Dong Z, Wang D, Xue J, Mao X, Yan Y, Li T. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00938-6] [Reference Citation Analysis]
121 Lee H, Guo Y, Ross JL, Schoen S, Degertekin FL, Arvanitis C. Spatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade. Sci Adv 2022;8. [DOI: 10.1126/sciadv.add2288] [Reference Citation Analysis]
122 Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R, Iliodromitis EK. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. Int J Mol Sci 2022;23. [PMID: 36430599 DOI: 10.3390/ijms232214121] [Reference Citation Analysis]
123 Faria SS, Fernando AJ, de Lima VCC, Rossi AG, de Carvalho JMA, Magalhães KG. Induction of pyroptotic cell death as a potential tool for cancer treatment. J Inflamm 2022;19:19. [DOI: 10.1186/s12950-022-00316-9] [Reference Citation Analysis]
124 Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K, Thommen DS. PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clin Cancer Res 2022;28:4893-906. [PMID: 35852792 DOI: 10.1158/1078-0432.CCR-22-0992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
125 Grimaldi C, Ibraghimov A, Kiessling A, Rattel B, Ji C, Fuller CL, Brennan FR, Regenass-Lechner F, Shenton J, Price KD, Piché MS, Steeves MA, Prell R, Dudal S, Kronenberg S, Freebern W, Blanset D. Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discov Today 2022;28:103440. [PMID: 36375739 DOI: 10.1016/j.drudis.2022.103440] [Reference Citation Analysis]
126 Fitzgerald KN, Motzer RJ, Lee C. Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade. Nat Rev Urol 2022. [DOI: 10.1038/s41585-022-00666-2] [Reference Citation Analysis]
127 Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 2023;220. [PMID: 36367776 DOI: 10.1084/jem.20221333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Gergely TG, Kucsera D, Tóth VE, Kovács T, Sayour NV, Drobni ZD, Ruppert M, Petrovich B, Ágg B, Onódi Z, Fekete N, Pállinger É, Buzás EI, Yousif LI, Meijers WC, Radovits T, Merkely B, Ferdinandy P, Varga ZV. Molecular characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals IL-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. Br J Pharmacol 2022. [PMID: 36356191 DOI: 10.1111/bph.15984] [Reference Citation Analysis]
129 Tanabe J, Watanabe N, Ito M, Kanasaki K, Tanabe K. Differentiating Immune-Related Adrenal Insufficiency From Low Cardiac Output Syndrome: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.31349] [Reference Citation Analysis]
130 Zwergel C, Fioravanti R, Mai A. PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy? Drug Discov Today 2022;28:103435. [PMID: 36370994 DOI: 10.1016/j.drudis.2022.103435] [Reference Citation Analysis]
131 Nahar KJ, Marsh-Wakefield F, Rawson RV, Gide TN, Ferguson AL, Allen R, Quek C, da Silva IP, Tattersal S, Kiely CJ, Sandanayake N, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM, Palendira U. Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight 2022;7. [PMID: 36173679 DOI: 10.1172/jci.insight.157839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Yamaguchi A, Saito Y, Narumi K, Furugen A, Takekuma Y, Shinagawa N, Shimizu Y, Dosaka-akita H, Sugawara M, Kobayashi M. Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04425-z] [Reference Citation Analysis]
133 Ma Y, He X, Di Y, Liu S, Zhan Q, Bai Z, Qiu T, Corpe C, Wang J. Identification of prognostic immune-related lncRNAs in pancreatic cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1005695] [Reference Citation Analysis]
134 Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J 2022;43:4458-68. [PMID: 36040835 DOI: 10.1093/eurheartj/ehac456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Boesch M, Horvath L, Baty F, Pircher A, Wolf D, Spahn S, Straussman R, Tilg H, Brutsche MH. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. J Immunother Cancer 2022;10. [PMID: 36343977 DOI: 10.1136/jitc-2022-005401] [Reference Citation Analysis]
136 Zhang X, Xu S, Wang J, Lv Y, Wang N, Lai R, Sha Z, Zhao Q, Guo Z. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer? BMC Cancer 2022;22:1136. [DOI: 10.1186/s12885-022-10199-x] [Reference Citation Analysis]
137 Chen R, Zhou M, Zhu F. Immune Checkpoint Inhibitors Related to Cardiotoxicity. JCDD 2022;9:378. [DOI: 10.3390/jcdd9110378] [Reference Citation Analysis]
138 Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, Silvestris N, Carerj S. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers 2022;14:5403. [DOI: 10.3390/cancers14215403] [Reference Citation Analysis]
139 Dahl EK, Abed OK, Kjeldsen J, Donia M, Svane IM, Dige A, Agnholt JS, Bjerrum JT, Seidelin JB. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2022;56:1370-82. [PMID: 36123319 DOI: 10.1111/apt.17201] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Fujita K, Elkington P, Redelman-sidi G, Kanai O, Yamamoto Y, Imakita T, Okamura M, Nakatani K, Mio T. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study. Cancer Immunol Immunother 2022;71:2757-2764. [DOI: 10.1007/s00262-022-03198-1] [Reference Citation Analysis]
141 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, Lancellotti P, Thuny F, Abdelhamid M, Aboyans V, Aleman B, Alexandre J, Barac A, Borger MA, Casado-Arroyo R, Cautela J, Čelutkienė J, Cikes M, Cohen-Solal A, Dhiman K, Ederhy S, Edvardsen T, Fauchier L, Fradley M, Grapsa J, Halvorsen S, Heuser M, Humbert M, Jaarsma T, Kahan T, Konradi A, Koskinas KC, Kotecha D, Ky B, Landmesser U, Lewis BS, Linhart A, Lip GYH, Løchen ML, Malaczynska-Rajpold K, Metra M, Mindham R, Moonen M, Neilan TG, Nielsen JC, Petronio AS, Prescott E, Rakisheva A, Salem JE, Savarese G, Sitges M, Ten Berg J, Touyz RM, Tycinska A, Wilhelm M, Zamorano JL; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361. [PMID: 36017568 DOI: 10.1093/eurheartj/ehac244] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 61.0] [Reference Citation Analysis]
142 Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol 2022;176:149-56. [PMID: 36209942 DOI: 10.1016/j.radonc.2022.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Varma R, Wright M, Abraham J, Kruse M. Immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Rev Anticancer Ther 2022;22:1225-38. [PMID: 36278877 DOI: 10.1080/14737140.2022.2139240] [Reference Citation Analysis]
144 Gonzalez-gutierrez J, Sanchez-salcedo P, de Torres JP. Emphysema: the risk of cancer and the impact on cancer care. Lung Diseases and Cancer 2022. [DOI: 10.1183/2312508x.10018821] [Reference Citation Analysis]
145 Mukherjee A, Ghosh R. Pembrolizumab Induced Acute Tubulointerstitial Nephritis. Am J Ther 2022;29:e722-4. [PMID: 33021536 DOI: 10.1097/MJT.0000000000001248] [Reference Citation Analysis]
146 El Helali A, Tao J, Wong CHL, Chan WW, Mok K, Wu WF, Shitara K, Mohler M, Boku N, Pang H, Lam KO. A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.908026] [Reference Citation Analysis]
147 Wang Y, Chen R, Zhang J, Zeng P. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.. [DOI: 10.21203/rs.3.rs-2215057/v1] [Reference Citation Analysis]
148 Zhang H, Huang Y, Yang E, Gao X, Zou P, Sun J, Tian Z, Bao M, Liao D, Ge J, Yang Q, Li X, Zhang Z, Luo P, Jiang X. Identification of a Fibroblast-Related Prognostic Model in Glioma Based on Bioinformatics Methods. Biomolecules 2022;12:1598. [DOI: 10.3390/biom12111598] [Reference Citation Analysis]
149 Pantano F, Tramontana F, Iuliani M, Leanza G, Simonetti S, Piccoli A, Paviglianiti A, Cortellini A, Spinelli GP, Longo UG, Strollo R, Vincenzi B, Tonini G, Napoli N, Santini D. Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis. J Bone Oncol 2022;37:100459. [PMID: 36338920 DOI: 10.1016/j.jbo.2022.100459] [Reference Citation Analysis]
150 Abudayyeh A, Suo L, Lin H, Mamlouk O, Abdel-wahab N, Tchakarov A. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury. Cancers 2022;14:5267. [DOI: 10.3390/cancers14215267] [Reference Citation Analysis]
151 Zhou G, Zhang N, Meng K, Pan F. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1001623] [Reference Citation Analysis]
152 Xu Y, Zuo F, Wang H, Jing J, He X. The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1045957] [Reference Citation Analysis]
153 Sheng Y, Tu Z, Sun C, Long X, Wu L, Huang K, Zhu X. Prognostic and Immunological Role of RBMX in cancers.. [DOI: 10.21203/rs.3.rs-2179142/v1] [Reference Citation Analysis]
154 Yamamoto T, Morooka H, Ito T, Ishigami M, Mizuno K, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Yokota K, Hase T, Maeda O, Hashimoto N, Ando Y, Akiyama M, Kawashima H. Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury. J Gastroenterol Hepatol 2022. [PMID: 36302734 DOI: 10.1111/jgh.16038] [Reference Citation Analysis]
155 Yu Y, Wu X, Wang M, Liu W, Zhang L, Zhang Y, Hu Z, Zhou X, Jiang W, Zou Q, Cai F, Ye H. Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nat Commun 2022;13:6357. [PMID: 36289204 DOI: 10.1038/s41467-022-33891-9] [Reference Citation Analysis]
156 Berz AM, Dromain C, Vietti-violi N, Boughdad S, Duran R. Tumor response assessment on imaging following immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.982983] [Reference Citation Analysis]
157 Alexander Coukos, Julien Vionnet, Michel Obeid, Hasna Bouchaab, Solange Peters, Sofiya Latifyan, Alexandre Wicky, Olivier Michielin, Haithem Chtioui, Darius Moradpour, François Fasquelle, Christine Sempoux, Montserrat Fraga. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2022;10:e005635. [PMID: 36283734 DOI: 10.1136/jitc-2022-005635] [Reference Citation Analysis]
158 Shi X, Yang Y, Zhang W, Wang J, Xiao D, Ren H, Wang T, Gao F, Liu Z, Zhou K, Li P, Zhou Z, Zhang P, Shen X, Liu Y, Zhao J, Wang Z, Liu F, Shao C, Wu D, Zhang H. FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy. Proc Natl Acad Sci U S A 2022;119:e2208506119. [PMID: 36256824 DOI: 10.1073/pnas.2208506119] [Reference Citation Analysis]
159 Lv C, Wu C, Zhang Y, Li W, Wang X, Liang L. Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review. Curr Oncol 2022;29:7987-93. [PMID: 36354692 DOI: 10.3390/curroncol29110632] [Reference Citation Analysis]
160 Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. Int Urol Nephrol 2022. [DOI: 10.1007/s11255-022-03395-y] [Reference Citation Analysis]
161 Udagawa C, Nakano MH, Yoshida T, Ohe Y, Kato K, Mushiroda T, Zembutsu H. Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics 2022. [PMID: 36268685 DOI: 10.2217/pgs-2022-0113] [Reference Citation Analysis]
162 Weingarden AR, Gubatan J, Singh S, Balabanis TC, Patel A, Sharma A, Habtezion A. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. World J Gastroenterol 2022; 28(39): 5750-5763 [DOI: 10.3748/wjg.v28.i39.5750] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Shannon VR, Eapen GA, Jimenez CA, Grosu HB, Morice RC, Bashoura L, Sheshadre A, Evans SE, Adachi R, Kroll M, Faiz SA, Balachandran DD, Pravinkumar SE, Dickey BF. Respiratory Complications. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm134.pub2] [Reference Citation Analysis]
164 Bresalier RS, Coronel ES, Zhang HC. Gastrointestinal and Hepatic Complications in Cancer Patients. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm135.pub2] [Reference Citation Analysis]
165 Huang Y, Liu J, Zhu X. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients. Digit Health 2022;8:20552076221133699. [PMID: 36312851 DOI: 10.1177/20552076221133699] [Reference Citation Analysis]
166 Zou H, Mou XZ, Zhu B. Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Glob Chall 2023;7:2200094. [PMID: 36618103 DOI: 10.1002/gch2.202200094] [Reference Citation Analysis]
167 Liu Z, Xiang Y, Zheng Y, Kang X. Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology. Front Immunol 2022;13:1027124. [DOI: 10.3389/fimmu.2022.1027124] [Reference Citation Analysis]
168 Everdell E, Tsao H. Update on immune checkpoint therapy for melanoma. Dermatological Reviews 2022. [DOI: 10.1002/der2.164] [Reference Citation Analysis]
169 Pęczek P, Gajda M, Rutkowski K, Fudalej M, Deptała A, Badowska-Kozakiewicz AM. Cancer-associated inflammation: pathophysiology and clinical significance. J Cancer Res Clin Oncol 2022. [PMID: 36260158 DOI: 10.1007/s00432-022-04399-y] [Reference Citation Analysis]
170 Khodadadi K, Moghimi M, Mansouri R. Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study. Clin Case Rep 2022;10:e6392. [PMID: 36267821 DOI: 10.1002/ccr3.6392] [Reference Citation Analysis]
171 Thomas NJ, Brondfield S. Clinical progress note: Life-threatening side effects of targeted therapies for solid tumors. J Hosp Med 2022. [PMID: 36239331 DOI: 10.1002/jhm.12975] [Reference Citation Analysis]
172 Shroff GS, Strange CD, Ahuja J, Altan M, Sheshadri A, Unlu E, Truong MT, Vlahos I. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. Radiographics 2022;:220108. [PMID: 36240075 DOI: 10.1148/rg.220108] [Reference Citation Analysis]
173 Martin M, Nguyen HM, Beuvon C, Bene J, Palassin P, Atzenhoffer M, Rouby F, Sassier M, Pérault-Pochat MC, Roblot P, Allouchery M, Puyade M; French Network of Regional Pharmacovigilance Centers. Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. Cancers (Basel) 2022;14:5030. [PMID: 36291814 DOI: 10.3390/cancers14205030] [Reference Citation Analysis]
174 Turner CN, Mullins GN, Hoyer KK. CXCR5+CD8 T cells: Potential immunotherapy targets or drivers of immune-mediated adverse events? Front Med (Lausanne) 2022;9:1034764. [PMID: 36314014 DOI: 10.3389/fmed.2022.1034764] [Reference Citation Analysis]
175 Hagiwara S, Komeda Y, Nishida N, Yoshida A, Kudo M. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. Cancer Rep (Hoboken) 2022;5:e1721. [PMID: 36224043 DOI: 10.1002/cnr2.1721] [Reference Citation Analysis]
176 Riveiro-barciela M, Soler MJ, Barreira-diaz A, Bermejo S, Bruera S, Suarez-almazor ME. Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. JCM 2022;11:5977. [DOI: 10.3390/jcm11205977] [Reference Citation Analysis]
177 Li Q, Liu Q, Li H, Dong L, Zhou Y, Zhu J, Yang L, Tao J. Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy. Front Bioeng Biotechnol 2022;10:1039154. [DOI: 10.3389/fbioe.2022.1039154] [Reference Citation Analysis]
178 Pan J, Liu Y, Guo X, Bai Z, Levi Sandri GB, Méndez-Sánchez N, Qi X. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Expert Opin Drug Saf 2022. [PMID: 36214583 DOI: 10.1080/14740338.2022.2134854] [Reference Citation Analysis]
179 Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer 2022;21:194. [PMID: 36209106 DOI: 10.1186/s12943-022-01663-0] [Reference Citation Analysis]
180 Chiang CH, Chiang CH, Ma KS, Hsia YP, Lee YW, Wu HR, Chiang CH, Peng CY, Wei JC, Shiah HS, Peng CM, Neilan TG. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol 2022;52:1389-98. [PMID: 36208180 DOI: 10.1093/jjco/hyac150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
181 Chen N, Qian MJ, Zhang RH, Gao QQ, He CC, Yao YK, Zhou JY, Zhou H. Tislelizumab-related enteritis successfully treated with adalimumab: A case report. World J Clin Cases 2022; 10(28): 10186-10192 [DOI: 10.12998/wjcc.v10.i28.10186] [Reference Citation Analysis]
182 Tison A, Garaud S, Chiche L, Cornec D, Kostine M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol 2022. [PMID: 36198831 DOI: 10.1038/s41584-022-00841-0] [Reference Citation Analysis]
183 Liu W, Zhang Q, Zhang T, Li L, Xu C. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. World J Surg Oncol 2022;20:333. [PMID: 36192730 DOI: 10.1186/s12957-022-02800-1] [Reference Citation Analysis]
184 Xie X, Li Y, Lian S, Lu Y, Jia L. Cancer metastasis chemoprevention prevents circulating tumour cells from germination. Signal Transduct Target Ther 2022;7:341. [PMID: 36184654 DOI: 10.1038/s41392-022-01174-w] [Reference Citation Analysis]
185 Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet 2022;400:1103-16. [DOI: 10.1016/s0140-6736(22)01658-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
186 Khalatbari H, Shulkin BL, Parisi MT. Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.10.002] [Reference Citation Analysis]
187 Gritsch D, Valencia-sanchez C. Drug-related immune-mediated myelopathies. Front Neurol 2022;13:1003270. [DOI: 10.3389/fneur.2022.1003270] [Reference Citation Analysis]
188 De Risi I, Sciacovelli AM, Guida M. Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment? Biomedicines 2022;10:2424. [DOI: 10.3390/biomedicines10102424] [Reference Citation Analysis]
189 Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol 2022. [PMID: 36168055 DOI: 10.1038/s41581-022-00630-8] [Reference Citation Analysis]
190 Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol 2022. [PMID: 36163559 DOI: 10.1007/s00432-022-04367-6] [Reference Citation Analysis]
191 van der Vegt SA, Wang Y, Polonchuk L, Wang K, Waters SL, Baker RE. A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis. Front Pharmacol 2022;13:966180. [DOI: 10.3389/fphar.2022.966180] [Reference Citation Analysis]
192 Deharo F, Carvelli J, Cautela J, Garcia M, Sarles C, Maues de Paula A, Bourenne J, Gainnier M, Bichon A. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. JCM 2022;11:5611. [DOI: 10.3390/jcm11195611] [Reference Citation Analysis]
193 Buzzetti R, Maddaloni E, Gaglia J, Leslie RD, Wong FS, Boehm BO. Adult-onset autoimmune diabetes. Nat Rev Dis Primers 2022;8:63. [PMID: 36138034 DOI: 10.1038/s41572-022-00390-6] [Reference Citation Analysis]
194 Achim A, Liblik K, Gevaert S. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price. Trends Cardiovasc Med 2022:S1050-1738(22)00121-9. [PMID: 36152788 DOI: 10.1016/j.tcm.2022.09.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Chen J, Lu L, Qu C, A G, Deng F, Cai M, Chen W, Zheng L, Chen J. Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy. Front Med 2022;9. [DOI: 10.3389/fmed.2022.981001] [Reference Citation Analysis]
196 Huang L, Zhang J, Gong F, Han Y, Huang X, Luo W, Cai H, Zhang F. Identification and validation of ferroptosis-related lncRNA signatures as a novel prognostic model for glioma. Front Genet 2022;13:927142. [DOI: 10.3389/fgene.2022.927142] [Reference Citation Analysis]
197 Yuasa T. Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab. IJU Case Reports 2022. [DOI: 10.1002/iju5.12538] [Reference Citation Analysis]
198 Zhou X, Ni Y, Liang X, Lin Y, An B, He X, Zhao X. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol 2022;13:915094. [DOI: 10.3389/fimmu.2022.915094] [Reference Citation Analysis]
199 Wang Y, Wang Y, Yu J, Meng X. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. Front Immunol 2022;13:998516. [DOI: 10.3389/fimmu.2022.998516] [Reference Citation Analysis]
200 Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, Weber JS, Zhong J, Osman I. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade. Clin Cancer Res 2022;28:4121-30. [PMID: 36106402 DOI: 10.1158/1078-0432.CCR-22-0404] [Reference Citation Analysis]
201 Chen X, Wang H, Ai J, Shen L, Lin K, Yuan G, Sheng X, Jin X, Deng Z, Xu J, Lu G, Chen S, Cai J, Zhang Y, Zhang H, Wang S, Zhang W, Fan C. Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-center cohort study. Emerging Microbes & Infections. [DOI: 10.1080/22221751.2022.2122581] [Reference Citation Analysis]
202 Giri A, Bauman JR. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma. Expert Review of Anticancer Therapy. [DOI: 10.1080/14737140.2022.2125382] [Reference Citation Analysis]
203 Hassel JC, Luke JJ. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clinical Cancer Research 2022;28:3914-6. [DOI: 10.1158/1078-0432.ccr-22-1664] [Reference Citation Analysis]
204 Imai H, Kaira K, Kagamu H. Advanced Research on Immune Checkpoint Inhibitor Therapy. JCM 2022;11:5392. [DOI: 10.3390/jcm11185392] [Reference Citation Analysis]
205 Zhang L, Bo R, Wu Y, Li L, Zhu Z, Ma AH, Xiao W, Huang Y, Rojalin T, Yin X, Mao C, Wang F, Wang Y, Zhang H, Low KE, Lee K, Ajena Y, Jing D, Zhang D, Baehr CM, Liu R, Wang L, Li Y, Lam KS. Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment. Nano Lett 2022;22:6866-76. [PMID: 35926215 DOI: 10.1021/acs.nanolett.2c00582] [Reference Citation Analysis]
206 Kurzhals JK, Klee G, Hagelstein V, Zillikens D, Terheyden P, Langan EA. Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center. IJMS 2022;23:10723. [DOI: 10.3390/ijms231810723] [Reference Citation Analysis]
207 Jiang N, Yu Y, Zhang M, Tang Y, Wu D, Wang S, Fang Y, Zhang Y, Meng L, Li Y, Miao H, Ma P, Huang H, Li N. Association between germ-line HLA and immune-related adverse events. Front Immunol 2022;13:952099. [DOI: 10.3389/fimmu.2022.952099] [Reference Citation Analysis]
208 Hu Y, Lu W, Tang B, Zhao Z, An Z. Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study. Front Oncol 2022;12:954468. [DOI: 10.3389/fonc.2022.954468] [Reference Citation Analysis]
209 Tian Y, Huang A, Tian M, Wang K, Dang Q, Zhang C, Liu H, Zhao J, Yang X, Zhang C, Guo L, Chen F. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30151. [PMID: 36086680 DOI: 10.1097/MD.0000000000030151] [Reference Citation Analysis]
210 Ter Maat LS, van Duin IAJ, Elias SG, van Diest PJ, Pluim JPW, Verhoeff JJC, de Jong PA, Leiner T, Veta M, Suijkerbuijk KPM. Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. Eur J Cancer 2022;175:60-76. [PMID: 36096039 DOI: 10.1016/j.ejca.2022.07.034] [Reference Citation Analysis]
211 Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
212 Wang Y, Zou J, Li Y, Jiao X, Wang Y, Zhuo N, Gao M, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li J, Li Y, Shen L, Zhang H, Lu Z. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. Front Immunol 2022;13:987568. [DOI: 10.3389/fimmu.2022.987568] [Reference Citation Analysis]
213 Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of Appendicitis after Immune Checkpoint Inhibitor Therapy among Cancer Patients.. [DOI: 10.21203/rs.3.rs-2027490/v1] [Reference Citation Analysis]
214 Matsui JK, Perlow HK, Raj RK, Nalin AP, Lehrer EJ, Kotecha R, Trifiletti DM, Mcclelland S, Kendra K, Williams N, Owen DH, Presley CJ, Thomas EM, Beyer SJ, Blakaj DM, Ahluwalia MS, Raval RR, Palmer JD. Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines 2022;10:2211. [DOI: 10.3390/biomedicines10092211] [Reference Citation Analysis]
215 He H, Cen Y, Wang P, Zeng X, Zeng S, Li X, Lu X, Zhong C, Ming Y, Chen L, Peng L. The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model. J Cancer Res Clin Oncol 2022. [PMID: 36066620 DOI: 10.1007/s00432-022-04281-x] [Reference Citation Analysis]
216 Guo M, Liu J, Miao R, Ahmed Z, Yu J, Guan J, Ahmad S, Zhou S, Grove A, Manoucheri M, Socinski MA, Mekhail T. A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. J Immunother 2022. [PMID: 36066505 DOI: 10.1097/CJI.0000000000000440] [Reference Citation Analysis]
217 Bouleftour W, Bonjean P, Grangeon K, Magné N. COVID-19 vaccine-related adverse events in solid cancer patients treated with immunotherapy. Cancer Invest 2022;:1-10. [PMID: 36062881 DOI: 10.1080/07357907.2022.2121966] [Reference Citation Analysis]
218 Seo JH, Lim T, Ham A, Kim YA, Lee M. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report. Medicine 2022;101:e30456. [DOI: 10.1097/md.0000000000030456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
219 Chu CE, Iyer G, Bochner BH. Neoadjuvant Systemic Therapies in Bladder Cancer. Front Urol 2022;2. [DOI: 10.3389/fruro.2022.890761] [Reference Citation Analysis]
220 Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, Vilmann P, Johansen JS, Boisen MK, Eefsen RHL, Marie Svane I, Nielsen DL, Chen IM. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer 2022;10:e005111. [PMID: 36096534 DOI: 10.1136/jitc-2022-005111] [Reference Citation Analysis]
221 Coudert V, Penel N, Le Deley MC, Forestier A. Gestion des toxicités induites par les inhibiteurs des points de contrôle immunitaire en oncologie : cartographie des pratiques françaises. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.07.005] [Reference Citation Analysis]
222 Provinciali N, Paleari L, Briata IM, Piccardo A, Bacigalupo L, Rutigliani M, Decensi A. Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report. Current Problems in Cancer: Case Reports 2022;7:100172. [DOI: 10.1016/j.cpccr.2022.100172] [Reference Citation Analysis]
223 Men M, Tsui E. Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab. American Journal of Ophthalmology Case Reports 2022;27:101631. [DOI: 10.1016/j.ajoc.2022.101631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Moubarak S, Merheb D, Basbous L, Chamseddine N, Bou Zerdan M, Assi HI. COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges. J Int Med Res 2022;50:3000605221125047. [PMID: 36154328 DOI: 10.1177/03000605221125047] [Reference Citation Analysis]
225 Ankireddypalli AR, Chow LS, Radulescu A, Kawakami Y, Araki T. A Case of Hypophysitis Associated With SARS-CoV-2 Vaccination. AACE Clinical Case Reports 2022;8:204-209. [DOI: 10.1016/j.aace.2022.06.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Cappelli LC, Bingham CO, Forde PM, Anagnostou V, Brahmer J, Lipson EJ, Mammen J, Schollenberger M, Shah AA, Darrah E. Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis. RMD Open 2022;8:e002511. [PMID: 36096522 DOI: 10.1136/rmdopen-2022-002511] [Reference Citation Analysis]
227 Tsuji M, Hayashi N. An Exploratory Cross-sectional Study of Immune Checkpoint Inhibitors and Immuno-related Adverse Events: Knowledge and Influencing Factors among Japanese Oncology Nurses. Asia-Pacific Journal of Oncology Nursing 2022. [DOI: 10.1016/j.apjon.2022.100147] [Reference Citation Analysis]
228 Nielsen DL, Juhl CB, Chen IM, Kellermann L, Nielsen OH. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews 2022;109:102440. [DOI: 10.1016/j.ctrv.2022.102440] [Reference Citation Analysis]
229 Yan W, Lang T, Yuan W, Yin Q, Li Y. Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. Acta Pharmacol Sin. [DOI: 10.1038/s41401-022-00976-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Jang SY, Lee SY, Lee HL, Choi J. Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma. Respirology Case Reports 2022;10. [DOI: 10.1002/rcr2.1025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Sachpekidis C, Hassel JC, Dimitrakopoulou-strauss A. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03453-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Alexander JL, Ibraheim H, Richards C, Shum B, Pavlidis P, Hunter N, Teare JP, Wotherspoon A, Furness A, Turajlic S, Pickering L, Larkin J, Speight A, Papa S, Powell N. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. J Immunother Cancer 2022;10:e005490. [PMID: 36113896 DOI: 10.1136/jitc-2022-005490] [Reference Citation Analysis]
233 Lopez-mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, Chen MY, Meyersohn N, Daly R, Slim A, Rochitte C, Blaha M, Whelton S, Dzaye O, Dent S, Milgrom S, Ky B, Iliescu C, Mamas MA, Ferencik M. Cardiac Computed Tomographic Imaging in Cardio-Oncology: An Expert Consensus Statement from the Society of Cardiovascular Computed Tomography, Endorsed by the International Cardio-Oncology Society (ICOS). Journal of Cardiovascular Computed Tomography 2022. [DOI: 10.1016/j.jcct.2022.09.002] [Reference Citation Analysis]
234 Ramos-casals M, Flores-chávez A, Brito-zerón P, Lambotte O, Mariette X. Immune-related adverse events of cancer immunotherapies targeting kinases. Pharmacology & Therapeutics 2022;237:108250. [DOI: 10.1016/j.pharmthera.2022.108250] [Reference Citation Analysis]
235 Chen X, Gao M, An S, Zhao L, Han W, Wan W, Chen J, Ma S, Cai W, Cao Y, Ding D, Yang YY, Cheng L, Zheng Y. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. Nanomedicine: Nanotechnology, Biology and Medicine 2022;45:102591. [DOI: 10.1016/j.nano.2022.102591] [Reference Citation Analysis]
236 Simek S, Lue B, Rao A, Ravipati G, Vallabhaneni S, Zhang K, Zaha VG, Chandra A. Gender Differences in Diagnosis, Prevention, and Treatment of Cardiotoxicity in Cardio-Oncology. JCM 2022;11:5167. [DOI: 10.3390/jcm11175167] [Reference Citation Analysis]
237 Langouo Fontsa M, Padonou F, Willard-Gallo K. Biomarkers and immunotherapy: where are we? Curr Opin Oncol 2022;34:579-86. [PMID: 35943441 DOI: 10.1097/CCO.0000000000000891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Anderson MA, Khauli MA, Furtado F, Pourvaziri A, Catalano O. Immunotherapy-related renal toxicity causes reversible renal enlargement. Abdom Radiol (NY) 2022;47:3301-7. [PMID: 35776145 DOI: 10.1007/s00261-022-03594-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Jiang T, Xie L, Zhou S, Liu Y, Huang Y, Mei N, Ma F, Gong J, Gao X, Chen J. Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment. J Nanobiotechnology 2022;20:394. [PMID: 36045429 DOI: 10.1186/s12951-022-01592-6] [Reference Citation Analysis]
240 Gan L, Liu D, Ma Y, Chen X, Dai A, Zhao S, Jin X, Gu G. Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges. Front Pharmacol 2022;13:962596. [DOI: 10.3389/fphar.2022.962596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Chen J, Wen Y, Chu X, Liu Y, Su C. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. Front Pharmacol 2022;13:944342. [DOI: 10.3389/fphar.2022.944342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Cui R, Yang Z, Liu L. What does radiomics do in PD-L1 blockade therapy of NSCLC patients? Thorac Cancer 2022. [PMID: 36039482 DOI: 10.1111/1759-7714.14620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Shen Y, Li X, Wang D, Zhang L, Li X, Su L, Fan X, Yang X. COL3A1: Potential prognostic predictor for head and neck cancer based on immune-microenvironment alternative splicing. Cancer Med 2022. [PMID: 36039012 DOI: 10.1002/cam4.5170] [Reference Citation Analysis]
244 Erlandsson MC, Erdogan S, Wasén C, Andersson KME, Silfverswärd ST, Pullerits R, Bemark M, Bokarewa MI. IGF1R signalling is a guardian of self-tolerance restricting autoantibody production. Front Immunol 2022;13:958206. [DOI: 10.3389/fimmu.2022.958206] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Ge S, Jia T, Li J, Zhang B, Sang S, Deng S. Molecular imaging of immune checkpoints in oncology: Current and future applications. Cancer Lett 2022;:215896. [PMID: 36041658 DOI: 10.1016/j.canlet.2022.215896] [Reference Citation Analysis]
246 Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022:jeac106. [PMID: 36017575 DOI: 10.1093/ehjci/jeac106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
247 Akiyama T, Kishino K, Furukawa E, Konno Y, Takei K, Akiyama K, Shindo S, Otsuki I, Ojima S, Kobayashi M, Sata M, Yamamoto C, Fujiwara S. NIVOLUMAB-INDUCED AUTOIMMUNE HAEMOLYTIC ANAEMIA. JJTC 2022;68:486-490. [DOI: 10.3925/jjtc.68.486] [Reference Citation Analysis]
248 Wu P, Xiong D, Feng Y, Xiang L, Zhu J. Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event. Front Immunol 2022;13:939873. [DOI: 10.3389/fimmu.2022.939873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Winship AL, Alesi LR, Sant S, Stringer JM, Cantavenera A, Hegarty T, Requesens CL, Liew SH, Sarma U, Griffiths MJ, Zerafa N, Fox SB, Brown E, Caramia F, Zareie P, La Gruta NL, Phillips K, Strasser A, Loi S, Hutt KJ. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 2022;3:1-13. [DOI: 10.1038/s43018-022-00413-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Wu C, Wan L, Xie X. Fatal pneumonitis associated with immune checkpoint inhibitors: a study based on 128 cohorts with 26,994 participants.. [DOI: 10.21203/rs.3.rs-1982106/v1] [Reference Citation Analysis]
251 Liu G, Qiu Y, Zhang P, Chen Z, Chen S, Huang W, Wang B, Yu X, Guo D. Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. Pharmaceutics 2022;14:1762. [DOI: 10.3390/pharmaceutics14091762] [Reference Citation Analysis]
252 Zhang A, Yang F, Gao L, Shi X, Yang J. Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer. Cancer Manag Res 2022;14:2469-83. [PMID: 35991677 DOI: 10.2147/CMAR.S374648] [Reference Citation Analysis]
253 Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, Vidal Guitart X, Carreras Soler M, Farriols Danés A, Felip E, Braña I, Carles Galceran J, Morales Barrera R, Muñoz-couselo E, Agustí Escasany A. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice. Front Med 2022;9. [DOI: 10.3389/fmed.2022.891179] [Reference Citation Analysis]
254 Sawa K, Sato I, Takeuchi M, Kawakami K. Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03281-7] [Reference Citation Analysis]
255 Pang L, Chen Z, Xu D, Cheng W. Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. Front Immunol 2022;13:972302. [DOI: 10.3389/fimmu.2022.972302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2022. [PMID: 35989535 DOI: 10.1002/hep.32740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Cui C, Deng L, Wang W, Ren X, Wang Y, Cui W. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database. Front Oncol 2022;12:941079. [DOI: 10.3389/fonc.2022.941079] [Reference Citation Analysis]
258 Matsumura S, Kato T, Kujime Y, Kitakaze H, Nakano K, Hongo S, Yoshioka I, Okumi M, Nonomura N, Takada S. Pre-treatment metastatic growth rate predicts clinical outcome of metastatic renal cell carcinoma treated with nivolumab.. [DOI: 10.21203/rs.3.rs-1936031/v1] [Reference Citation Analysis]
259 Han T, Li Y, Wang X. PD-1/PD-L1 Blockade in Cancer Immunotherapy: Clinical Benefits, Limitations and Beyond. HSET 2022;8:84-93. [DOI: 10.54097/hset.v8i.1114] [Reference Citation Analysis]
260 Xuan TT, Li GY, Meng SB, Wang ZM, Qu LL. Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. World J Clin Cases 2022; 10(23): 8284-8290 [DOI: 10.12998/wjcc.v10.i23.8284] [Reference Citation Analysis]
261 Hollander B, Khurana S, Jacob JS, Altan M, Wang J, Zhao D, Varatharajalu K, Alasadi M, Thomas AS, Wang Y. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis. J Cancer Res Clin Oncol 2022. [PMID: 35972690 DOI: 10.1007/s00432-022-04116-9] [Reference Citation Analysis]
262 Hao Y, Zhang X, Yu L. Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. Front Oncol 2022;12:911906. [DOI: 10.3389/fonc.2022.911906] [Reference Citation Analysis]
263 Palamaris K, Alexandris D, Stylianou K, Giatras I, Stofas A, Kaitatzoglou C, Migkou M, Goutas D, Psimenou E, Theodoropoulou E, Theocharis S, Alevizopoulos N, Kastritis E, Gerakis A, Gakiopoulou H. Immune Checkpoint Inhibitors’ Associated Renal Toxicity: A Series of 12 Cases. JCM 2022;11:4786. [DOI: 10.3390/jcm11164786] [Reference Citation Analysis]
264 Ponce A, Frade-sosa B, Sarmiento-monroy JC, Sapena N, Ramírez J, Azuaga AB, Morlà R, Ruiz-esquide V, Cañete JD, Sanmartí R, Gómez-puerta JA. Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis. Diagnostics 2022;12:1961. [DOI: 10.3390/diagnostics12081961] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Mann J, Caruana D, Luo E, Gottesman E, Agrawal N, Lozeau D, Hessel J, Neumann M, Khanijo S, Hasan Z, Rizvi K, Gunther R, Donovan D, Chan D, Lee-wong M, Szema AM. Attenuation of Human Growth Hormone-Induced Rash With Graded Dose Challenge. Cureus 2022. [DOI: 10.7759/cureus.27920] [Reference Citation Analysis]
266 Conway SE, Pua DKA, Holroyd KB, Galetta K, Bhattacharyya S. Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors. Mult Scler 2022;:13524585221117949. [PMID: 35957594 DOI: 10.1177/13524585221117949] [Reference Citation Analysis]
267 Geng D, Wang Y, Zhang X, Zhao C, Fan Y, Liu C, Wei J, Huo B, Zhao Y, Zhang F, Zhang R. Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review. Front Oncol 2022;12:981084. [DOI: 10.3389/fonc.2022.981084] [Reference Citation Analysis]
268 Moss EM, Perazella MA. The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. Front Med 2022;9. [DOI: 10.3389/fmed.2022.964335] [Reference Citation Analysis]
269 Rienzo M, Skirecki T, Monneret G, Timsit JF. Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development. Expert Opin Investig Drugs 2022. [PMID: 35944174 DOI: 10.1080/13543784.2022.2102477] [Reference Citation Analysis]
270 Gao J, Miao J, Sun H, Fu X, Zhang P, Chen Z, Zhu P. TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. Front Immunol 2022;13:955812. [DOI: 10.3389/fimmu.2022.955812] [Reference Citation Analysis]
271 Huang F, Wu J, Cheng X, Wang J, Wen X, Li J, Zhang Q, Jiang H, Ding Q, Zhu X, Zhang X, Ding Y, Li D. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. Front Immunol 2022;13:902167. [DOI: 10.3389/fimmu.2022.902167] [Reference Citation Analysis]
272 Bir Yucel K, Sutcuoglu O, Yazıcı O, Yıldız Y, Şenol E, Uner A. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. J Oncol Pharm Pract 2022;:10781552221118529. [PMID: 35938177 DOI: 10.1177/10781552221118529] [Reference Citation Analysis]
273 Masi G, O'Connor KC. Novel pathophysiological insights in autoimmune myasthenia gravis. Curr Opin Neurol 2022. [PMID: 35942663 DOI: 10.1097/WCO.0000000000001088] [Reference Citation Analysis]
274 Gerasimova EV, Tabakov DV, Gerasimova DA, Popkova TV. Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases. IJMS 2022;23:8656. [DOI: 10.3390/ijms23158656] [Reference Citation Analysis]
275 Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Front Immunol 2022;13:897991. [DOI: 10.3389/fimmu.2022.897991] [Reference Citation Analysis]
276 Weng J, Ajani JA, Murphy MB, Badgwell BD, Tchakarov AS, Mamlouk O, Das P. Immunotherapy Recall: Chemoradiation-Induced Reactivation of Immune Checkpoint Inhibitor Nephritis. JCO Precis Oncol 2022;6:e2200049. [PMID: 35952321 DOI: 10.1200/PO.22.00049] [Reference Citation Analysis]
277 Xiong X, Ke X, Wang L, Lin Y, Wang S, Yao Z, Li K, Luo Y, Liu F, Pan Y, Yeung SJ, Helfrich W, Zhang H. Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles. J Extracell Vesicles 2022;11:e12243. [PMID: 35927827 DOI: 10.1002/jev2.12243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
278 Muñiz-castrillo S, Vogrig A, Ciano-petersen NL, Villagrán-garcía M, Joubert B, Honnorat J. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. Cerebellum 2022;21:573-591. [DOI: 10.1007/s12311-021-01363-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
279 Liang X, Mu M, Fan R, Zou B, Guo G. Functionalized chitosan as a promising platform for cancer immunotherapy: A review. Carbohydrate Polymers 2022;290:119452. [DOI: 10.1016/j.carbpol.2022.119452] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
280 Wu Q, Qu M, Kim HJ, Zhou X, Jiang X, Chen Y, Zhu J, Ren L, Wolter T, Kang H, Xu C, Gu Z, Sun W, Khademhosseini A. A Shear-Thinning Biomaterial-Mediated Immune Checkpoint Blockade. ACS Appl Mater Interfaces 2022. [PMID: 35913267 DOI: 10.1021/acsami.2c06137] [Reference Citation Analysis]
281 Gonçalves Pimenta DA, Carvalho R, Pereira R, Rolo R, Ferreira L. Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma. Monaldi Arch Chest Dis 2022. [DOI: 10.4081/monaldi.2022.2368] [Reference Citation Analysis]
282 Ratanasrimetha P, Reddy VD, Kala J, Tchakarov A, Glass WF, Msaouel P, Lin JS. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol 2022;13:898811. [DOI: 10.3389/fimmu.2022.898811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol 2022;20:242. [PMID: 35897018 DOI: 10.1186/s12957-022-02695-y] [Reference Citation Analysis]
284 Khatoon E, Parama D, Kumar A, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci 2022;:120827. [PMID: 35907493 DOI: 10.1016/j.lfs.2022.120827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Lopez-Olivo MA, Valerio V, Karpes Matusevich AR, Brizio M, Kwok M, Geng Y, Suarez-Almazor ME, Colmegna I. Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis. Vaccines (Basel) 2022;10. [PMID: 36016085 DOI: 10.3390/vaccines10081195] [Reference Citation Analysis]
286 Liu J, Shi Y, Liu X, Zhang D, Zhang H, Chen M, Xu Y, Zhao J, Zhong W, Wang M. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus. Transl Oncol 2022;24:101473. [PMID: 35905639 DOI: 10.1016/j.tranon.2022.101473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Bredin P, Naidoo J. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer Metastasis Rev 2022. [PMID: 35876944 DOI: 10.1007/s10555-022-10039-1] [Reference Citation Analysis]
288 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
289 Wu Y, Zhu W, Wang J, Liu L, Zhang W, Wang Y, Shi J, Xia J, Gu Y, Qian Q, Hong Y. Using machine learning for mortality prediction and risk stratification in atezolizumab‐treated cancer patients: Integrative analysis of eight clinical trials. Cancer Medicine. [DOI: 10.1002/cam4.5060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S, Chen X. Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers 2022;14:3568. [DOI: 10.3390/cancers14153568] [Reference Citation Analysis]
291 Chirra M, Newton HS, Gawali VS, Wise-draper TM, Chimote AA, Conforti L. How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity. Cancers 2022;14:3564. [DOI: 10.3390/cancers14153564] [Reference Citation Analysis]
292 Yang Y, Zhao T, Chen Q, Li Y, Xiao Z, Xiang Y, Wang B, Qiu Y, Tu S, Jiang Y, Nan Y, Huang Q, Ai K. Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC. Advanced Science. [DOI: 10.1002/advs.202202797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
293 Zhou C, Yang Y, Lin X, Fang N, Chen L, Jiang J, Deng H, Deng Y, Wan M, Qiu G, Sun N, Wu D, Long X, Zhong C, Xie X, Xie Z, Liu M, Ouyang M, Qin Y, Petrella F, Fiorelli A, Bravaccini S, Kataoka Y, Watanabe S, Goto T, Solli P, Igai H, Saito Y, Tsoukalas N, Nakada T, Li S, Chen R. Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis. Front Immunol 2022;13:935779. [DOI: 10.3389/fimmu.2022.935779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
294 Abaza Y, Zeidan AM. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Cells 2022;11:2249. [DOI: 10.3390/cells11142249] [Reference Citation Analysis]
295 Jing N, Wang L, Zhuang H, Ai C, Jiang G, Liu Z, Wang R. Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer. Journal of Immunology Research 2022;2022:1-26. [DOI: 10.1155/2022/9202491] [Reference Citation Analysis]
296 Xie X, Wang L, Li Y, Xu Y, Wu J, Lin X, Lin W, Mai Q, Chen Z, Zhang J, Xie Z, Qin Y, Liu M, Lu M, Luo B, Zhou C. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. Front Immunol 2022;13:879900. [DOI: 10.3389/fimmu.2022.879900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
297 Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
298 Bolte FJ, Hall RD, Shah NL. Immune checkpoint inhibitor–related liver toxicity. Clinical Liver Disease. [DOI: 10.1002/cld.1241] [Reference Citation Analysis]
299 Xu J, Cao W, Wang P, Liu H. Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy. Pharmaceuticals (Basel) 2022;15:876. [PMID: 35890175 DOI: 10.3390/ph15070876] [Reference Citation Analysis]
300 Agrawal R, Guzman G, Karimi S, Giulianotti PC, Lora AJM, Jain S, Khan M, Boulay BR, Chen Y. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. World J Clin Cases 2022; 10(20): 7124-7129 [DOI: 10.12998/wjcc.v10.i20.7124] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
301 Nigen B, Chéné AL, Liberge R, Sagan C, Blanc FX. [Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia]. Rev Mal Respir 2022:S0761-8425(22)00258-3. [PMID: 35906150 DOI: 10.1016/j.rmr.2022.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Inamura K, Hamada T, Bullman S, Ugai T, Yachida S, Ogino S. Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. Gut 2022:gutjnl-2022-327209. [PMID: 35820782 DOI: 10.1136/gutjnl-2022-327209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
303 Purcell V, Preti B, Fernandes R. Suspected immune checkpoint inhibitor-induced pulmonary sarcoid reaction in metastatic renal cell carcinoma. Clin Case Rep 2022;10:e5960. [PMID: 35846932 DOI: 10.1002/ccr3.5960] [Reference Citation Analysis]
304 Yamamoto A, Nagashima T, Imai Y, Akitsu K, Yamanaka Z, Nishi H. A case of recurrent endometrial cancer with long-term complete remission following pembrolizumab-induced severe immune-related adverse event colitis. J Obstet Gynaecol Res 2022. [PMID: 35801666 DOI: 10.1111/jog.15346] [Reference Citation Analysis]
305 Long X, Zhang L, Wang WQ, Zhang EL, Lv X, Huang ZY. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review. Onco Targets Ther 2022;15:703-16. [PMID: 35791424 DOI: 10.2147/OTT.S365652] [Reference Citation Analysis]
306 Han CY, Fitzgerald C, Lee M, Valero C, Gönen M, Shoushtari A, Morris LGT. Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. JAMA Oncol 2022. [PMID: 35797031 DOI: 10.1001/jamaoncol.2022.2081] [Reference Citation Analysis]
307 Kim GT, Kim EY, Shin SH, Lee H, Lee SH, Sohn KY, Kim JW. Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma. BMC Cancer 2022;22:727. [PMID: 35787261 DOI: 10.1186/s12885-022-09815-7] [Reference Citation Analysis]
308 Issa M, Tang J, Guo Y, Coss C, Mace TA, Bischof J, Phelps M, Presley CJ, Owen DH. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2022;:1-14. [PMID: 35786142 DOI: 10.1080/14737140.2022.2094772] [Reference Citation Analysis]
309 Wu D, Hu L, Han M, Deng Y, Zhang Y, Ren G, Zhao X, Li Z, Li P, Zhang Y, Chen S, Li J, Shi Y, Xue J, Wang P, Zhong C. PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. Nat Metab 2022. [PMID: 35788761 DOI: 10.1038/s42255-022-00595-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
310 Boland L, Bitterlich LM, Hogan AE, Ankrum JA, English K. Translating MSC Therapy in the Age of Obesity. Front Immunol 2022;13:943333. [DOI: 10.3389/fimmu.2022.943333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Andón FT, Leon S, Ummarino A, Redin E, Allavena P, Serrano D, Anfray C, Calvo A. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists. Biomedicines 2022;10:1590. [DOI: 10.3390/biomedicines10071590] [Reference Citation Analysis]
312 Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study. Ann Rheum Dis 2022:annrheumdis-2022-222186. [PMID: 35788496 DOI: 10.1136/ard-2022-222186] [Reference Citation Analysis]
313 Grunhut J, Brown S, Lutzky J, Skoczylas L. Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neck. BMJ Case Rep 2022;15:e249411. [DOI: 10.1136/bcr-2022-249411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Pluye M, Gouraud A, Herve M, Le H, Dagonneau T, Dalle S, Cottin J, Cucherat M, Atzenhoffer M. Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort. Therapies 2022. [DOI: 10.1016/j.therap.2022.07.001] [Reference Citation Analysis]
315 Montera MW, Marcondes-Braga FG, Simões MV, Moura LAZ, Fernandes F, Mangine S, Oliveira Júnior AC, Souza ALAAG, Ianni BM, Rochitte CE, Mesquita CT, de Azevedo Filho CF, Freitas DCA, Melo DTP, Bocchi EA, Horowitz ESK, Mesquita ET, Oliveira GH, Villacorta H, Rossi Neto JM, Barbosa JMB, Figueiredo Neto JA, Luiz LF, Hajjar LA, Beck-da-Silva L, Campos LAA, Danzmann LC, Bittencourt MI, Garcia MI, Avila MS, Clausell NO, Oliveira NA Jr, Silvestre OM, Souza OF, Mourilhe-Rocha R, Kalil Filho R, Al-Kindi SG, Rassi S, Alves SMM, Ferreira SMA, Rizk SI, Mattos TAC, Barzilai V, Martins WA, Schultheiss HP. Brazilian Society of Cardiology Guideline on Myocarditis - 2022. Arq Bras Cardiol 2022;119:143-211. [PMID: 35830116 DOI: 10.36660/abc.20220412] [Reference Citation Analysis]
316 Rali A, Huang Y, Yeh S. Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. Int Ophthalmol Clin 2022;62:49-63. [PMID: 35752885 DOI: 10.1097/IIO.0000000000000434] [Reference Citation Analysis]
317 Alruwaii ZI, Montgomery EA. Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. Adv Anat Pathol 2022;29:183-93. [PMID: 35470287 DOI: 10.1097/PAP.0000000000000346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Joly F, Michot J, Dourthe LM, Fléchon A, Mahammedi H, Maillet D, Mouillet G, Pouessel D, Rolland F, Topart D, Albiges L. Cancer du rein métastatique : gestion des toxicités des combinaisons. Bulletin du Cancer 2022;109:844-861. [DOI: 10.1016/j.bulcan.2022.04.019] [Reference Citation Analysis]
319 Reeves DJ, Rao VU. Update on cancer therapy-induced atherosclerosis. Curr Opin Cardiol 2022;37:372-9. [PMID: 35731682 DOI: 10.1097/HCO.0000000000000969] [Reference Citation Analysis]
320 Liu X, Wu W, Fang L, Liu Y, Chen W. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. Front Immunol 2022;13:922782. [DOI: 10.3389/fimmu.2022.922782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
321 Upshaw JN, Mohanty S, Rastogi A. Cardioprotection of High-Risk Individuals. Heart Fail Clin 2022;18:385-402. [PMID: 35718414 DOI: 10.1016/j.hfc.2022.02.001] [Reference Citation Analysis]
322 Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00382-5] [Reference Citation Analysis]
323 Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, Wauters E, Staessen J, Janssens S, Van Aelst L. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. J Clin Oncol 2022;:JCO2101808. [PMID: 35772044 DOI: 10.1200/JCO.21.01808] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
324 Stefanile A, Cellerino M, Koudriavtseva T. Elevated risk of thrombotic manifestations of SARS-CoV-2 infection in cancer patients: A literature review. EXCLI J 2022;21:906-20. [PMID: 36172074 DOI: 10.17179/excli2022-5073] [Reference Citation Analysis]
325 Tang Q, Peng X, Xu B, Zhou X, Chen J, Cheng L. Current Status and Future Directions of Bacteria-Based Immunotherapy. Front Immunol 2022;13:911783. [PMID: 35757741 DOI: 10.3389/fimmu.2022.911783] [Reference Citation Analysis]
326 Tampe D, Kopp SB, Baier E, Hakroush S, Tampe B. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity. Front Med (Lausanne) 2022;9:902256. [PMID: 35755033 DOI: 10.3389/fmed.2022.902256] [Reference Citation Analysis]
327 Huang W, Xu R, Zhou B, Lin C, Guo Y, Xu H, Guo X. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Front Cardiovasc Med 2022;9:912329. [PMID: 35757327 DOI: 10.3389/fcvm.2022.912329] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han SJ, Collins N, Belkaid Y. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc Natl Acad Sci U S A 2022;119:e2200348119. [PMID: 35727974 DOI: 10.1073/pnas.2200348119] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
329 Manenti S, Orrico M, Masciocchi S, Mandelli A, Finardi A, Furlan R. PD-1/PD-L Axis in Neuroinflammation: New Insights. Front Neurol 2022;13:877936. [PMID: 35756927 DOI: 10.3389/fneur.2022.877936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Chung CK, Beekmann U, Kralisch D, Bierau K, Chan A, Ossendorp F, Cruz LJ. Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies. Pharmaceutics 2022;14:1351. [DOI: 10.3390/pharmaceutics14071351] [Reference Citation Analysis]
331 Shen T, Zhang J, Wang Y, Liu B. FCGBP Is a Promising Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Oral Squamous Cell Carcinoma. J Immunol Res 2022;2022:8443392. [PMID: 35733916 DOI: 10.1155/2022/8443392] [Reference Citation Analysis]
332 Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022. [PMID: 35736631 DOI: 10.3322/caac.21731] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 34.0] [Reference Citation Analysis]
333 Ai Q, Chen W, Li Y, Li G. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis. Front Immunol 2022;13:840916. [PMID: 35720298 DOI: 10.3389/fimmu.2022.840916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Les I, Pérez-Francisco I, Cabero M, Sánchez C, Hidalgo M, Teijeira L, Arrazubi V, Domínguez S, Anaut P, Eguiluz S, Elejalde I, Herrera A, Martínez M. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. Front Pharmacol 2022;13:894550. [PMID: 35721217 DOI: 10.3389/fphar.2022.894550] [Reference Citation Analysis]
335 Wang J, He Y, Zhang B, Lv H, Nie C, Chen B, Xu W, Zhao J, Cheng X, Li Q, Tu S, Chen X. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. Front Oncol 2022;12:924149. [PMID: 35719979 DOI: 10.3389/fonc.2022.924149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Kuo AM, Kraehenbuehl L, King S, Leung DYM, Goleva E, Moy AP, Lacouture ME, Shah NJ, Faleck DM. Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. Cancers (Basel) 2022;14:2995. [PMID: 35740660 DOI: 10.3390/cancers14122995] [Reference Citation Analysis]
337 Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis CC, Ascierto PA, Eggermont AMM, Grob JJ, Hauschild A, Sekulovic LK, Long GV, Luke JJ, Michielin O, Peris K, Schadendorf D, Kirkwood JM, Lorigan PC. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022;:JCO2200202. [PMID: 35709414 DOI: 10.1200/JCO.22.00202] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
338 Gómez-puerta JA, Lobo-prat D, Perez-garcía C, Ponce A, Frade-sosa B, Millán Arciniegas AM, Ojeda F, Ruiz-esquide V, Corominas H. Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study. Front Med 2022;9:888377. [DOI: 10.3389/fmed.2022.888377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
339 Cardeña-gutiérrez A, López Barahona M. Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. Front Med 2022;9:908752. [DOI: 10.3389/fmed.2022.908752] [Reference Citation Analysis]
340 Bermejo S, Bolufer M, Riveiro-barciela M, Soler MJ. Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment? Front Med 2022;9:906565. [DOI: 10.3389/fmed.2022.906565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Falotico JM, Lipner SR. The pharmacotherapeutic management of nail unit and acral melanomas. Expert Opin Pharmacother 2022;:1-17. [PMID: 35702037 DOI: 10.1080/14656566.2022.2088279] [Reference Citation Analysis]
342 Gao RW, Day CN, Yu NY, Bush A, Amundson AC, Prodduturvar P, Majeed U, Butts E, Oliver T, Schwecke AJ, Moffett JN, Routman DM, Breen WG, Potter AL, Rivera-Concepcion J, Hoppe BS, Schild SE, Sio TT, Lou Y, Ernani V, Ko S, Olivier KR, Merrell KW, Garces YI, Manochakian R, Harmsen WS, Leventakos K, Owen D. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab. Lung Cancer 2022;170:58-64. [PMID: 35716632 DOI: 10.1016/j.lungcan.2022.06.003] [Reference Citation Analysis]
343 Gao Y, Pan J, Shen D, Peng L, Mao Z, Wang C, Meng H, Zhou Q, Chen S. Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature. Brain Sci 2022;12:773. [PMID: 35741658 DOI: 10.3390/brainsci12060773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
344 Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022;27:3798. [PMID: 35744922 DOI: 10.3390/molecules27123798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
345 Tyan K, Abu-Shawer O, Baginska J, Severgnini M, Manos M, Vaitkevicius H, Grover S, Hodi FS, Rahma OE. Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling. Immunotherapy 2022. [PMID: 35695027 DOI: 10.2217/imt-2021-0298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol 2022;15:80. [PMID: 35690784 DOI: 10.1186/s13045-022-01298-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
347 Dong Y, Liu D, Zhou H, Gao Y, Nueraihemaiti Y, Xu Y. A Prognostic Signature for Clear Cell Renal Cell Carcinoma Based on Ferroptosis-Related lncRNAs and Immune Checkpoints. Front Genet 2022;13:912190. [PMID: 35685438 DOI: 10.3389/fgene.2022.912190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
348 Vistoso Monreal A, Polonsky G, Shiboski C, Sankar V, Villa A. Salivary Gland Dysfunction Secondary to Cancer Treatment. Front Oral Health 2022;3:907778. [DOI: 10.3389/froh.2022.907778] [Reference Citation Analysis]
349 Xu Y, Song Y, Liu X, Shi Y, Liu Y, Qian H, Gao X, Chen M, Pan R, Zhao J, Zhong W, Wu W, Wang M. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis. Cancer Commun (Lond) 2022. [PMID: 35678260 DOI: 10.1002/cac2.12320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Dimitriou F, Hauschild A, Mehnert JM, Long GV. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. Am Soc Clin Oncol Educ Book 2022;42:1-22. [PMID: 35658500 DOI: 10.1200/EDBK_351123] [Reference Citation Analysis]
351 Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S, Ohdo S. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Mol Cancer Res 2022;20:972-82. [PMID: 35190830 DOI: 10.1158/1541-7786.MCR-21-0786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
352 Tyebally S, Ghose A, Chen DH, Abiodun AT, Ghosh AK. Chest Pain in the Cancer Patient. Eur Cardiol 2022;17:e15. [DOI: 10.15420/ecr.2021.45] [Reference Citation Analysis]
353 Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, Wong A, Yang SP. Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers 2022;14:2687. [DOI: 10.3390/cancers14112687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
354 Li S, Zhu Y, Xu Z, Liu J, Liu H. Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. Front Oncol 2022;12:866013. [PMID: 35619897 DOI: 10.3389/fonc.2022.866013] [Reference Citation Analysis]
355 Sagiv-Barfi I, Czerwinski DK, Shree T, Lohmeyer JJK, Levy R. Intratumoral immunotherapy relies on B and T cell collaboration. Sci Immunol 2022;7:eabn5859. [PMID: 35622903 DOI: 10.1126/sciimmunol.abn5859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Zhou X, Chen X, Han L, Liu H. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. Clin Sci (Lond) 2022;136:771-85. [PMID: 35621125 DOI: 10.1042/CS20210042] [Reference Citation Analysis]
357 Liu Y, Li R, Wang X, Xue Z, Yang X, Tang B. Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:824938. [DOI: 10.3389/fcell.2022.824938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Huang P, Xu L, Jin M, Li L, Ke Y, Zhang M, Zhang K, Lu K, Huang G. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. Genes 2022;13:951. [DOI: 10.3390/genes13060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Muir CA, Tsang VHM, Menzies AM, Clifton-bligh RJ. Immune Related Adverse Events of the Thyroid – A Narrative Review. Front Endocrinol 2022;13:886930. [DOI: 10.3389/fendo.2022.886930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review. JAMA Dermatol 2022. [PMID: 35612829 DOI: 10.1001/jamadermatol.2022.1624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Tew A, Khoja L, Pallan L, Steven N. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. J Oncol Pharm Pract 2022;:10781552221103548. [PMID: 35607278 DOI: 10.1177/10781552221103548] [Reference Citation Analysis]
362 Shim MK, Song SK, Jeon SI, Hwang KY, Kim K. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2081683] [Reference Citation Analysis]
363 Zhang Z, Liu F, Chen W, Liao Z, Zhang W, Zhang B, Liang H, Chu L, Zhang Z. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy. Exp Hematol Oncol 2022;11:30. [PMID: 35590394 DOI: 10.1186/s40164-022-00281-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
364 Li H, Sahu KK, Maughan BL. Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. Cancers (Basel) 2022;14:2460. [PMID: 35626064 DOI: 10.3390/cancers14102460] [Reference Citation Analysis]
365 Liu Y, Long K, Kang W, Wang T, Wang W. Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization. Advanced NanoBiomed Research. [DOI: 10.1002/anbr.202200017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Morisaki T, Morisaki T, Kubo M, Morisaki S, Nakamura Y, Onishi H. Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. Cancers 2022;14:2438. [DOI: 10.3390/cancers14102438] [Reference Citation Analysis]
367 Alekseenko IV, Pleshkan VV, Kuzmich AI, Kondratieva SA, Sverdlov ED. Gene-Immune Therapy of Cancer: Approaches and Problems. Russ J Genet 2022;58:491-506. [DOI: 10.1134/s1022795422040020] [Reference Citation Analysis]
368 Lee JH, Baek SK, Han JJ, Kim HJ, Lee YA, Yoo D, Maeng CH. Lambert-Eaton myasthenic syndrome (LEMS) in a patient with lung cancer under treatment with pembrolizumab: a case study. J Chemother 2022;:1-6. [PMID: 35549636 DOI: 10.1080/1120009X.2022.2073162] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022;40:509-523.e6. [PMID: 35537412 DOI: 10.1016/j.ccell.2022.04.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
370 Xu Y, Chen C, Guo Y, Hu S, Sun Z. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. Front Immunol 2022;13:848327. [PMID: 35300341 DOI: 10.3389/fimmu.2022.848327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Dai X, Li X, Liu Y, Yan F. Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy. Materials & Design 2022;217:110656. [DOI: 10.1016/j.matdes.2022.110656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Spallone A, Alotaibi AS, Jiang Y, Daver N, Kontoyiannis DP. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors. Clinical Lymphoma Myeloma and Leukemia 2022;22:305-310. [DOI: 10.1016/j.clml.2021.10.012] [Reference Citation Analysis]
373 Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology 2022;19:101383. [DOI: 10.1016/j.tranon.2022.101383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Brito MHD. Neurologic adverse events of cancer immunotherapy. Arq Neuro-Psiquiatr 2022;80:270-280. [DOI: 10.1590/0004-282x-anp-2022-s116] [Reference Citation Analysis]
375 Rodrigo-aliaga M, Bosquet-sanz M, Barrios-arnau L, Sánchez-llopis A, Ponce-blasco P, Monsonís-usó R, Planelles-soler P, Garau-perelló C. Desarrollo e implementación de una unidad de inmunoterapia en un servicio de urología. Actas Urológicas Españolas 2022. [DOI: 10.1016/j.acuro.2022.03.001] [Reference Citation Analysis]
376 Wang CW, Divito SJ, Chung WH, Hung SI. Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. Immunol Allergy Clin North Am 2022;42:357-73. [PMID: 35469623 DOI: 10.1016/j.iac.2022.01.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Hayashi-tanner Y, Polewski PJ, Gaddam M, Fisher NR, Kovacs AJ, Marinier DE. Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.05.007] [Reference Citation Analysis]
378 Mccrae KR, Swaidani S, Diaz-montero CM, Khorana AA. Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. Thrombosis Research 2022;213:S51-7. [DOI: 10.1016/j.thromres.2022.01.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
379 Xiao Z, Wang D, Wang C, Chen Z, Huang C, Yang Y, Xie L, Zhang L, Xu L, Zhang M, Hu K, Li Z, Luo L. PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
380 Chan KK, Bass AR. Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. JIR 2022;Volume 15:3105-18. [DOI: 10.2147/jir.s282600] [Reference Citation Analysis]
381 Hou Y, Liu Y, Tang C, Tan Y, Zheng X, Deng Y, He N, Li S. Recent advance in nanomaterials for cancer immunotherapy. Chemical Engineering Journal 2022;435:134145. [DOI: 10.1016/j.cej.2021.134145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
382 Ruan S, Huang Y, He M, Gao H. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. Adv Sci (Weinh) 2022;9:e2200027. [PMID: 35343112 DOI: 10.1002/advs.202200027] [Reference Citation Analysis]
383 Sirgi Y, Krochmal R, Fleury CM, Holmes M, Dewitt CA, Cardis M, Kim C. Pembrolizumab-associated cutaneous and pulmonary sarcoidosis in non-small cell lung cancer treatment. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.05.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 Zeng W, Li Z, Chen H, Zeng X, Mei L. An optimal portfolio of photothermal combined immunotherapy. Cell Reports Physical Science 2022. [DOI: 10.1016/j.xcrp.2022.100898] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Fattizzo B, Rampi N, Barcellini W. Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. Pharmaceuticals 2022;15:557. [DOI: 10.3390/ph15050557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Cho YT, Lin YT, Yang CW, Chu CY. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit. Sci Rep 2022;12:7021. [PMID: 35487955 DOI: 10.1038/s41598-022-11128-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Teimouri A, Minard LV, Scott SN, Daniels A, Snow S. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. Current Oncology 2022;29:3104-17. [DOI: 10.3390/curroncol29050252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
388 Yamada H, Washino S, Suzuki D, Saikawa R, Tonezawa S, Hagiwara R, Funazaki S, Yoshida M, Konishi T, Saito K, Miyagawa T, Hara K. Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma. BMC Endocr Disord 2022;22:110. [PMID: 35468815 DOI: 10.1186/s12902-022-01024-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
389 Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03203-7] [Reference Citation Analysis]
390 Quaquarini E, Sottotetti F, Agustoni F, Pozzi E, Malovini A, Teragni CM, Palumbo R, Saltalamacchia G, Tagliaferri B, Balletti E, Rinaldi P, Canino C, Pedrazzoli P, Bernardo A. Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study. JPM 2022;12:679. [DOI: 10.3390/jpm12050679] [Reference Citation Analysis]
391 Mulder EEAP, Damman J, Verver D, van der Veldt AAM, Tas S, Khemai-Mehraban T, Heezen KC, Wouters RA, Verhoef C, Verjans GMGM, Langerak AW, Grünhagen DJ, Mooyaart AL. Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. Melanoma Res 2022. [PMID: 35446267 DOI: 10.1097/CMR.0000000000000824] [Reference Citation Analysis]
392 Ballman M, Zhao C, McAdams MJ, Rajan A. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword. Cancers (Basel) 2022;14:2060. [PMID: 35565190 DOI: 10.3390/cancers14092060] [Reference Citation Analysis]
393 Katariya NN, Lizaola-Mayo BC, Chascsa DM, Giorgakis E, Aqel BA, Moss AA, Uson Junior PLS, Borad MJ, Mathur AK. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers (Basel) 2022;14:2056. [PMID: 35565184 DOI: 10.3390/cancers14092056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
394 Levy DA, Patel JJ, Nguyen SA, Nicholas Jungbauer W, Neskey DM, Cohen EEW, Paulos CM, Kaczmar JA, Knochelmann HM, Day TA. Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis. World j otorhinolaryngol -head neck surg . [DOI: 10.1002/wjo2.15] [Reference Citation Analysis]
395 Tzoras E, Zerdes I, Tsiknakis N, Manikis GC, Mezheyeuski A, Bergh J, Matikas A, Foukakis T. Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers 2022;14:1999. [DOI: 10.3390/cancers14081999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Badiee P, Maritz MF, Dmochowska N, Cheah E, Thierry B. Intratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution. ACS Appl Mater Interfaces 2022;14:15881-93. [PMID: 35357803 DOI: 10.1021/acsami.1c22479] [Reference Citation Analysis]
397 Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N, Yamada S. Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. Front Pharmacol 2022;13:803706. [PMID: 35401222 DOI: 10.3389/fphar.2022.803706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Ghosh N, Bass AR. Rheumatic Complications of Immune Checkpoint Inhibitors. Rheum Dis Clin North Am 2022;48:411-28. [PMID: 35400368 DOI: 10.1016/j.rdc.2022.02.002] [Reference Citation Analysis]
399 Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Zarif TE, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani A, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with immunotherapy-related adverse events.. [DOI: 10.1101/2022.04.10.22273627] [Reference Citation Analysis]
400 Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D, Li X, Yin J. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01561-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
401 Connolly KA, Fitzgerald B, Damo M, Joshi NS. Novel Mouse Models for Cancer Immunology. Annu Rev Cancer Biol 2022;6:269-291. [DOI: 10.1146/annurev-cancerbio-070620-105523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, Li X, Chen X. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. Front Immunol 2022;13:840313. [PMID: 35222434 DOI: 10.3389/fimmu.2022.840313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
403 Bai X, Zhou Y, Yokota Y, Matsumoto Y, Zhai B, Maarouf N, Hayashi H, Carlson R, Zhang S, Sousa A, Sun B, Ghanbari H, Dong X, Wands JR. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. J Exp Clin Cancer Res 2022;41:132. [PMID: 35392977 DOI: 10.1186/s13046-022-02307-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Lyon JF, Basnet A. Acquired Hemophilia as a Paraneoplastic Syndrome in a Patient With Small Cell Lung Carcinoma. Cureus 2022. [DOI: 10.7759/cureus.23926] [Reference Citation Analysis]
405 Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 2022;20:44. [PMID: 35392976 DOI: 10.1186/s12964-022-00854-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
406 Araújo FC, Afonso PD. Sacroiliitis as an immune-related adverse event of pembrolizumb treatment for melanoma. Scand J Rheumatol 2022;:1-2. [PMID: 35383526 DOI: 10.1080/03009742.2022.2053301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Duarte HS, Veiga CRP, Veiga CP, Wainstein AJA, Drummond-Lage AP. Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study. Int Immunopharmacol 2022;108:108727. [PMID: 35397393 DOI: 10.1016/j.intimp.2022.108727] [Reference Citation Analysis]
408 Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther 2022;7:117. [PMID: 35387984 DOI: 10.1038/s41392-022-00951-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
409 Moser K, Soto M, Geba D, Allen P, Lindpaintner K. Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors.. [DOI: 10.1101/2022.04.01.22269254] [Reference Citation Analysis]
410 Ye Z, Zheng S, Chen J, Zhang Y, Yang S, Hong Y, Yang H, Xuan Z, Zhao Q. Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients? Int Immunopharmacol 2022;108:108738. [PMID: 35395468 DOI: 10.1016/j.intimp.2022.108738] [Reference Citation Analysis]
411 Lu C, Zhang YC, Chen ZH, Zhou Q, Wu YL. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. Front Oncol 2022;12:836891. [PMID: 35359372 DOI: 10.3389/fonc.2022.836891] [Reference Citation Analysis]
412 Glezerman IG, Gutgarts V. Acute Kidney Injury in Cancer Patients. nephsap 2022;21:100-107. [DOI: 10.1681/nsap.2022.21.1.8] [Reference Citation Analysis]
413 Emery J, Butow P, Lai-kwon J, Nekhlyudov L, Rynderman M, Jefford M. Management of common clinical problems experienced by survivors of cancer. The Lancet 2022;399:1537-50. [DOI: 10.1016/s0140-6736(22)00242-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
414 Juan-carpena G, Palazón-cabanes J, Blanes-martínez M. [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review. Actas Dermo-Sifiliográficas 2022;113:T376-T387. [DOI: 10.1016/j.ad.2021.09.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Nusrat S, Borogovac A, George JN, Curtis BR, Reese JA. Drug (vaccine)-induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features. Am J Hematol 2022;97:E162-5. [PMID: 35092624 DOI: 10.1002/ajh.26482] [Reference Citation Analysis]
416 Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y, Shi M, Liao W, Huang N. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis. Front Pharmacol 2022;13:817662. [DOI: 10.3389/fphar.2022.817662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
417 Kyu Shim M, Yang S, Sun IC, Kim K. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery. Adv Drug Deliv Rev 2022;183:114177. [PMID: 35245568 DOI: 10.1016/j.addr.2022.114177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
418 Juan-carpena G, Palazón-cabanes J, Blanes-martínez M. Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico. Actas Dermo-Sifiliográficas 2022;113:376-387. [DOI: 10.1016/j.ad.2021.09.005] [Reference Citation Analysis]
419 Serino M, Freitas C, Martins M, Ferreira P, Cardoso C, Veiga F, Santos V, Araújo D, Novais-bastos H, Magalhães A, Queiroga H, Fernandes G, Hespanhol V. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.03.003] [Reference Citation Analysis]
420 Yamaguchi Y. Exploring the deeper linkage between adverse drug reactions and autoimmune diseases. Allergol Int 2022;71:161-2. [PMID: 35272956 DOI: 10.1016/j.alit.2022.02.003] [Reference Citation Analysis]
421 Sueki H, Watanabe Y, Sugiyama S, Mizukawa Y. Drug allergy and non-HIV immune reconstitution inflammatory syndrome. Allergol Int 2022;71:185-92. [PMID: 35236619 DOI: 10.1016/j.alit.2021.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Xu H, Feng H, Zhang W, Wei F, Zhou L, Liu L, Zhao Y, Lv Y, Shi X, Zhang J, Ren X. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
423 Hu M, Huang L. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Adv Drug Deliv Rev 2022;183:114137. [PMID: 35143893 DOI: 10.1016/j.addr.2022.114137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
424 Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 2022;71:169-78. [PMID: 35101349 DOI: 10.1016/j.alit.2022.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
425 Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 2022;10:540. [DOI: 10.3390/vaccines10040540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
426 Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R, Chandra AB. Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge. Biomedicines 2022;10:790. [DOI: 10.3390/biomedicines10040790] [Reference Citation Analysis]
427 Cheng KH, Contreras GP, Yeh TY. Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology. Int J Mol Sci 2022;23:3573. [PMID: 35408933 DOI: 10.3390/ijms23073573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
428 Barnabei A, Strigari L, Corsello A, Paragliola RM, Falzone L, Salvatori R, Corsello SM, Torino F. Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose? Front Oncol 2022;12:798517. [PMID: 35311088 DOI: 10.3389/fonc.2022.798517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S, Lu S. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol 2022. [PMID: 35311347 DOI: 10.2217/fon-2021-1336] [Reference Citation Analysis]
430 Xue T, Zhang Z, Fang T, Li B, Li Y, Li L, Jiang Y, Duan F, Meng F, Liang X, Zhang X. Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer. Nano Res . [DOI: 10.1007/s12274-022-4182-0] [Reference Citation Analysis]
431 Yamazaki T, Abue M, Itoh S, Sato I. A Case in which Mycophenolate Mofetil Administration Was Effective against Steroid-Refractory Liver Dysfunction Arising as a Nivolumab-Induced Immune-Related Adverse Event. Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) 2022;125:285-290. [DOI: 10.3950/jibiinkotokeibu.125.3_285] [Reference Citation Analysis]
432 Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol 2022;15:24. [PMID: 35279217 DOI: 10.1186/s13045-022-01242-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 37.0] [Reference Citation Analysis]
433 Kristan MM, Toro-Tobon D, Francis N, Desale S, Bikas A, Jonklaas J, Goyal RM. Immunotherapy-Associated Hypothyroidism: Comparison of the Pre-Existing With De-Novo Hypothyroidism. Front Endocrinol (Lausanne) 2022;13:798253. [PMID: 35360059 DOI: 10.3389/fendo.2022.798253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Zhou Y, Liu Z, Chen T. Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Front Oncol 2022;12:847350. [PMID: 35252014 DOI: 10.3389/fonc.2022.847350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Loo K, Smithy JW, Postow MA, Betof Warner A. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Front Immunol 2021;12:810388. [PMID: 35087529 DOI: 10.3389/fimmu.2021.810388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
436 Zhou H, Liu Z, Wang Y, Wen X, Amador EH, Yuan L, Ran X, Xiong L, Ran Y, Chen W, Wen Y. Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Target Ther 2022;7:70. [PMID: 35246503 DOI: 10.1038/s41392-022-00922-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
437 Grümme L, Schulze-koops H. Checkpoint-Inhibitoren beim malignen Melanom: Rheumatologische Symptome beherrschen. Deutsches Ärzteblatt Online 2022. [DOI: 10.3238/personko.2022.03.04.02] [Reference Citation Analysis]
438 Sun Z, Xie C, Liu H, Yuan X. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report. Front Immunol 2022;13:778192. [PMID: 35154102 DOI: 10.3389/fimmu.2022.778192] [Reference Citation Analysis]
439 Meilhac A, Cautela J, Thuny F. Cancer Therapies and Vascular Toxicities. Curr Treat Options Oncol 2022. [PMID: 35244888 DOI: 10.1007/s11864-022-00964-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
440 Lerner A, Benzvi C. Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. Biomedicines 2022;10:609. [DOI: 10.3390/biomedicines10030609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
441 Li X, Sinha S, Thirumalai D. Universality of distribution of tumor mutation burden - a biomarker for the tumor evolution and disease risk.. [DOI: 10.1101/2022.03.03.482775] [Reference Citation Analysis]
442 Zheng H, Luo W, Li Y, Peng G, Zhou D, Tang D, Cheng J, Wu S. Identification and Development of Inflammatory Response–Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer. Front Cell Dev Biol 2022;10:837849. [DOI: 10.3389/fcell.2022.837849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Nguyen AH, Sagvand BT, Hwang DG, Legesse T, Cross RK. Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection. ACG Case Rep J 2022;9:e00747. [PMID: 35224125 DOI: 10.14309/crj.0000000000000747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
444 Zhang H, Lin J, Shen Y, Pan J, Wang C, Cheng L. Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway. JIR 2022;Volume 15:1653-66. [DOI: 10.2147/jir.s348464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
445 Fan Z, Wu C, Chen M, Jiang Y, Wu Y, Mao R, Fan Y. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B 2022;12:1041-53. [PMID: 35530130 DOI: 10.1016/j.apsb.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Sun X, Song Z, Jiang H, Ma Y, Chen M. Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients. Clinical Imaging 2022. [DOI: 10.1016/j.clinimag.2022.03.012] [Reference Citation Analysis]
447 Lou S, Wang Y, Zhang J, Yin X, Zhang Y, Wang Y, Xue Y. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. Front Immunol 2021;12:806324. [PMID: 35082793 DOI: 10.3389/fimmu.2021.806324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
448 Lomas-francis C, Westhoff CM. Red Cell Antigens and Antibodies. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.12.002] [Reference Citation Analysis]
449 Avelino AR, Elmanaseer O, Wrzesinski S, Raval M. T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizumab). BMJ Case Rep 2022;15:e245603. [DOI: 10.1136/bcr-2021-245603] [Reference Citation Analysis]
450 Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology 2022;75:531-40. [PMID: 34709662 DOI: 10.1002/hep.32215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
451 Jung M, Kang M, Kim BS, Hong J, Kim C, Koh CH, Choi G, Chung Y, Kim BS. Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. Adv Mater 2022;34:e2106516. [PMID: 34962660 DOI: 10.1002/adma.202106516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Park BC, Stone CA, Dewan AK, Johnson DB. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America 2022. [DOI: 10.1016/j.iac.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Taylor BC, Balko JM. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Front Immunol 2022;13:844866. [DOI: 10.3389/fimmu.2022.844866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
454 Villa-Crespo L, Podlipnik S, Anglada N, Izquierdo C, Giavedoni P, Iglesias P, Dominguez M, Aya F, Arance A, Malvehy J, Puig S, Carrera C. Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival. Cancers (Basel) 2022;14:1237. [PMID: 35267545 DOI: 10.3390/cancers14051237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, Kume H. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis. J Immunother Cancer 2022;10:e003965. [PMID: 35210308 DOI: 10.1136/jitc-2021-003965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
456 Wang T, Xu H. Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy. Exploration of Medicine. [DOI: 10.37349/emed.2022.00076] [Reference Citation Analysis]
457 Mosaferi T, Tsai K, Sovich S, Wilhalme H, Kathuria-Prakash N, Praw SS, Drakaki A, Angell TE, Lechner MG. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. Thyroid 2022;32:496-504. [PMID: 35199588 DOI: 10.1089/thy.2021.0685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
458 Wing JR, Kimball A, Rengarajan M. Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia. N Engl J Med 2022;386:781-7. [PMID: 35196431 DOI: 10.1056/NEJMcpc2115848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
459 Li C, Bhatti SA, Ying J. Immune Checkpoint Inhibitors-Associated Cardiotoxicity. Cancers (Basel) 2022;14:1145. [PMID: 35267453 DOI: 10.3390/cancers14051145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
460 Makunda N, Vallabhaneni S, Lefebvre B, Fradley MG. Cardiotoxicity of Systemic Melanoma Treatments. Curr Treat Options Oncol 2022. [PMID: 35192138 DOI: 10.1007/s11864-021-00924-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
461 Koh Y, Nakano K, Katayama K, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T, Hatano K, Kawashima A, Ujike T, Imamura R, Yamaguchi R, Imoto S, Shiotsu Y, Nonomura N, Uemura M. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. Int J of Urology. [DOI: 10.1111/iju.14816] [Reference Citation Analysis]
462 Shi J, Lai D, Zuo X, Liu D, Chen B, Zheng Y, Lu C, Gu X. Identification of Ferroptosis-Related Biomarkers for Prognosis and Immunotherapy in Patients With Glioma. Front Cell Dev Biol 2022;10:817643. [PMID: 35174152 DOI: 10.3389/fcell.2022.817643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
463 Barnabei A, Corsello A, Paragliola RM, Iannantuono GM, Falzone L, Corsello SM, Torino F. Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. Cancers (Basel) 2022;14:1057. [PMID: 35205804 DOI: 10.3390/cancers14041057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Grümme L, Schulze-koops H. Checkpoint-Inhibitoren in der Onkologie: Rheumatologische Symptome beherrschen. Deutsches Ärzteblatt Online 2022. [DOI: 10.3238/personko.2022.02.18.03] [Reference Citation Analysis]
465 Zhu S, Bian L, Lv J, Liu B, Shen J. A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors. Front Immunol 2021;12:788629. [PMID: 35003107 DOI: 10.3389/fimmu.2021.788629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
466 Glare P, Aubrey K, Gulati A, Lee YC, Moryl N, Overton S. Pharmacologic Management of Persistent Pain in Cancer Survivors. Drugs 2022. [PMID: 35175587 DOI: 10.1007/s40265-022-01675-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
467 Huang S, Jordan A, Jenneman D, Shafique M, Holmstrom B. Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. Cureus 2022. [DOI: 10.7759/cureus.22295] [Reference Citation Analysis]
468 Chan P, Peskov K, Song X. Applications of Model-Based Meta-Analysis in Drug Development. Pharm Res 2022. [PMID: 35174432 DOI: 10.1007/s11095-022-03201-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
469 Gilon D, Iakobishvili Z, Leibowitz D. The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. Vaccines 2022;10:304. [DOI: 10.3390/vaccines10020304] [Reference Citation Analysis]
470 Ansel S, Rulach R, Trotter N, Steele N. Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion. J Oncol Pharm Pract 2022;:10781552221079356. [PMID: 35167399 DOI: 10.1177/10781552221079356] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
471 Küçükarda A, Gökmen İ, Özcan E, Peker P, Akgül F, Çiçin İ. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma. Immunotherapy. [DOI: 10.2217/imt-2021-0275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
472 Ding J, Wang T, Chen Z, Lin Z, Chen X, He C. Enhanced antitumor chemo‐immunotherapy by local co‐delivery of chemotherapeutics, immune checkpoint blocking antibody and IDO inhibitor using an injectable polypeptide hydrogel. Journal of Polymer Science. [DOI: 10.1002/pol.20210955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
473 Meftahpour V, Aghebati-Maleki A, Fotouhi A, Safarzadeh E, Aghebati-Maleki L. Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma. EXCLI J 2022;21:250-68. [PMID: 35145371 DOI: 10.17179/excli2021-4094] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
474 Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Front Immunol 2021;12:800879. [PMID: 34992611 DOI: 10.3389/fimmu.2021.800879] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
475 Sagie S, Gadot M, Levartovsky M, Gantz Sorotsky H, Berger R, Sarfaty M, Percik R. Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2022;14:875. [PMID: 35205622 DOI: 10.3390/cancers14040875] [Reference Citation Analysis]
476 Schagen SB, Tsvetkov AS, Compter A, Wefel JS. Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach? Nat Rev Neurol 2022. [PMID: 35140379 DOI: 10.1038/s41582-021-00617-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
477 Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res 2022;41:56. [PMID: 35139879 DOI: 10.1186/s13046-022-02273-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
478 Fernández Madrigal L, Montero Pérez O, Rodriguez Garcés MY, Inoriza Rueda Á, Martínez Marcos FJ. Pericardial effusion with pembrolizumab. J Oncol Pharm Pract 2022;:10781552221077974. [PMID: 35133214 DOI: 10.1177/10781552221077974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
479 Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, Chen H, Luo Z. Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study. Front Immunol 2021;12:756872. [PMID: 34975845 DOI: 10.3389/fimmu.2021.756872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
480 Okada H, Takahashi K, Yaku H, Kobiyama K, Iwaisako K, Zhao X, Shiokawa M, Uza N, Kodama Y, Ishii KJ, Seno H. In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy. Sci Rep 2022;12:2132. [PMID: 35136110 DOI: 10.1038/s41598-022-05702-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
481 Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Nardi Agmon I, Itzhaki Ben Zadok O, Kornowski R. The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. J Clin Med 2022;11:865. [PMID: 35160316 DOI: 10.3390/jcm11030865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
483 Gu J, Shi L, Jiang X, Wen J, Zheng X, Cai H, Zhang W. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. Cancer Immunol Immunother 2022. [PMID: 35124713 DOI: 10.1007/s00262-022-03140-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
484 Boyer T, Blaye C, Larmonier N, Domblides C. Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives. Cells 2022;11:554. [PMID: 35159363 DOI: 10.3390/cells11030554] [Reference Citation Analysis]
485 Cai Z, Ang X, Xu Z, Li S, Zhang J, Pei C, Zhou F. A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets. Transl Cancer Res 2021;10:3993-4001. [PMID: 35116697 DOI: 10.21037/tcr-21-561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
486 Chen H, Yang Y, Deng Y, Wei F, Zhao Q, Liu Y, Liu Z, Yu B, Huang Z. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy. J Immunother Cancer 2022;10:e003737. [PMID: 35110357 DOI: 10.1136/jitc-2021-003737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
487 Zhang Y, Zhang X, Li W, Du Y, Hu W, Zhao J. Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. Hum Vaccin Immunother 2022;:1-12. [PMID: 35108160 DOI: 10.1080/21645515.2021.2018894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
488 Baker AE, Bahlmann LC, Xue C, Lu YH(, Chin AA, Cruickshank J, Cescon DW, Shoichet MS. Chemically and mechanically defined hyaluronan hydrogels emulate the extracellular matrix for unbiased in vivo and in vitro organoid formation and drug testing in cancer. Materials Today 2022. [DOI: 10.1016/j.mattod.2022.01.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Koldenhof J, van der Baan F, Verberne E, Kamphuis A, Verheijden R, Tonk E, van Lindert A, van der Stap J, Teunissen S, Witteveen P, Suijkerbuijk K. Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice. Journal of Pain and Symptom Management 2022. [DOI: 10.1016/j.jpainsymman.2022.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Won Min J, Uk Lim J. Review: A narrative review of predicting acute kidney injury induced by immune checkpoint inhibitors and the appropriate usage of ICI in chronic kidney disease patients. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.01.012] [Reference Citation Analysis]
491 Mcgregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews 2022;103:102333. [DOI: 10.1016/j.ctrv.2021.102333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
492 Vela-patiño S, Salazar MI, Remba-shapiro I, Peña-martínez E, Silva-roman G, Andoneui-elguera S, Ordoñez-garcia JDJ, Taniguchi-ponciano K, Bonifaz L, Aguilar-flores C, Marrero-rodríguez D, Mercado M. Neuroendocrine-immune Interface: Interactions of Two Complex Systems in Health and Disease. Archives of Medical Research 2022. [DOI: 10.1016/j.arcmed.2022.01.003] [Reference Citation Analysis]
493 Zeng Y, Li S, Zhang S, Wang L, Yuan H, Hu F. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
494 Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N, Song Y, Zhou C. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis. Front Immunol 2021;12:818492. [PMID: 35095920 DOI: 10.3389/fimmu.2021.818492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
495 Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, Di Lorenzo G, Porpiglia F, Mari A, Necchi A, Rouprêt M, Psutka SP, Autorino R. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Eur Urol 2022:S0302-2838(22)00065-3. [PMID: 35101302 DOI: 10.1016/j.eururo.2022.01.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
496 Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022. [PMID: 35082367 DOI: 10.1038/s41571-022-00600-w] [Cited by in Crossref: 39] [Cited by in F6Publishing: 54] [Article Influence: 39.0] [Reference Citation Analysis]
497 Michielin O, Lalani A, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer 2022;10:e003024. [DOI: 10.1136/jitc-2021-003024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
498 Barnabei A, Senes P, Scoppola A, Chiefari A, Iannantuono GM, Appetecchia M, Torino F. Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic. Cancers (Basel) 2022;14:593. [PMID: 35158860 DOI: 10.3390/cancers14030593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Zhang C, Zhang J, Liang F, Guo H, Gao S, Yang F, Guo H, Wang G, Wang W, Zhou G. Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples. Front Med . [DOI: 10.1007/s11684-021-0868-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
500 Li J, Tian X, Nie Y, He Y, Wu W, Lei X, Zhang T, Wang Y, Mao Z, Zhang H, Zhang X, Song W. BTBD10 is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:762541. [PMID: 35059434 DOI: 10.3389/fmolb.2021.762541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Tan AC, Boggs DH, Lee EQ, Kim MM, Mehta MP, Khasraw M. Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. Front Oncol 2021;11:780379. [PMID: 35047397 DOI: 10.3389/fonc.2021.780379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
502 Bai J, Li D, Yang P, Xu K, Wang Y, Li Q, Liu J, Du W, Zhang F, Feng R. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. Front Oncol 2021;11:778185. [PMID: 35047395 DOI: 10.3389/fonc.2021.778185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]
504 Pratumchart N, Chanprapaph K, Topibulpong N, Tankunakorn J. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review. Clin Cosmet Investig Dermatol 2022;15:51-62. [PMID: 35046689 DOI: 10.2147/CCID.S344445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer 2022;10:e003779. [DOI: 10.1136/jitc-2021-003779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
506 Nakashima K, Demura Y, Kurokawa K, Takeda T, Jikuya N, Oi M, Tada T, Akai M, Ishizuka T. Immune Checkpoint Inhibitor-Induced Limbic Encephalitis during Treatment with Atezolizumab in a Patient with Small-Cell Lung Cancer: A Case Report and Review of the Literature. Case Reports Immunol 2022;2022:9290922. [PMID: 35036012 DOI: 10.1155/2022/9290922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
507 Valantin M, Royston L, Hentzien M, Jary A, Makinson A, Veyri M, Ronot-bregigeon S, Isnard S, Palich R, Routy J. Therapeutic Perspectives in the Systemic Treatment of Kaposi’s Sarcoma. Cancers 2022;14:484. [DOI: 10.3390/cancers14030484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022. [PMID: 35039679 DOI: 10.1038/s41571-021-00597-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
509 Nelson D, Kodsi M, Cockrell D, Morgan J, Key N. Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab. J Oncol Pharm Pract 2022;:10781552211073883. [PMID: 35037788 DOI: 10.1177/10781552211073883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
510 Khan E, Shrestha AK, Elkhooly M, Wilson H, Ebbert M, Srivastava S, Wen S, Rollins S, Sriwastava S. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. J Neurol Sci 2022;432:120089. [PMID: 34942546 DOI: 10.1016/j.jns.2021.120089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
511 Abe K, Ishikawa Y, Fujiwara M, Yukawa H, Yanagihara T, Takei S, Arioka H, Kita Y. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report. Medicine (Baltimore) 2022;101:e28428. [PMID: 35029182 DOI: 10.1097/MD.0000000000028428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
512 Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, Usmani A, Turner BE, Steen CB, Luca BA, Badri T, Gulati GS, Vahid MR, Khameneh F, Harris PK, Chen DY, Dhodapkar K, Sznol M, Halaban R, Newman AM. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med 2022. [PMID: 35027754 DOI: 10.1038/s41591-021-01623-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 27.0] [Reference Citation Analysis]
513 Nakamura R, Ando SI, Kato S, Kadokami T. Acute Lymphocyte Myocarditis Associated with Influenza Vaccination. Intern Med 2022. [PMID: 35022355 DOI: 10.2169/internalmedicine.8855-21] [Reference Citation Analysis]
514 Nettersheim FS, Picard FSR, Hoyer FF, Winkels H. Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin. Front Cardiovasc Med 2022;8:812702. [DOI: 10.3389/fcvm.2021.812702] [Reference Citation Analysis]
515 Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE. Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 2022;11:2017162. [PMID: 35003896 DOI: 10.1080/2162402X.2021.2017162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
516 Apalla Z, Rapoport B, Sibaud V. Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management. Int J Womens Dermatol 2021;7:625-35. [PMID: 35005180 DOI: 10.1016/j.ijwd.2021.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
517 Tu L, Ye Y, Tang X, Liang Z, You Q, Zhou J, Pan Z. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events. Front Oncol 2021;11:757069. [PMID: 35004277 DOI: 10.3389/fonc.2021.757069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
518 Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat 2022. [PMID: 35015209 DOI: 10.1007/s10549-021-06480-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
519 Cheng R, Xu Z, Luo M, Wang P, Cao H, Jin X, Zhou W, Xiao L, Jiang Q. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development. Briefings in Bioinformatics. [DOI: 10.1093/bib/bbab553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
520 Long Y, Sun Y, Liu R, Zhang M, Zhao J, Wang Y, Zhou Y, Cheng K, Chen Y, Zhu C, Liu J. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). Current Oncology 2022;29:267-82. [DOI: 10.3390/curroncol29010025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Cretu I, Cretu B, Cirstoiu C, Cursaru A, Milicescu M, Bojinca M, Ionescu R. Rheumatological Adverse Events Following Immunotherapy for Cancer. Medicina (Kaunas) 2022;58:94. [PMID: 35056402 DOI: 10.3390/medicina58010094] [Reference Citation Analysis]
522 Bai X, Wang X, Ma G, Song J, Liu X, Wu X, Zhao Y, Liu X, Liu Z, Zhang W, Zhao X, Zheng Z, Jing J, Shi H. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Front Immunol 2021;12:793831. [PMID: 34987517 DOI: 10.3389/fimmu.2021.793831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
523 Lu J, Ding J, Liu Z, Chen T. Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). Int J Oncol 2022;60:12. [PMID: 34981814 DOI: 10.3892/ijo.2022.5302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
524 Roman R. Rheumatic side effects of cancer immunotherapy with immune checkpoint inhibitors. Klin Farmakol Farm 2022;35:106-111. [DOI: 10.36290/far.2021.025] [Reference Citation Analysis]
525 Aboo C, Krastrup TW, Tenstad HB, Ren J, Just SA, Ladekarl M, Stensballe A. Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now? Expert Review of Precision Medicine and Drug Development 2022;7:162-168. [DOI: 10.1080/23808993.2022.2156785] [Reference Citation Analysis]
526 Oo TH, Rojas-hernandez CM. Hematology. Managing Immunotherapy Related Organ Toxicities 2022. [DOI: 10.1007/978-3-031-00241-0_6] [Reference Citation Analysis]
527 Khoshnood AM. Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_76] [Reference Citation Analysis]
528 Andersen BM, Reardon DA. Neurologic complications of immune modulatory therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00025-6] [Reference Citation Analysis]
529 Jalal SI, Mamdani H, Turchi AM, Turchi JJ. Lung Cancer. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00063-3] [Reference Citation Analysis]
530 费 鹏. Recent Developments Related to the Toxic Side Effects of Immunosuppressive Combination Therapy. ACM 2022;12:7292-7299. [DOI: 10.12677/acm.2022.1281053] [Reference Citation Analysis]
531 Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, Kwee TC, Gietema JA, Fehrmann RSN, Fine BM, Sanabria Bohórquez SM, Yadav M, Koeppen H, Jing J, Guelman S, Lin MT, Mamounas MJ, Eastham JR, Kimes PK, Williams SP, Ungewickell A, de Groot DJA, de Vries EGE. Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nat Med 2022;28:2601-10. [PMID: 36471036 DOI: 10.1038/s41591-022-02084-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Caliman E, Fancelli S, Ottanelli C, Mazzoni F, Paglialunga L, Lavacchi D, Michelet MRG, Giommoni E, Napolitano B, Scolari F, Voltolini L, Comin CE, Pillozzi S, Antonuzzo L. Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications 2022;32:100603. [DOI: 10.1016/j.ctarc.2022.100603] [Reference Citation Analysis]
533 Gerber PA. Oncology: Immune Checkpoint Inhibitors. Cutaneous Drug Hypersensitivity 2022. [DOI: 10.1007/978-3-030-82743-4_16] [Reference Citation Analysis]
534 Pacheco C, Baião A, Sousa F, Sarmento B. Implantable and long-lasting drug delivery systems for cancer treatment. Long-Acting Drug Delivery Systems 2022. [DOI: 10.1016/b978-0-12-821749-8.00011-2] [Reference Citation Analysis]
535 Saxena S, O’shea P, Singh K, Rauf Y, Ahluwalia MS. Neurological complications of systemic cancer of the head and neck. Neurological Complications of Systemic Cancer and Antineoplastic Therapy 2022. [DOI: 10.1016/b978-0-12-821976-8.00037-2] [Reference Citation Analysis]
536 Gauthier LM. Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies. Cancer Immunology and Immunotherapy 2022. [DOI: 10.1016/b978-0-12-823397-9.00015-6] [Reference Citation Analysis]
537 Lau KCK, Weyant B, Cervera C. Immune Checkpoint Inhibitors. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_13] [Reference Citation Analysis]
538 Quinn M, Carroll PV, Joshi MN. Endocrine Toxicities Related to Immunotherapy. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_348-1] [Reference Citation Analysis]
539 Zhang L, Tian Y, Li M, Wang M, Wu S, Jiang Z, Wang Q, Wang W. Peptide nano ‘bead-grafting’ for SDT-facilitated immune checkpoints blocking. Chem Sci 2022. [DOI: 10.1039/d2sc02728c] [Reference Citation Analysis]
540 Xia T, Brucker AJ, McGeehan B, VanderBeek BL. Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. Br J Ophthalmol 2022;106:87-90. [PMID: 33087313 DOI: 10.1136/bjophthalmol-2020-317060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
541 Živković SA, Al-lahham T; Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Neurologic Complications of Immune Checkpoint Inhibitors. Neurology 2022;18:58. [DOI: 10.17925/usn.2022.18.1.58] [Reference Citation Analysis]
542 Shaikh S. Immunoimaging. Advances in Imaging 2022. [DOI: 10.1007/978-981-16-9535-3_17] [Reference Citation Analysis]
543 Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer 2022;3:11-24. [PMID: 35121998 DOI: 10.1038/s43018-021-00319-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
544 Kuwayama N, Hoshino I, Gunji H, Kurosaki T, Nabeya Y, Takayama W. A Case of NOMI during Treatment with Nivolumab for Recurrent Hodgkin Lymphoma. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2022;83:92-97. [DOI: 10.3919/jjsa.83.92] [Reference Citation Analysis]
545 Malek AE, Okhuysen PC. Infectious Diseases. Managing Immunotherapy Related Organ Toxicities 2022. [DOI: 10.1007/978-3-031-00241-0_8] [Reference Citation Analysis]
546 Muzaffar R, Osman MM, Sarikaya I, Elgazzar AH. Nuclear Oncology. The Pathophysiologic Basis of Nuclear Medicine 2022. [DOI: 10.1007/978-3-030-96252-4_12] [Reference Citation Analysis]
547 Huang J, Zhang S, Yang Y, Zhang Z, Jiang N, Li W, Shen J, Zhong B, Zhu X. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Clin Med Insights Oncol 2022;16:117955492211348. [DOI: 10.1177/11795549221134832] [Reference Citation Analysis]
548 Yoon E, Kim TY, Mun SK, Cho D. Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors. Korean J Blood Transfus 2021;32:201-208. [DOI: 10.17945/kjbt.2021.32.3.201] [Reference Citation Analysis]
549 Klavdianou K, Melissaropoulos K, Filippopoulou A, Daoussis D. Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases. Mediterr J Rheumatol 2021;32:218-26. [PMID: 34964025 DOI: 10.31138/mjr.32.3.218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
550 Sordo RD, Lougaris V, Bassotti G, Armuzzi A, Villanacci V. Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects. Clin Immunol 2021;234:108916. [PMID: 34971840 DOI: 10.1016/j.clim.2021.108916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
551 Baldessari C, Pugliese G, Venturelli M, Greco S, Ferrara L, Longo G, Dominici M, Depenni R. Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab. J Oncol Pharm Pract 2021;:10781552211067424. [PMID: 34964671 DOI: 10.1177/10781552211067424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
552 He F, Liu J, Shen X, Wang Z, Li Q, Li G. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Ann Pharmacother 2021;:10600280211058385. [PMID: 34963337 DOI: 10.1177/10600280211058385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
553 Sweep B, Wilgenhof S, Anten S. Nivolumab-Induced Exocrine Pancreatic Insufficiency. Case Rep Oncol 2021;14:1627-31. [PMID: 34950007 DOI: 10.1159/000519588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
554 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
555 Chen R, Peng L, Qiu Z, Wang Y, Wei F, Zhou M, Zhu F. Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. Front Cardiovasc Med 2021;8:727445. [PMID: 34938778 DOI: 10.3389/fcvm.2021.727445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
556 Hamada N, Maeda A, Takase-Minegishi K, Kirino Y, Sugiyama Y, Namkoong H, Horita N, Yoshimi R, Nakajima H; YCU irAE Working Group. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. Front Immunol 2021;12:803410. [PMID: 34938300 DOI: 10.3389/fimmu.2021.803410] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
557 Seethapathy H, Herrmann SM, Sise ME. Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. Kidney Med 2021;3:1074-81. [PMID: 34939017 DOI: 10.1016/j.xkme.2021.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
558 Wang C, Lin J, Wang Y, Hsi DH, Chen J, Liu T, Zhou Y, Ren Z, Zeng Z, Cheng L, Ge J. Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. Front Pharmacol 2021;12:770631. [PMID: 34938185 DOI: 10.3389/fphar.2021.770631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
559 Do TVC, Gudipati MK, Ganti SS, Depa J, Sajnani K. Immunotherapy: A Case Series. Cureus 2021;13:e19726. [PMID: 34934589 DOI: 10.7759/cureus.19726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
560 D'Souza M, Bagger M, Alberti M, Malmborg M, Schou M, Torp-Pedersen C, Gislason G, Svane IM, Kiilgaard JF. Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer-A Nationwide Cohort Study. Cancers (Basel) 2021;14:49. [PMID: 35008211 DOI: 10.3390/cancers14010049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
561 Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2021. [PMID: 34937915 DOI: 10.1038/s41573-021-00345-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
562 Zhan R, Wang S, Guo W, Gao X, Liu X, Xu K, Tang B. A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples. Chem Commun (Camb) 2021. [PMID: 34931643 DOI: 10.1039/d1cc06496g] [Reference Citation Analysis]
563 Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, Ding C, Ai B, Gu Y, Yao Y, Sun H, Guo H, Zhang C, Song X, Li J, Xu B, Han Z, Song M, Tang T, Chen P, Lu H, Shui Y, Lou G, Zhang D, Liu J, Liu X, Liu X, Gao X, Zhou Q, Chen M, Zhao J, Zhong W, Xu Y, Wang M. Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. Thorac Cancer 2021. [PMID: 34935288 DOI: 10.1111/1759-7714.14274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
564 Zhang Z, Zhou J, Verma V, Liu X, Wu M, Yu J, Chen D. Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. Front Immunol 2021;12:774807. [PMID: 34925345 DOI: 10.3389/fimmu.2021.774807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
565 Cortijo-Cascajares S, Cercós-Lletí AC, Ortiz-Pérez S, Caro-Teller JM, Ferrari-Piquero JM. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. J Oncol Pharm Pract 2021;:10781552211067429. [PMID: 34907812 DOI: 10.1177/10781552211067429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
566 Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. J Eur Acad Dermatol Venereol 2021. [PMID: 34910332 DOI: 10.1111/jdv.17855] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
567 He X, Yu J, Shi H. Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Front Pharmacol 2021;12:797852. [PMID: 34899357 DOI: 10.3389/fphar.2021.797852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
568 Xiao K, Xiao K, Li K, Xue P, Zhu S. Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis. J Immunol Res 2021;2021:5440572. [PMID: 34888386 DOI: 10.1155/2021/5440572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
569 Gemelli M, Carbone M, Abbate MI, Mancin M, Zucchini N, Colonese F, Invernizzi P, Bidoli P, Cortinovis D. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy 2021. [PMID: 34873918 DOI: 10.2217/imt-2021-0078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
570 Wong SK, Nebhan CA, Johnson DB. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Front Immunol 2021;12:786046. [PMID: 34868071 DOI: 10.3389/fimmu.2021.786046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
571 Gilardi M, Saddawi-konefka R, Wu VH, Lopez-ramirez MA, Wang Z, Soto F, Steffen DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS. Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited irAEs.. [DOI: 10.1101/2021.12.07.471658] [Reference Citation Analysis]
572 Caballero D, Abreu CM, Lima AC, Neves NN, Reis RL, Kundu SC. Precision biomaterials in cancer theranostics and modelling. Biomaterials 2022;280:121299. [PMID: 34871880 DOI: 10.1016/j.biomaterials.2021.121299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
573 Wang D, Sun K, Wang T, Zhang D, Sun F, Cui Y, Zhao H, Wu J. Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. Front Pharmacol 2021;12:710943. [PMID: 34867321 DOI: 10.3389/fphar.2021.710943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
574 Schilling HL, Glehr G, Kapinsky M, Ahrens N, Riquelme P, Cordero L, Bitterer F, Schlitt HJ, Geissler EK, Haferkamp S, Hutchinson JA, Kronenberg K. Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. Front Immunol 2021;12:765644. [PMID: 34868015 DOI: 10.3389/fimmu.2021.765644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
575 Zhao H, Luo F, Xue J, Li S, Xu RH. Emerging immunological strategies: recent advances and future directions. Front Med 2021. [PMID: 34874513 DOI: 10.1007/s11684-021-0886-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
576 Blethen KE, Arsiwala TA, Fladeland RA, Sprowls SA, Panchal DM, Adkins CE, Kielkowski BN, Earp LE, Glass MJ, Pritt TA, Cabuyao YM, Aulakh S, Lockman PR. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neurooncol Adv 2021;3:v133-43. [PMID: 34859240 DOI: 10.1093/noajnl/vdab123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
577 Mason NJ, Chester N, Xiong A, Rotolo A, Wu Y, Yoshimoto S, Glassman P, Gulendran G, Siegel DL. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. MAbs 2021;13:2004638. [PMID: 34856888 DOI: 10.1080/19420862.2021.2004638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
578 Latif MB, Shukla S, Estrada PMDR, Ribeiro SP, Sekaly RP, Sharma AA. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res 2021:S1931-5244(21)00284-X. [PMID: 34871809 DOI: 10.1016/j.trsl.2021.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
579 Kobe H, Sato Y, Ohmura K, Fujita S, Mochizuki R, Tomii K. Multitarget therapy for pembrolizumab-induced refractory hemophagocytic lympho histiocytosis. Current Problems in Cancer: Case Reports 2021;4:100120. [DOI: 10.1016/j.cpccr.2021.100120] [Reference Citation Analysis]
580 Shankar A, Wallbridge IG, Yau C, Saini D, Roy S, Bharati SJ, Mishra S, Singh P, Seth T. Development of Management Strategies for Immune Related Adverse Effects of Immunotherapies used in Oncological Treatment. Asia-Pacific Journal of Oncology Nursing 2021. [DOI: 10.1016/j.apjon.2021.12.007] [Reference Citation Analysis]
581 da Silva JA, Falcão D, Cardoso C, Pires AL, Araújo A, Castro-Poças F. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience. Ann Hepatol 2021;26:100561. [PMID: 34653687 DOI: 10.1016/j.aohep.2021.100561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
582 Urrego-Callejas T, Sandoval-Álvarez S, Gómez-Wolff R, Vásquez G. Cutaneous and Pulmonary Sarcoid-Like Reaction Induced by Nivolumab: Case Report and Brief Literature Review. J Clin Rheumatol 2021;27:S460-4. [PMID: 31895111 DOI: 10.1097/RHU.0000000000001227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
583 El Husseini K, Lafoeste H, Mansuet-lupo A, Arrondeau J, Villeminey C, Bennani S, Revel M, Wislez M. A case of severe interstitial cystitis associated with pembrolizumab. Current Problems in Cancer: Case Reports 2021;4:100101. [DOI: 10.1016/j.cpccr.2021.100101] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
584 Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer. JACC CardioOncol 2021;3:635-49. [PMID: 34988472 DOI: 10.1016/j.jaccao.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
585 Beuthien-Baumann B, Sachpekidis C, Gnirs R, Sedlaczek O. Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring. Cancers (Basel) 2021;13:6019. [PMID: 34885129 DOI: 10.3390/cancers13236019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
586 Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest 2021;:1-10. [PMID: 34658277 DOI: 10.1080/07357907.2021.1994586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
587 Gao L, Xue J, Liu X, Cao L, Wang R, Lei L. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. Aging (Albany NY) 2021;13:24866-81. [PMID: 34839280 DOI: 10.18632/aging.203721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
588 Zou XL, Chen WY, Zhang GY, Ke H, Yang QH, Li XB. Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:747075. [PMID: 34819857 DOI: 10.3389/fphar.2021.747075] [Reference Citation Analysis]
589 Ma B, Anandasabapathy N. Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. J Invest Dermatol 2021:S0022-202X(21)02308-3. [PMID: 34844731 DOI: 10.1016/j.jid.2021.06.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
590 Li AR, Valdebran M, Reuben DY. Emerging Developments in Management of Melanoma During the COVID-19 Era. Front Med (Lausanne) 2021;8:769368. [PMID: 34820401 DOI: 10.3389/fmed.2021.769368] [Reference Citation Analysis]
591 Xiong L, Cai Y, Zhou X, Dai P, Wei Y, Zhao J, Tang H. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis. Future Oncol 2021. [PMID: 34825576 DOI: 10.2217/fon-2021-1217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
592 Zhang Q, Wang W, Yuan Q, Li L, Wang YC, Chi CZ, Xu CH. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol 2021. [PMID: 34821962 DOI: 10.1007/s00280-021-04375-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
593 Ngamphaiboon N, Ithimakin S, Siripoon T, Sintawichai N, Sriuranpong V. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. BMC Cancer 2021;21:1275. [PMID: 34823493 DOI: 10.1186/s12885-021-09003-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
594 Wang W, Gu X, Wang L, Pu X, Feng H, Xu C, Lou G, Shao L, Xu Y, Wang Q, Wang S, Gao W, Zhang Y, Song Z. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 2021. [PMID: 34817639 DOI: 10.1007/s00262-021-03115-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
595 Xu PC, Luan Y, Yu SY, Xu J, Coulter DW, Kim SY. Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse. J Endocrinol 2021;252:15-30. [PMID: 34647523 DOI: 10.1530/JOE-21-0209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
596 Oyibo SO, Mahgoub MO. Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Graves' Disease: A Case Report and Literature Review. Cureus 2021;13:e19736. [PMID: 34812334 DOI: 10.7759/cureus.19736] [Reference Citation Analysis]
597 Shen P, Deng X, Hu Z, Chen Z, Huang Y, Wang K, Qin K, Huang Y, Ba X, Yan J, Han L, Tu S. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Front Med (Lausanne) 2021;8:762247. [PMID: 34805229 DOI: 10.3389/fmed.2021.762247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
598 Urasaki T, Nishizawa M, Yoshida A, Tomomatsu J, Yuasa T, Yonese J, Takahashi S. Severe pseudomembranous keratoconjunctivitis with deterioration of eyesight induced by immune checkpoint inhibitors. Immunotherapy 2021. [PMID: 34812050 DOI: 10.2217/imt-2021-0067] [Reference Citation Analysis]
599 Asan MF, Castelino RL, Babu SG, Rao K, Pandita V. Oral Immune-Related Adverse Events - Current Concepts and their Management. Asia Pac J Oncol Nurs 2021;8:604-9. [PMID: 34790844 DOI: 10.4103/apjon.apjon-2136] [Reference Citation Analysis]
600 Wang J, Hong J, Yang F, Liu F, Wang X, Shen Z, Wu D. A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. Cell Biol Toxicol 2021. [PMID: 34797429 DOI: 10.1007/s10565-021-09672-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
601 Yan X, Zhou Q, Zhu H, Liu W, Xu H, Yin W, Zhao M, Jiang X, Ren C. The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas. iScience 2021;24:103249. [PMID: 34755091 DOI: 10.1016/j.isci.2021.103249] [Reference Citation Analysis]
602 Zhang L, Lu Y. Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. Asia Pac J Oncol Nurs 2021;8:596-603. [PMID: 34790843 DOI: 10.4103/apjon.apjon-2129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
603 Fang H, Guo Z, Chen J, Lin L, Hu Y, Li Y, Tian H, Chen X. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat Commun 2021;12:6742. [PMID: 34795289 DOI: 10.1038/s41467-021-27078-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
604 Westdorp H, Sweep MWD, Gorris MAJ, Hoentjen F, Boers-Sonderen MJ, van der Post RS, van den Heuvel MM, Piet B, Boleij A, Bloemendal HJ, de Vries IJM. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Front Immunol 2021;12:768957. [PMID: 34777387 DOI: 10.3389/fimmu.2021.768957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
605 von Knethen A, Rodriguez-Barbosa JI. Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases. Front Immunol 2021;12:795495. [PMID: 34777402 DOI: 10.3389/fimmu.2021.795495] [Reference Citation Analysis]
606 Mulder EEAP, Smit L, Grünhagen DJ, Verhoef C, Sleijfer S, van der Veldt AAM, Uyl-de Groot CA. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. ESMO Open 2021;6:100303. [PMID: 34781194 DOI: 10.1016/j.esmoop.2021.100303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
607 Tsunoda M, Aoki H, Shimizu H, Shichino S, Matsushima K, Ueha S. Proportional Tumor Infiltration of T Cells via Circulation Duplicates the T Cell Receptor Repertoire in a Bilateral Tumor Mouse Model. Front Immunol 2021;12:744381. [PMID: 34759926 DOI: 10.3389/fimmu.2021.744381] [Reference Citation Analysis]
608 Nakako S, Nakashima Y, Okamura H, Tani Y, Ueda T, Makuuchi Y, Kuno M, Takakuwa T, Nishimoto M, Koh H, Nakamae H, Hino M. Delayed immune-related neutropenia with hepatitis by pembrolizumab. Immunotherapy 2021. [PMID: 34758635 DOI: 10.2217/imt-2021-0131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
609 Dietz H, Weinmann SC, Salama AK. Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. Cancer Manag Res 2021;13:8199-208. [PMID: 34754240 DOI: 10.2147/CMAR.S283217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
610 Zhu X, Shanzhou Q, Li D, Pang X, Ma D. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. BMC Cancer 2021;21:1195. [PMID: 34758782 DOI: 10.1186/s12885-021-08958-3] [Reference Citation Analysis]
611 Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis. Front Oncol 2021;11:765608. [PMID: 34746007 DOI: 10.3389/fonc.2021.765608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
612 Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. J Clin Med 2021;10:5160. [PMID: 34768681 DOI: 10.3390/jcm10215160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
613 Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W, Wang M. Risk factors for immune-related adverse events: what have we learned and what lies ahead? Biomark Res 2021;9:79. [PMID: 34732257 DOI: 10.1186/s40364-021-00314-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
614 Percik R, Liel Y, Urban D, Bar J, Ben-Ami E, Abu Tailakh M. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. Acta Oncol 2021;60:1466-71. [PMID: 34379562 DOI: 10.1080/0284186X.2021.1958006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
615 Arai M, Ohno I, Takahashi K, Fan MM, Tawada A, Ishioka C, Takiguchi Y. Current status of medical oncology in Japan and changes over the most recent 7-year period: results of a questionnaire sent to designated cancer care hospitals. Jpn J Clin Oncol 2021;51:1622-7. [PMID: 34414432 DOI: 10.1093/jjco/hyab135] [Reference Citation Analysis]
616 Llewellyn HP, Arat S, Gao J, Wen J, Xia S, Kalabat D, Oziolor E, Virgen-Slane R, Affolter T, Ji C. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model. J Hepatol 2021;75:1083-95. [PMID: 34242700 DOI: 10.1016/j.jhep.2021.06.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
617 Kim BW. Overt Hyperthyroidism May Be a Good Prognostic Sign in Immune Checkpoint Inhibitor Treatment. Clinical Thyroidology 2021;33:467-9. [DOI: 10.1089/ct.2021;33.467-469] [Reference Citation Analysis]
618 Bataille P, Chasset F, Monfort JB, De Risi-Pugliese T, Soria A, Francès C, Barbaud A, Senet P. Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs. Ann Dermatol Venereol 2021;148:211-20. [PMID: 34711400 DOI: 10.1016/j.annder.2021.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
619 Kim DW, Jeon H, Kim S, Lee W, Kim HJ, Rhee H, Song SH, Seong EY. Pembrolizumab-induced focal segmental glomerulosclerosis: A case report. Medicine (Baltimore) 2021;100:e27546. [PMID: 34713828 DOI: 10.1097/MD.0000000000027546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
620 Bent EH, Millán-Barea LR, Zhuang I, Goulet DR, Fröse J, Hemann MT. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun 2021;12:6218. [PMID: 34711820 DOI: 10.1038/s41467-021-26407-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
621 Ogasawara H, Noguchi M. Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells. Cells 2021;10:2906. [PMID: 34831128 DOI: 10.3390/cells10112906] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
622 Conteduca V, Medri M, Mazzoni L, De Giorgi U, Stanganelli I. Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. Cancer Immunol Immunother 2021. [PMID: 34705086 DOI: 10.1007/s00262-021-03094-0] [Reference Citation Analysis]
623 Nakashima K, Fujii Y, Sato M, Igarashi K, Kobayashi M, Ishizuka T. A case of non-small cell lung cancer presenting anti-amphiphysin antibody-positive paraneoplastic neurological syndrome. Respir Med Case Rep 2021;34:101525. [PMID: 34692399 DOI: 10.1016/j.rmcr.2021.101525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
624 Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, Khoshavi N, Karimi N, Shirinisaz A, Abedi F, Rad MR, Sharifi P. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol 2021;232:108873. [PMID: 34688855 DOI: 10.1016/j.clim.2021.108873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
625 Ben Shimol J, Guzman-Prado Y, Karlinskaya M, Davidson T. Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review. Crit Rev Oncol Hematol 2021;167:103499. [PMID: 34687896 DOI: 10.1016/j.critrevonc.2021.103499] [Reference Citation Analysis]
626 Tseng PJ, Yan MT. Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report. Front Med (Lausanne) 2021;8:742489. [PMID: 34671624 DOI: 10.3389/fmed.2021.742489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
627 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
628 Liu X, Yi Y. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma. Immunotherapy 2021;13:1387-93. [PMID: 34665016 DOI: 10.2217/imt-2021-0062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
629 Wang R, Singaraju A, Marks KE, Shakib L, Dunlap G, Cunningham-bussel A, Chen L, Tirpack A, Fein MR, Todd DJ, Macfarlane L, Goodman SM, Dicarlo EF, Massarotti EM, Sparks JA, Hamnvik OR, Min L, Jonsson AH, Brenner MB, Chan KK, Bass AR, Donlin LT, Rao DA. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis.. [DOI: 10.1101/2021.10.19.464961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
630 Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria. Front Neurol 2021;12:706169. [PMID: 34659082 DOI: 10.3389/fneur.2021.706169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
631 Yuan M, Zang L, Xu A, Gong M, Liu Q, Huo B, Wang J, Fu H, Tse G, Roever L, Li G, Wang H, Liu T. Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:748677. [PMID: 34658887 DOI: 10.3389/fphar.2021.748677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
632 Mocan-Hognogi DL, Trancǎ S, Farcaş AD, Mocan-Hognogi RF, Pârvu AV, Bojan AS. Immune Checkpoint Inhibitors and the Heart. Front Cardiovasc Med 2021;8:726426. [PMID: 34660728 DOI: 10.3389/fcvm.2021.726426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
633 Vasyuk YA, Gendlin GE, Emelina EI, Shupenina EY, Ballyuzek MF, Barinova IV, Vitsenya MV, Davydkin IL, Dundua DP, Duplyakov DV, Zateishchikov DA, Zolotovskaya IA, Konradi AO, Lopatin YM, Moiseeva OM, Nedogoda SV, Nedoshivin AO, Nikitin IG, Poltavskaya MG, Potievskaya VI, Repin AN, Sumin АN, Zotova LA, Tumyan GS, Shlyakhto EV, Khatkov IE, Yakushin SS, Belenkov YN. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russ J Cardiol 2021;26:4703. [DOI: 10.15829/1560-4071-2021-4703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
634 Ando H, Suzuki K, Yanagihara T. Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines 2021;9:1484. [PMID: 34680601 DOI: 10.3390/biomedicines9101484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
635 Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021;184:5309-37. [PMID: 34624224 DOI: 10.1016/j.cell.2021.09.020] [Cited by in Crossref: 104] [Cited by in F6Publishing: 143] [Article Influence: 52.0] [Reference Citation Analysis]
636 Liu Q, Zhang Y, Liu M, Xu R, Yi F, Wei Y, Zhu S, Zhang W. The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials. World J Surg Oncol 2021;19:298. [PMID: 34645484 DOI: 10.1186/s12957-021-02410-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
637 Yang T, Mochida Y, Liu X, Zhou H, Xie J, Anraku Y, Kinoh H, Cabral H, Kataoka K. Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. Nat Biomed Eng 2021;5:1274-87. [PMID: 34635819 DOI: 10.1038/s41551-021-00803-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
638 Wang L, Li X, Zhao B, Mei D, Jiang J, Duan J. Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study. Front Pharmacol 2021;12:679207. [PMID: 34630077 DOI: 10.3389/fphar.2021.679207] [Reference Citation Analysis]
639 Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N, Zheng S, Fang Y, Wang J. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Front Oncol 2021;11:582664. [PMID: 34631507 DOI: 10.3389/fonc.2021.582664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
640 Zheng S, Song Q, Zhang P. Metabolic Modifications, Inflammation, and Cancer Immunotherapy. Front Oncol 2021;11:703681. [PMID: 34631531 DOI: 10.3389/fonc.2021.703681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
641 Lin Z, Pang K, Li H, Zhang X, Wan J, Zheng T, Liu T, Peng W. Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma. Front Cell Dev Biol 2021;9:709241. [PMID: 34631703 DOI: 10.3389/fcell.2021.709241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
642 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
643 Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, Alexandre YO, Gong F, Zhang X, Xie W, Li Y, Shao M, Zhu Y, Sinclair JE, Miao M, Chen Y, Short KR, Mueller SN, Sun X, Yu D, Li Z. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog 2021;17:e1009858. [PMID: 34618873 DOI: 10.1371/journal.ppat.1009858] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
644 Holroyd KB, Rubin DB, Vaitkevicius H. Neurologic Complications in Patients with Cancer. Semin Neurol 2021;41:588-605. [PMID: 34619783 DOI: 10.1055/s-0041-1733788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
645 Wu W, Jia L, Zhang Y, Zhao J, Dong Y, Qiang Y. Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes. Bioengineered 2021;12:7417-31. [PMID: 34612148 DOI: 10.1080/21655979.2021.1974779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
646 Min J, Dong F, Wu P, Xu X, Wu Y, Tan Y, Yang F, Chai Y. A Radiomic Approach to Access Tumor Immune Status by CD8+TRMs on Surgically Resected Non-Small-Cell Lung Cancer. Onco Targets Ther 2021;14:4921-31. [PMID: 34611410 DOI: 10.2147/OTT.S316994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
647 Wilmas KM, Nguyen QB, Patel J, Silapunt S, Migden MR. Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. Future Oncol 2021;17:4971-82. [PMID: 34608809 DOI: 10.2217/fon-2021-0901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
648 Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, Barker KA, Korkmaz FT, Ramanujan A, Etesami NS, Soucy AM, Martin IMC, Tilton BR, Hinds A, Goltry WN, Kathuria H, Braun T, Jones MR, Quinton LJ, Belkina AC, Mizgerd JP. Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity. Nat Commun 2021;12:5834. [PMID: 34611166 DOI: 10.1038/s41467-021-26045-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
649 Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, Chen X. Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:708195. [PMID: 34604047 DOI: 10.3389/fonc.2021.708195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
650 García Campelo MR, Arriola E, Campos Balea B, López-Brea M, Fuentes-Pradera J, de Castro Carpeno J, Aguado C, Pérez Parente D, de Oro Pulido F, Ruiz-Gracia P, Rodríguez-Abreu D. PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. J Clin Med 2021;10:4583. [PMID: 34640601 DOI: 10.3390/jcm10194583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
651 Wang M, Zhu J, Zhao F, Xiao J. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression. Front Oncol 2021;11:643503. [PMID: 34595103 DOI: 10.3389/fonc.2021.643503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
652 Wesemann A. Malignes Melanom: Herausforderungen im Team begegnen. Im Fokus Onkologie 2021;24:14-17. [DOI: 10.1007/s15015-021-3622-0] [Reference Citation Analysis]
653 Tomioka H. Drug-induced sarcoidosis-like reactions. JJSOGD 2021;41:35-8. [DOI: 10.7878/jjsogd.41.1_2_35] [Reference Citation Analysis]
654 Sørup S, Darvalics B, Khalil AA, Nordsmark M, Hæe M, Donskov F, Agerbæk M, Russo L, Oksen D, Boutmy E, Verpillat P, Cronin-Fenton D. Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clin Epidemiol 2021;13:871-82. [PMID: 34588817 DOI: 10.2147/CLEP.S326470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
655 Dougan M. Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed. Gastroenterology 2021;161:1106-8. [PMID: 34256056 DOI: 10.1053/j.gastro.2021.07.007] [Reference Citation Analysis]
656 Mito T, Takeda S, Motono N, Sasaki H. Atezolizumab-induced bilateral anterior uveitis: A case report. Am J Ophthalmol Case Rep 2021;24:101205. [PMID: 34585023 DOI: 10.1016/j.ajoc.2021.101205] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
657 Cheng KH, Wu YW, Hou CJ, Hung CM. An Overview of Cardio-Oncology, a New Frontier to Be Explored. Acta Cardiol Sin 2021;37:457-63. [PMID: 34584378 DOI: 10.6515/ACS.202109_37(5).20210706A] [Reference Citation Analysis]
658 Faron A, Isaak A, Mesropyan N, Reinert M, Schwab K, Sirokay J, Sprinkart AM, Bauernfeind FG, Dabir D, Pieper CC, Heine A, Kuetting D, Attenberger U, Landsberg J, Luetkens JA. Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. Radiology 2021;301:602-9. [PMID: 34581628 DOI: 10.1148/radiol.2021210814] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
659 Mandel-brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Miao B, Disse E, Cugnet-anceau C, Dalle S, Orlova E, Frolova E, Oftedal BE, Lionakis MS, Husebye ES, Derisi JL, Anderson MS. Perilipin-1 autoantibodies linked to idiopathic lipodystrophy in the setting of two distinct breaks in immune tolerance.. [DOI: 10.1101/2021.09.24.21263657] [Reference Citation Analysis]
660 Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 2021. [PMID: 34580473 DOI: 10.1038/s41571-021-00552-7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 77] [Article Influence: 32.5] [Reference Citation Analysis]
661 Lerrer S, Tocheva AS, Bukhari S, Adam K, Mor A. PD-1-stimulated T cell subsets are transcriptionally and functionally distinct. iScience 2021;24:103020. [PMID: 34522863 DOI: 10.1016/j.isci.2021.103020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
662 Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer 2021;9:e002886. [PMID: 34544895 DOI: 10.1136/jitc-2021-002886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
663 Ceccarini G, Magno S, Gilio D, Pelosini C, Santini F. Autoimmunity in lipodystrophy syndromes. Presse Med 2021;50:104073. [PMID: 34547374 DOI: 10.1016/j.lpm.2021.104073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Drobni ZD, Murphy SP, Alvi RM, Lee C, Gong J, Mosarla RC, Rambarat PK, Hartmann SB, Gilman HK, Zubiri L, Raghu VK, Sullivan RJ, Zafar A, Zlotoff DA, Sise ME, Guidon AC, Reynolds KL, Dougan M, Neilan TG. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv 2021;1:ltab014. [PMID: 34541581 DOI: 10.1093/immadv/ltab014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
665 Shimizu N, Hasumi M, Muramatsu K, Tsuji Y, Takaku Y. Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report. Urol Case Rep 2021;39:101843. [PMID: 34540590 DOI: 10.1016/j.eucr.2021.101843] [Reference Citation Analysis]
666 Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer 2020;8:e001754. [PMID: 33310772 DOI: 10.1136/jitc-2020-001754] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 19.5] [Reference Citation Analysis]
667 Thomas MF, Slowikowski K, Manakongtreecheep K, Sen P, Tantivit J, Nasrallah M, Smith NP, Ramesh S, Zubiri L, Tirard A, Arnold BY, Nieman LT, Chen JH, Eisenhaure T, Pelka K, Xu KH, Jorgji V, Pinto CJ, Sharova T, Glasser R, Chan EP, Sullivan RJ, Khalili H, Juric D, Boland GM, Dougan M, Hacohen N, Reynolds KL, Li B, Villani A. Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors.. [DOI: 10.1101/2021.09.17.460868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
668 Nishio Y, Furuhashi A, Hayashi T, Ito K, Ono T, Kazaoka Y. A case of bullous pemphigoid in the oral cavity after treatment with nivolumab. Jpn J Oral Maxillofac Surg 2021;67:520-525. [DOI: 10.5794/jjoms.67.520] [Reference Citation Analysis]
669 Liu Y, Chen Y, Zeng Z, Liu A. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis]. Zhongguo Fei Ai Za Zhi 2021;24:668-72. [PMID: 34521189 DOI: 10.3779/j.issn.1009-3419.2021.102.27] [Reference Citation Analysis]
670 Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer 2021;157:214-24. [PMID: 34536945 DOI: 10.1016/j.ejca.2021.08.031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
671 Bussies PL, Richards EG, Rotz SJ, Falcone T. Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. Reprod Biomed Online 2021:S1472-6483(21)00434-X. [PMID: 34674940 DOI: 10.1016/j.rbmo.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
672 Shirali AC. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY. Kidney360 2022;3:806-8. [PMID: 36129422 DOI: 10.34067/KID.0005592021] [Reference Citation Analysis]
673 Fujiwara N, Watanabe M, Katayama A, Noda Y, Eguchi J, Kataoka H, Kagawa S, Wada J. Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases. Clin Case Rep 2021;9:e04574. [PMID: 34522382 DOI: 10.1002/ccr3.4574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
674 Kelly K, Manitz J, Patel MR, D'Angelo SP, Apolo AB, Rajan A, Kasturi V, Speit I, Bajars M, Warth J, Gulley JL. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer 2020;8:e001427. [PMID: 33219092 DOI: 10.1136/jitc-2020-001427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
675 Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane AF, Legallois D, L'Orphelin JM, Alexandre J. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 2021:ehab618. [PMID: 34529770 DOI: 10.1093/eurheartj/ehab618] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
676 McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 2021;21:680-6. [PMID: 34518662 DOI: 10.1038/s41577-021-00603-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
677 Yamaguchi Y, Aso M, Nagasawa H, Wada M. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. Intern Med 2021;60:3025-9. [PMID: 33776010 DOI: 10.2169/internalmedicine.6917-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
678 Abu-Shawer O, Singh P, Yenulevich E, Brito A, Ni J, Abdulnour RE, Grover S, Manos M, Bowling P, LeBoeuf NR, Ott P, Stephen Hodi F, Jacobson J, Rahma O. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J Immunother Cancer 2020;8:e000992. [PMID: 32817360 DOI: 10.1136/jitc-2020-000992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
679 Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol 2021;14:147. [PMID: 34526102 DOI: 10.1186/s13045-021-01161-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
680 Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. Front Immunol 2021;12:711217. [PMID: 34512631 DOI: 10.3389/fimmu.2021.711217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
681 Hagiwara R, Suzuki D, Tonezawa S, Saikawa R, Funazaki S, Yoshida M, Washino S, Miyagawa T, Hara K, Yamada H. Spontaneous recovery of immune checkpoint inhibitor-induced thyroiditis with high free T4 level: A case report. Clin Case Rep 2021;9:e04781. [PMID: 34512984 DOI: 10.1002/ccr3.4781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
682 Amereller F, Deutschbein T, Joshi M, Schopohl J, Schilbach K, Detomas M, Duffy L, Carroll P, Papa S, Störmann S. Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study. Pituitary 2021. [PMID: 34518996 DOI: 10.1007/s11102-021-01182-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
683 Seki M, Kitano S, Suzuki S. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol Immunother 2021. [PMID: 34515815 DOI: 10.1007/s00262-021-03053-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
684 Zhou L, Wei X. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol 2021;12:701951. [PMID: 34504488 DOI: 10.3389/fimmu.2021.701951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
685 Xiong W, Zhao Y, Du H, Guo X. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. Front Oncol 2021;11:704336. [PMID: 34490104 DOI: 10.3389/fonc.2021.704336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
686 Zhao J, Galvez C, Beckermann KE, Johnson DB, Sosman JA. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Rev Precis Med Drug Dev 2021;6:281-94. [PMID: 34485698 DOI: 10.1080/23808993.2021.1938545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
687 Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. J Immunother Cancer 2021;9:e002627. [PMID: 34479924 DOI: 10.1136/jitc-2021-002627] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
688 Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. Mol Clin Oncol 2021;15:221. [PMID: 34476105 DOI: 10.3892/mco.2021.2379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
689 Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J 2021;14:2012-22. [PMID: 34476087 DOI: 10.1093/ckj/sfab090] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
690 Gudsoorkar P, Langote A, Vaidya P, Meraz-Muñoz AY. Acute Kidney Injury in Patients With Cancer: A Review of Onconephrology. Adv Chronic Kidney Dis 2021;28:394-401.e1. [PMID: 35190106 DOI: 10.1053/j.ackd.2021.09.008] [Reference Citation Analysis]
691 Wang B, Wang Y, Sun X, Deng G, Huang W, Wu X, Gu Y, Tian Z, Fan Z, Xu Q, Chen H, Sun Y. CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell. J Immunother Cancer 2021;9:e003100. [PMID: 34462326 DOI: 10.1136/jitc-2021-003100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
692 Greillier L, Grigoriu B. Maladies auto-immunes, cancers bronchiques et immunothérapies. Revue des Maladies Respiratoires Actualités 2021;13:2S310-2S314. [DOI: 10.1016/s1877-1203(21)00124-5] [Reference Citation Analysis]
693 Nuzzo PV, Pond GR, Abou Alaiwi S, Nassar AH, Flippot R, Curran C, Kilbridge KL, Wei XX, McGregor BA, Choueiri T, Harshman LC, Sonpavde G. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. J Immunother Cancer 2020;8:e000371. [PMID: 32234849 DOI: 10.1136/jitc-2019-000371] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
694 Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol Immunother 2021. [PMID: 34462870 DOI: 10.1007/s00262-021-03045-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
695 Piña Y, Evernden BR, Khushalani N, Margolin K, Tawbi H, Tran ND, Macaulay R, Forsyth P, Peguero E. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. SAGE Open Med Case Rep 2021;9:2050313X211042215. [PMID: 34457306 DOI: 10.1177/2050313X211042215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
696 Placke JM, Rawitzer J, Reis H, Rashidi-Alavijeh J, Livingstone E, Ugurel S, Hadaschik E, Griewank K, Schmid KW, Schadendorf D, Roesch A, Zimmer L. Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition - Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry. Front Oncol 2021;11:725549. [PMID: 34458154 DOI: 10.3389/fonc.2021.725549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
697 Castrillon JA, Eng C, Cheng F. Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Hum Mol Genet 2020;29:R186-96. [PMID: 32620943 DOI: 10.1093/hmg/ddaa137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
698 Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer 2021;9:e002804. [PMID: 34446577 DOI: 10.1136/jitc-2021-002804] [Reference Citation Analysis]
699 Aye L, Song X, Yang J, Hu L, Sun X, Zhou J, Liu Q, Yu H, Wang D. Identification of a Costimulatory Molecule Gene Signature to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:695533. [PMID: 34434928 DOI: 10.3389/fcell.2021.695533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
700 Albarrán V, Pozas J, Rodríguez F, Carrasco Á, Corral E, Lage Y, Álvarez-Ballesteros P, Soria A, Garrido P. Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature. Transl Lung Cancer Res 2021;10:3303-11. [PMID: 34430366 DOI: 10.21037/tlcr-21-222] [Reference Citation Analysis]
701 Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T. Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease. Transl Lung Cancer Res 2021;10:3132-43. [PMID: 34430353 DOI: 10.21037/tlcr-21-198] [Reference Citation Analysis]
702 Ghaffari S, Khalili N, Rezaei N. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy. J Exp Clin Cancer Res 2021;40:269. [PMID: 34446084 DOI: 10.1186/s13046-021-02076-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
703 Lin GF, Xu Y, Lin H, Yang DY, Chen L, Huang LL, Su XS, Xu YX, Zeng YM. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials. Int Immunopharmacol 2021;99:108011. [PMID: 34426108 DOI: 10.1016/j.intimp.2021.108011] [Reference Citation Analysis]
704 Tu K, Yu Y, Wang Y, Yang T, Hu Q, Qin X, Tu J, Yang C, Kong L, Zhang Z. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade. ACS Appl Mater Interfaces 2021;13:39003-17. [PMID: 34433253 DOI: 10.1021/acsami.1c08290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
705 Fitzner M, Schmidt J. Ursache von Muskelschwäche: Spektrum neuromuskulärer Erkrankungen und diagnostisches Vorgehen. Aktuelle Rheumatologie 2021;46:373-81. [DOI: 10.1055/a-1548-8821] [Reference Citation Analysis]
706 Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Zöchbauer-Müller S, Preusser M, Pabinger I, Ay C. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137:1669-78. [PMID: 33067632 DOI: 10.1182/blood.2020007878] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 33.0] [Reference Citation Analysis]
707 Diamanti L, Picca A, Bini P, Gastaldi M, Alfonsi E, Pichiecchio A, Rota E, Rudà R, Bruno F, Villani V, Galiè E, Vogrig A, Valente M, Zoccarato M, Poretto V, Giometto B, Cimminiello C, Del Vecchio M, Marchioni E. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. Neurol Sci 2021. [PMID: 34424427 DOI: 10.1007/s10072-021-05561-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
708 Lim JU, Kim SH, Kang HS, Kim SK, Kim JS, Kim JW, Kim SJ, Yeo CD, Choi CM. Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy. J Clin Med 2021;10:3719. [PMID: 34442015 DOI: 10.3390/jcm10163719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
709 Abou-Samra A, Tzekov R, Yannuzzi NA, Tarabishy AB. Electroretinographic Findings in Melanoma-Associated Retinopathy Treated by Intravitreal Dexamethasone Implant. Ophthalmic Surg Lasers Imaging Retina 2021;52:454-6. [PMID: 34410186 DOI: 10.3928/23258160-20210727-09] [Reference Citation Analysis]
710 Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. Respir Med Case Rep 2021;33:101439. [PMID: 34401279 DOI: 10.1016/j.rmcr.2021.101439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
711 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
712 Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A, Antonuzzo A, Marconcini R, Roviello G, Matucci-cerinic M, Capaccioli D, Pillozzi S, Antonuzzo L. Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno 2021;1:253-63. [DOI: 10.3390/immuno1030017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
713 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
714 Lapuente-Santana Ó, van Genderen M, Hilbers PAJ, Finotello F, Eduati F. Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns (N Y) 2021;2:100293. [PMID: 34430923 DOI: 10.1016/j.patter.2021.100293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
715 Bellastella G, Carbone C, Scappaticcio L, Cirillo P, Troiani T, Morgillo F, Vietri MT, Della Corte CM, De Falco V, Napolitano S, Maiorino MI, De Bellis A, Esposito K. Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers (Basel) 2021;13:4036. [PMID: 34439190 DOI: 10.3390/cancers13164036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
716 Mineiro Dos Santos Garrett NF, Carvalho da Costa AC, Barros Ferreira E, Damiani G, Diniz Dos Reis PE, Inocêncio Vasques C. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLoS One 2021;16:e0255716. [PMID: 34358260 DOI: 10.1371/journal.pone.0255716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
717 He J, Xu J, Gao J, Qian L. Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy. Eur J Cancer 2021;155:38-41. [PMID: 34352569 DOI: 10.1016/j.ejca.2021.06.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
718 Stellato M, Procopio G, De Giorgi U, Maruzzo M, Bimbatti D, Mennitto A, Sbrana A, Roviello G, Casadei C, Sepe P, Pignata S, Santini D. Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. J Transl Med 2021;19:328. [PMID: 34344414 DOI: 10.1186/s12967-021-03008-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
719 Tajima Y, Hommura F, Tsuji T, Yaguchi H, Mito Y. Fatal fulminant inflammation in the diaphragm resulting from pembrolizumab‐related myopathy. Clinical & Exp Neuroim 2021;12:179-181. [DOI: 10.1111/cen3.12643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
720 Smith MK, Chan Y, Suo AE, Shaheen AA, Congly SE, Tandon P, Bhanji RA, Wells MM, Cheng T, Ma C. Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. Journal of the Canadian Association of Gastroenterology 2022;5:39-47. [DOI: 10.1093/jcag/gwab019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
721 Waldron JL, Schworer SA, Kwan M. Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. Clin Rev Allergy Immunol 2021. [PMID: 34319562 DOI: 10.1007/s12016-021-08879-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
722 Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N, Nakanishi Y, Okamoto I, Ieiri I. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci Rep 2021;11:15057. [PMID: 34301991 DOI: 10.1038/s41598-021-94336-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
723 Gao S, Ruan H, Liu J, Liu Y, Liu D, Tong J, Shi J, Yang H, Xu T, Zhang X. A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:678694. [PMID: 34367965 DOI: 10.3389/fonc.2021.678694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
724 Hata K, Sakaguchi C, Tsuchiya M, Nagasaka Y. Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma. BMJ Case Rep 2021;14:e243093. [PMID: 34290022 DOI: 10.1136/bcr-2021-243093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
725 Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali SR, Subbiah V, Iyer SP. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 2020;5:e000866. [PMID: 32817069 DOI: 10.1136/esmoopen-2020-000866] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
726 Filipski K, Scherer M, Zeiner KN, Bucher A, Kleemann J, Jurmeister P, Hartung TI, Meissner M, Plate KH, Fenton TR, Walter J, Tierling S, Schilling B, Zeiner PS, Harter PN. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. J Immunother Cancer 2021;9:e002226. [PMID: 34281986 DOI: 10.1136/jitc-2020-002226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
727 Creţu I, Bojincă M, Milicescu M, Cursaru A, Șerban B, Crețu B, Iordache S, Pop CS, Cîrstoiu C, Ionescu R. Musculoskeletal adverse reactions after immunotherapy for cancer: A case series. Exp Ther Med 2021;22:1027. [PMID: 34373713 DOI: 10.3892/etm.2021.10459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
728 Jerome RN, Joly MM, Kennedy N, Shirey-Rice JK, Roden DM, Bernard GR, Holroyd KJ, Denny JC, Pulley JM. Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. Drug Saf 2020;43:567-82. [PMID: 32112228 DOI: 10.1007/s40264-020-00915-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
729 Lin YX, Wang Y, Ding J, Jiang A, Wang J, Yu M, Blake S, Liu S, Bieberich CJ, Farokhzad OC, Mei L, Wang H, Shi J. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med 2021;13:eaba9772. [PMID: 34162754 DOI: 10.1126/scitranslmed.aba9772] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
730 Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
731 Damo M, Cui C, William I, Hornick NI, Kwok D, Clulo K, Damsky WE, Leventhal JS, Joshi NS. The PD-1 checkpoint receptor maintains tolerance of self-reactive CD8 T cell in skin.. [DOI: 10.1101/2021.07.09.451765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
732 Woodford R, Briscoe K, Tustin R, Jain A. Immunotherapy-related gastritis: Two case reports and literature review. Clin Med Insights Oncol 2021;15:11795549211028570. [PMID: 34290539 DOI: 10.1177/11795549211028570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
733 Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021. [PMID: 34236546 DOI: 10.1007/s10555-021-09976-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
734 Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. Am J Clin Pathol 2021;156:214-28. [PMID: 33555016 DOI: 10.1093/ajcp/aqaa217] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
735 Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, Sharon E. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer 2021;9:e002119. [PMID: 34226280 DOI: 10.1136/jitc-2020-002119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
736 Kubo T, Shinkawa T, Kikuchi Y, Murata K, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T. Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. Front Oncol 2021;11:679095. [PMID: 34290982 DOI: 10.3389/fonc.2021.679095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
737 Kurzhals JK, Graf T, Boch K, Grzyska U, Frydrychowicz A, Zillikens D, Terheyden P, Langan EA. Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. Front Med (Lausanne) 2021;8:691618. [PMID: 34291066 DOI: 10.3389/fmed.2021.691618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
738 Bjursten S, Pandita A, Zhao Z, Fröjd C, Ny L, Jensen C, Ullerstam T, Jespersen H, Borén J, Levin M, Zetterberg H, Rudin A, Levin M. Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. J Immunother Cancer 2021;9:e002732. [PMID: 34215689 DOI: 10.1136/jitc-2021-002732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
739 Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q, Lyu J, Liu Y, Zhang Y, Zhao Z. Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Front Pharmacol 2021;12:663088. [PMID: 34276364 DOI: 10.3389/fphar.2021.663088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
740 Qin H, Vlaminck B, Owoyemi I, Herrmann SM, Leung N, Markovic SN. Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction. Mayo Clin Proc Innov Qual Outcomes 2021;5:670-4. [PMID: 34195558 DOI: 10.1016/j.mayocpiqo.2021.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
741 Dougherty SC, Lynch AC, Hall RD. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. Clin Case Rep 2021;9:e04227. [PMID: 34188921 DOI: 10.1002/ccr3.4227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
742 Bartl S, Dinkhauser P, Hofer H. Medikamentös-toxische Leberschädigung und Immuncheckpointinhibitor-induzierte Hepatitis. J Gastroenterol Hepatol Erkr 2021;19:34-43. [DOI: 10.1007/s41971-021-00100-1] [Reference Citation Analysis]
743 Gudd CLC, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, Kumar N, Mukherjee S, Dhar A, Woollard KJ, Yone Y, Pinato DJ, Thursz MR, Goldin RD, Gore ME, Larkin J, Khamri W, Antoniades CG, Turajlic S, Possamai LA. Activation and transcriptional profile of monocytes and CD8(+) T cells are altered in checkpoint inhibitor-related hepatitis. J Hepatol 2021;75:177-89. [PMID: 33631227 DOI: 10.1016/j.jhep.2021.02.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
744 Saeed M, Chen F, Ye J, Shi Y, Lammers T, De Geest BG, Xu ZP, Yu H. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Adv Mater 2021;33:e2008094. [PMID: 34048101 DOI: 10.1002/adma.202008094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
745 Domblides C, Rochefort J, Riffard C, Panouillot M, Lescaille G, Teillaud JL, Mateo V, Dieu-Nosjean MC. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Front Immunol 2021;12:698604. [PMID: 34276690 DOI: 10.3389/fimmu.2021.698604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
746 Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, Rognon A. Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Ther Clin Risk Manag 2021;17:669-77. [PMID: 34234443 DOI: 10.2147/TCRM.S308194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
747 Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:703893. [PMID: 34268127 DOI: 10.3389/fonc.2021.703893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
748 Yoon SJ, Lee CB, Chae SU, Jo SJ, Bae SK. The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. Int J Mol Sci 2021;22:6932. [PMID: 34203237 DOI: 10.3390/ijms22136932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
749 Ogishi M, Yang R, Aytekin C, Langlais D, Bourgey M, Khan T, Ali FA, Rahman M, Delmonte OM, Chrabieh M, Zhang P, Gruber C, Pelham SJ, Spaan AN, Rosain J, Lei WT, Drutman S, Hellmann MD, Callahan MK, Adamow M, Wong P, Wolchok JD, Rao G, Ma CS, Nakajima Y, Yaguchi T, Chamoto K, Williams SC, Emile JF, Rozenberg F, Glickman MS, Rapaport F, Kerner G, Allington G, Tezcan I, Cagdas D, Hosnut FO, Dogu F, Ikinciogullari A, Rao VK, Kainulainen L, Béziat V, Bustamante J, Vilarinho S, Lifton RP, Boisson B, Abel L, Bogunovic D, Marr N, Notarangelo LD, Tangye SG, Honjo T, Gros P, Boisson-Dupuis S, Casanova JL. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med 2021. [PMID: 34183838 DOI: 10.1038/s41591-021-01388-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
750 Poels K, Neppelenbroek SIM, Kersten MJ, Antoni ML, Lutgens E, Seijkens TTP. Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. J Immunother Cancer 2021;9:e002916. [PMID: 34168005 DOI: 10.1136/jitc-2021-002916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
751 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
752 Li S, Sharma N, Kazmierski D, Amjad MA, Dong Y, Wang Y, Sharma N, Ramakrishna S, Ochieng P. Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy. Cureus 2021;13:e15805. [PMID: 34306873 DOI: 10.7759/cureus.15805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
753 Li CM, Chen Z. Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation. Front Cell Dev Biol 2021;9:664305. [PMID: 34235145 DOI: 10.3389/fcell.2021.664305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
754 Bobircă A, Bobircă F, Ancuta I, Florescu A, Pădureanu V, Florescu DN, Pădureanu R, Florescu A, Mușetescu AE. Rheumatic Immune-Related Adverse Events-A Consequence of Immune Checkpoint Inhibitor Therapy. Biology (Basel) 2021;10:561. [PMID: 34203101 DOI: 10.3390/biology10060561] [Reference Citation Analysis]
755 Wang J, Li Q, Lv H, Nie C, Chen B, Xu W, Yang T, Zhang Y, Tu S, Chen X. A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report. Front Oncol 2021;11:671416. [PMID: 34221988 DOI: 10.3389/fonc.2021.671416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
756 Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, Raghu VK, Gongora C, Sise ME, Alvi RM, Zubiri L, Nohria A, Sullivan R, Reynolds KL, Zlotoff D, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002771. [PMID: 34145031 DOI: 10.1136/jitc-2021-002771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
757 Zhou C, Lin A, Cao M, Ding W, Mou W, Guo N, Chen Z, Zhang J, Luo P. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. Front Immunol 2021;12:634741. [PMID: 34220801 DOI: 10.3389/fimmu.2021.634741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
758 Kaweme NM, Zhou F. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol 2021;12:683381. [PMID: 34220833 DOI: 10.3389/fimmu.2021.683381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
759 Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. World J Clin Cases 2021; 9(17): 4415-4422 [PMID: 34141809 DOI: 10.12998/wjcc.v9.i17.4415] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
760 Kamyshova ES, Bobkova IN, Sekacheva MI. Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. Terapevticheskii arkhiv 2021;93:649-60. [DOI: 10.26442/00403660.2021.06.200860] [Reference Citation Analysis]
761 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 58] [Article Influence: 29.0] [Reference Citation Analysis]
762 Taliansky A, Furman O, Gadot M, Urban D, Bar J, Shapira-Frumer R, Kaufman B, Asher N, Leibowitz-Amit R, Itay A. Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Support Care Cancer 2021;29:7563-8. [PMID: 34120259 DOI: 10.1007/s00520-021-06331-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
763 Zhan L, Feng HF, Liu HQ, Guo LT, Chen C, Yao XL, Sun SR. Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Front Endocrinol (Lausanne) 2021;12:649863. [PMID: 34177799 DOI: 10.3389/fendo.2021.649863] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
764 Von Kemp B, Droogmans S, Cosyns B. Kanker als hartenbreker: cardio-oncologie, meer dan alleen hartfalen? Tijdschr Geneesk 2021. [DOI: 10.47671/tvg.77.21.068] [Reference Citation Analysis]
765 Sørup S, Darvalics B, Russo L, Oksen D, Lamy FX, Verpillat P, Aa K, Ht S, Cronin-Fenton D. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study. Cancer Med 2021;10:4957-63. [PMID: 34105315 DOI: 10.1002/cam4.4040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
766 Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B, Lam E, Zakharia Y, Mckay R, Shah S, Mortazavi A, R Harrison M, Sideris S, Kaymakcalan MD, Abou Alaiwi S, Nassar AH, Nuzzo PV, Hamid A, K Choueiri T, C Harshman L. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J Immunother Cancer 2020;8:e000538. [PMID: 32217762 DOI: 10.1136/jitc-2020-000538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
767 Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V, Bhangale T, Hunkapiller J, Mellman I, Albert ML, McCarthy MI, Chandler GS. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun 2021;12:3355. [PMID: 34099659 DOI: 10.1038/s41467-021-23661-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
768 Bian LF, Zheng C, Shi XL. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report. World J Clin Cases 2021; 9(16): 4110-4115 [PMID: 34141773 DOI: 10.12998/wjcc.v9.i16.4110] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
769 Gérard A, Doyen J, Cremoni M, Bailly L, Zorzi K, Ruetsch-Chelli C, Brglez V, Picard-Gauci A, Troin L, Esnault VLM, Passeron T, Montaudié H, Seitz-Polski B. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. J Immunother Cancer 2021;9:e002512. [PMID: 34088741 DOI: 10.1136/jitc-2021-002512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
770 Ferro A, Filoni A, Pavan A, Pasello G, Guarneri V, Conte P, Alaibac M, Bonanno L. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Front Med (Lausanne) 2021;8:570921. [PMID: 34179028 DOI: 10.3389/fmed.2021.570921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
771 Feng L, Yang L, Li L, Xiao J, Bie N, Xu C, Zhou J, Liu H, Gan L, Wu Y. Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy. Nano Res 2022;15:593-602. [DOI: 10.1007/s12274-021-3525-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
772 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
773 Okwundu N, Grossman D, Hu-Lieskovan S, Grossmann KF, Swami U. The dark side of immunotherapy. Ann Transl Med 2021;9:1041. [PMID: 34277841 DOI: 10.21037/atm-20-4750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
774 Miller AR, Manser R. The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. Transl Lung Cancer Res 2021;10:2752-65. [PMID: 34295675 DOI: 10.21037/tlcr-20-806] [Reference Citation Analysis]
775 Les I, Martínez M, Narro A, Pérez I, Sánchez C, Puntí L, Anaut P, Eguiluz S, Herrera A, Domínguez S. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann Med 2021;53:762-9. [PMID: 34060971 DOI: 10.1080/07853890.2021.1931956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
776 Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM, Stein JE, Grivas P, Zakharia Y, Singh N. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med 2021;9:1033. [PMID: 34277833 DOI: 10.21037/atm-20-8124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
777 McCallen JD, Naqash AR, Marie MA, Atwell DC, Muzaffar M, Sharma N, Amara S, Liles D, Walker PR, Yang LV. Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. Acta Oncol 2021;60:813-7. [PMID: 33939588 DOI: 10.1080/0284186X.2021.1917001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
778 Passiglia F, Cetoretta V, De Filippis M, Napoli V, Novello S. Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. Transl Lung Cancer Res 2021;10:2876-89. [PMID: 34295686 DOI: 10.21037/tlcr-20-635] [Reference Citation Analysis]
779 Spagnolo F, Boutros A, Croce E, Cecchi F, Arecco L, Tanda E, Pronzato P, Lambertini M. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. Eur J Clin Invest 2021;51:e13604. [PMID: 34021591 DOI: 10.1111/eci.13604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
780 Fu Y, Zheng Y, Wang PP, Ding ZY. Toxicities of Immunotherapy for Small Cell Lung Cancer. Front Oncol 2021;11:603658. [PMID: 34136376 DOI: 10.3389/fonc.2021.603658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
781 Parza K, Dao K, Patel P, Scibelli N, Mangano A, Gondal M. Immunotherapy-Induced Acute Tubulointerstitial Nephritis. Cureus 2021;13:e15358. [PMID: 34164249 DOI: 10.7759/cureus.15358] [Reference Citation Analysis]
782 George S, Bell EJ, Zheng Y, Kim R, White J, Devgan G, Smith J, Lal LS, Engel-Nitz NM, Liu FX. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. Oncologist 2021;26:e1205-15. [PMID: 33955118 DOI: 10.1002/onco.13812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
783 Cui W, Francis PA, Loi S, Hickey M, Stern C, Na L, Partridge AH, Loibl S, Anderson RA, Hutt KJ, Keogh LA, Phillips KA. Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. J Natl Cancer Inst 2021;113:1770-8. [PMID: 34048575 DOI: 10.1093/jnci/djab111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
784 Zhang Q, Tang L, Zhou Y, He W, Li W. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Front Immunol 2021;12:663986. [PMID: 34122422 DOI: 10.3389/fimmu.2021.663986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
785 Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:2653. [PMID: 34071259 DOI: 10.3390/cancers13112653] [Reference Citation Analysis]
786 Byun HK, Chang JS, Jung M, Koom WS, Chung KY, Oh BH, Roh MR, Kim KH, Lee CK, Shin SJ. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. Front Oncol 2021;11:659754. [PMID: 34123816 DOI: 10.3389/fonc.2021.659754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
787 Wiens L, Schäffeler N, Eigentler T, Garbe C, Forschner A. Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study. Cancers (Basel) 2021;13:2642. [PMID: 34072206 DOI: 10.3390/cancers13112642] [Reference Citation Analysis]
788 Zahnreich S, Schmidberger H. Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. Cancers (Basel) 2021;13:2607. [PMID: 34073340 DOI: 10.3390/cancers13112607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
789 OuYang Y, Gao J, Zhao L, Lu J, Zhong H, Tang H, Jin S, Yue L, Li Y, Guo W, Xu Q, Lai Y. Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. J Med Chem 2021;64:7646-66. [PMID: 34037385 DOI: 10.1021/acs.jmedchem.1c00370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
790 To KKW, Fong W, Cho WCS. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol 2021;11:635007. [PMID: 34113560 DOI: 10.3389/fonc.2021.635007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
791 Honan AM, Chen Z. Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support. Front Cell Dev Biol 2021;9:658984. [PMID: 34113615 DOI: 10.3389/fcell.2021.658984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
792 Shen S, Dai H, Fei Z, Chai Y, Hao Y, Fan Q, Dong Z, Zhu Y, Xu J, Ma Q, Han X, Xu L, Peng F, Liu Z, Wang C. Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver. ACS Nano 2021;15:9111-25. [PMID: 33988024 DOI: 10.1021/acsnano.1c02391] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
793 Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
794 Canestraro J, Do A, Potash SD, Panarelli J, Berkenstock M, Abramson DH, Francis JH. Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis). Am J Ophthalmol Case Rep 2021;23:101125. [PMID: 34124410 DOI: 10.1016/j.ajoc.2021.101125] [Reference Citation Analysis]
795 Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, Razeti MG, Tagliamento M, Cosso M, Fregatti P, Lambertini M. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. Breast Cancer (Dove Med Press) 2021;13:341-51. [PMID: 34079366 DOI: 10.2147/BCTT.S274283] [Reference Citation Analysis]
796 Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 2021;10:1927313. [PMID: 34104543 DOI: 10.1080/2162402X.2021.1927313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
797 Meraz-Muñoz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C, Kim J, Wald R, Kitchlu A. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 2020;8:e000467. [PMID: 32601079 DOI: 10.1136/jitc-2019-000467] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 19.5] [Reference Citation Analysis]
798 Zheng X, Wei H. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. Front Oncol 2021;11:628243. [PMID: 34094910 DOI: 10.3389/fonc.2021.628243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
799 Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8:e000958. [PMID: 32581063 DOI: 10.1136/jitc-2020-000958] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
800 Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling LM, Meder B, Völkers M, Müller OJ, Frey N, Katus HA, Leuschner F, Kaya Z, Lehmann LH. Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. Cancers (Basel) 2021;13:2498. [PMID: 34065419 DOI: 10.3390/cancers13102498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
801 Russo L, Avesani G, Gui B, Trombadori CML, Salutari V, Perri MT, Di Paola V, Rodolfino E, Scambia G, Manfredi R. Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean J Radiol 2021;22:1310-22. [PMID: 34047505 DOI: 10.3348/kjr.2020.1299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
802 Marchal C, Orillard E, Calais F, Westeel V. Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. Cochrane Database of Systematic Reviews 2021. [DOI: 10.1002/14651858.cd014907] [Reference Citation Analysis]
803 Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell 2020;183:1219-1233.e18. [PMID: 33242418 DOI: 10.1016/j.cell.2020.10.045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
804 Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 2021;18:558-76. [PMID: 34006998 DOI: 10.1038/s41571-021-00507-y] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 31.0] [Reference Citation Analysis]
805 Brancatella A, Lupi I, Montanelli L, Ricci D, Viola N, Sgrò D, Antonangeli L, Sardella C, Brogioni S, Piaggi P, Molinaro E, Bianchi F, Aragona M, Antonuzzo A, Sbrana A, Lucchesi M, Chella A, Falcone A, Del Prato S, Elisei R, Marcocci C, Caturegli P, Santini F, Latrofa F. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. J Endocr Soc 2021;5:bvab093. [PMID: 34337277 DOI: 10.1210/jendso/bvab093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
806 Bruyère CL, Souquet PJ, Dalle S, Corbaux P, Boespflug A, Duruisseaux M, Kiakouama-Maleka L, Reverdy T, Maugeais M, Sahin G, Maillet D, Péron J. Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. Cancers (Basel) 2021;13:2365. [PMID: 34068892 DOI: 10.3390/cancers13102365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
807 Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020;41:1733-43. [PMID: 32112560 DOI: 10.1093/eurheartj/ehaa051] [Cited by in Crossref: 138] [Cited by in F6Publishing: 150] [Article Influence: 69.0] [Reference Citation Analysis]
808 Carden MA, Gaddh M, Hoskote A, Brown M, Merrill V, Stowell SR, Chandrakasan S, Antun A, Kudchadkar R, Kotanchiyev S, Jaye DL, Bodó I. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv 2020;4:477-81. [PMID: 32027742 DOI: 10.1182/bloodadvances.2019001148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
809 Tsunoda M, Aoki H, Shimizu H, Shichino S, Matsushima K, Ueha S. T cell receptor (TCR) repertoire analysis reveals a highly conserved TCR repertoire in a bilateral tumor mouse model.. [DOI: 10.1101/2021.05.13.443732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
810 Huang G, Huang J, Zhang Z, Xue C, Liu Y. Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review. J Int Med Res 2020;48:300060520945075. [PMID: 32783492 DOI: 10.1177/0300060520945075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
811 Vallabhaneni S, Zhang KW, Alvarez-Cardona JA, Mitchell JD, Steen H, Woodard PK, Lenihan DJ. Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. Int J Cardiovasc Imaging 2021. [PMID: 33982196 DOI: 10.1007/s10554-021-02271-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
812 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
813 Kang MJ. Management of adverse events in cancer treatment with immune checkpoint inhibitors. J Korean Med Assoc 2021;64:358-365. [DOI: 10.5124/jkma.2021.64.5.358] [Reference Citation Analysis]
814 Mizukami K, Sakata Y, Seo K, Kitamoto S, Mura T, Kikkawa A, Hiraki K. Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. Jpn J Pharm Health Care Sci 2021;47:239-249. [DOI: 10.5649/jjphcs.47.239] [Reference Citation Analysis]
815 Bai R, Li L, Chen X, Chen N, Song W, Zhang Y, Lv Z, Han F, Zhao Y, Li W, Cui J. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. J Oncol 2021;2021:9935076. [PMID: 34335763 DOI: 10.1155/2021/9935076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
816 Chen M, Zhang L, Zhong W, Zheng K, Ye W, Wang M. Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. Front Immunol 2021;12:619147. [PMID: 34040602 DOI: 10.3389/fimmu.2021.619147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
817 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
818 El Boghdadly Z, Sarwar S, Lustberg ME. Infectious Challenges with Novel Antibody–Based Therapies. Curr Infect Dis Rep 2021;23. [DOI: 10.1007/s11908-021-00753-2] [Reference Citation Analysis]
819 Tucker CG, Dwyer AJ, Fife BT, Martinov T. The Role of Programmed Death-1 in Type 1 Diabetes. Curr Diab Rep 2021;21:20. [PMID: 33956235 DOI: 10.1007/s11892-021-01384-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
820 Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, Raschi E, Licitra L. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. Int J Cancer 2021;149:675-83. [PMID: 33844854 DOI: 10.1002/ijc.33592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
821 Saillard M, Cenerenti M, Romero P, Jandus C. Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. Vaccines (Basel) 2021;9:454. [PMID: 34064410 DOI: 10.3390/vaccines9050454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
822 Baik AH, Oluwole OO, Johnson DB, Shah N, Salem JE, Tsai KK, Moslehi JJ. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res 2021;128:1780-801. [PMID: 33934609 DOI: 10.1161/CIRCRESAHA.120.315894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
823 Miller K, Zamarin D. Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. Advances in Oncology 2021;1:113-123. [DOI: 10.1016/j.yao.2021.02.010] [Reference Citation Analysis]
824 Barat M, Guegan-Bart S, Cottereau AS, Guillo E, Hoeffel C, Barret M, Gaujoux S, Dohan A, Soyer P. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies. Abdom Radiol (NY) 2021;46:2219-35. [PMID: 33135115 DOI: 10.1007/s00261-020-02837-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
825 Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. J Immunother Precis Oncol 2021;4:35-44. [PMID: 35663537 DOI: 10.36401/JIPO-20-34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
826 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
827 Liu CH, Grodzinski P. Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities. Radiol Imaging Cancer 2021;3:e200052. [PMID: 34047667 DOI: 10.1148/rycan.2021200052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
828 Lee PH, Yang TY, Chen KC, Huang YH, Tseng JS, Hsu KH, Wu YC, Liu KJ, Chang GC. Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors. Sci Rep 2021;11:9381. [PMID: 33931705 DOI: 10.1038/s41598-021-89043-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
829 Tian CY, Ou YH, Chang SL, Lin CM. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep 2021;15:244. [PMID: 33926558 DOI: 10.1186/s13256-021-02722-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
830 Sakamoto A, Funamizu N, Iwata M, Nagaoka T, Tamura K, Sakamoto K, Takai A, Ogawa K, Takada Y. Acute-onset type 1 diabetes mellitus developing after administration of pembrolizumab: a case report. Journal of the Japan Pancreas Society 2021;36:158-162. [DOI: 10.2958/suizo.36.158] [Reference Citation Analysis]
831 Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol 2020;40:76-85. [PMID: 32130969 DOI: 10.1016/j.semnephrol.2019.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
832 Takatsuki K, Yanagihara T, Egashira A, Ogo N, Yoshizawa S, Sunami S, Asoh T, Maeyama T. A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin. Am J Case Rep 2021;22:e930286. [PMID: 33903584 DOI: 10.12659/AJCR.930286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
833 Michailidou D, Khaki AR, Morelli MP, Diamantopoulos L, Singh N, Grivas P. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep 2021;11:9029. [PMID: 33907229 DOI: 10.1038/s41598-021-88307-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
834 Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:650292. [PMID: 33968750 DOI: 10.3389/fonc.2021.650292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
835 Yang Y, Islam MS, Hu Y, Chen X. TNFR2: Role in Cancer Immunology and Immunotherapy. Immunotargets Ther 2021;10:103-22. [PMID: 33907692 DOI: 10.2147/ITT.S255224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
836 Go DM, Lee SH, Lee SH, Woo SH, Kim K, Kim K, Park KS, Park JH, Ha SJ, Kim WH, Choi JH, Kim DY. Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis. Cell Mol Gastroenterol Hepatol 2021;12:715-39. [PMID: 33894424 DOI: 10.1016/j.jcmgh.2021.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
837 Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 2021;17:389-99. [PMID: 33875857 DOI: 10.1038/s41574-021-00484-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 19.5] [Reference Citation Analysis]
838 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
839 Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. J Clin Invest 2021;131:140752. [PMID: 33690225 DOI: 10.1172/JCI140752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
840 Manz SM, Losa M, Fritsch R, Scharl M. Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211002018. [PMID: 33948110 DOI: 10.1177/17562848211002018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
841 Li L, Chen X, Hao L, Chen Q, Liu H, Zhou Q. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma. Biosci Rep 2020;40:BSR20201491. [PMID: 32662515 DOI: 10.1042/BSR20201491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
842 Schmidt T, Kebir S, Livingstone E, Junker A, Zülow S, Lazaridis L, Oster C, Chorti E, Pierscianek D, Pul R, Keyvani K, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Zimmer L, Glas M. Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma. Front Oncol 2021;11:637185. [PMID: 33937037 DOI: 10.3389/fonc.2021.637185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
843 Burgaletto C, Brunetti O, Munafò A, Bernardini R, Silvestris N, Cantarella G, Argentiero A. Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. Cancers (Basel) 2021;13:1906. [PMID: 33921021 DOI: 10.3390/cancers13081906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
844 Lake CM, Voss K, Bauman BM, Pohida K, Jiang T, Dveksler G, Snow AL. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death Dis 2021;12:400. [PMID: 33854046 DOI: 10.1038/s41419-021-03689-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
845 Badran O, Ouryvaev A, Baturov V, Shai A. Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: A case report. Mol Clin Oncol 2021;14:120. [PMID: 33903826 DOI: 10.3892/mco.2021.2282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
846 Balducci D, Quatraccioni C, Benedetti A, Marzioni M, Maroni L. Gastrointestinal disorders as immune-related adverse events. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00039] [Reference Citation Analysis]
847 Azeem Khan M, Florou V, Swami U. Immunotherapy and fatigue: what we know and what we don't know. Oncotarget 2021;12:719-20. [PMID: 33889294 DOI: 10.18632/oncotarget.27946] [Reference Citation Analysis]
848 Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front Oncol 2021;11:633032. [PMID: 33912454 DOI: 10.3389/fonc.2021.633032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
849 Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis 2021;13:1759720X211006963. [PMID: 33912248 DOI: 10.1177/1759720X211006963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
850 Kafita D, Daka V, Nkhoma P, Zulu M, Zulu E, Tembo R, Ngwira Z, Mwaba F, Sinkala M, Munsaka S. High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs. PLoS One 2021;16:e0248984. [PMID: 33836003 DOI: 10.1371/journal.pone.0248984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
851 Kraus KM, Fischer JC, Borm KJ, Vogel MME, Pigorsch SU, Devečka M, Combs SE. Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. Sci Rep 2021;11:7624. [PMID: 33828117 DOI: 10.1038/s41598-021-86863-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
852 Patrinely JR Jr, Dewan AK, Johnson DB. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. BioDrugs 2020;34:495-503. [PMID: 32447657 DOI: 10.1007/s40259-020-00428-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
853 Yoon JH, Hong AR, Kim HK, Kang HC. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. Endocrinol Metab (Seoul) 2021;36:413-23. [PMID: 33820396 DOI: 10.3803/EnM.2020.906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
854 Sheikh S, Alvi U, Soliven B, Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med 2021;10:1537. [PMID: 33917535 DOI: 10.3390/jcm10071537] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
855 Ai X, Cai Y, Chu Q, Han C, Lu Y, Qin S, Wu L, Xie C, Yuan Z, Zhong W, Zhu X, Chang JY, Zhu Z; Radiotherapy-Immunotherapy Discussion Group. [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics]. Zhongguo Fei Ai Za Zhi 2020;23:532-40. [PMID: 32517461 DOI: 10.3779/j.issn.1009-3419.2020.102.24] [Reference Citation Analysis]
856 Grigoriou M, Banos A, Hatzioannou A, Kloetgen A, Kouzis P, Aggouraki D, Zakopoulou R, Bamias G, Kassi E, Mavroudis D, Bamias A, Boumpas DT, Tsirigos A, Gogas H, Alissafi T, Verginis P. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. Cancer Immunol Res 2021;9:726-34. [PMID: 33820810 DOI: 10.1158/2326-6066.CIR-20-0969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
857 Knight T, Cooksley T. Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies. J Emerg Med 2021;61:140-6. [PMID: 33795170 DOI: 10.1016/j.jemermed.2021.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
858 Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S. Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. Acta Clin Belg 2021;76:144-8. [PMID: 31495282 DOI: 10.1080/17843286.2019.1664051] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
859 Pous A, Izquierdo C, Cucurull M, Sánchez S, Lezcano C, Domenech M, Llobera L, Plaja A, Moran T. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. Transl Lung Cancer Res 2021;10:1917-23. [PMID: 34012801 DOI: 10.21037/tlcr-20-1315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
860 Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma. Diabetol Int 2021;12:234-40. [PMID: 33786278 DOI: 10.1007/s13340-020-00459-1] [Cited by in Crossref: 4] [